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Osteoporosis is a common complication of many autoimmune diseases that is 
typically attributed to disease specific factors rather than a direct autoimmune 
process. This thesis arises from the investigation of a patient with severe high bone 
turnover osteoporosis who was identified as having autoimmune disease but whose 
osteoporosis deteriorated despite appropriate treatment. This presentation led to the 
hypothesis that neutralising autoantibodies to the bone protective cytokine 
osteoprotegerin (OPG) may have developed. 
 
Serum from the index patient, but not healthy controls, was able to 
immunoprecipitate recombinant OPG protein, demonstrating that OPG had become 
the target of an autoimmune response. Purified immunoglobulins from the index case 
were able to inhibit the function of OPG in vitro, by suppressing OPG-mediated 
inhibition of a luciferase reporter cell line. This represents the first description of 
disease associated with neutralising antibodies to OPG.  Whilst the 
immunoprecipitation assay did identify OPG antibodies in further patients these 
results were difficult to quantify.  A more robust enzyme linked immunosorbent 
assay for OPG antibodies was developed using OPG as a capture antigen, which 
allowed the screening of patient cohorts. Presence of OPG antibodies was defined as 
a titre greater than the mean plus three standard deviations of 101 healthy volunteers. 
A low prevalence of 14/864 (1.6%) was seen in a general population cohort and no 
association with bone density or turnover was seen. An association with higher 
vascular calcification score in this cohort requires replication. A prevalence of 
37/315 (11.7%) was seen in an osteoporosis cohort though no association was seen 
with bone density or response to treatment. In a coeliac cohort OPG antibodies were 
identified in 14/282 (5.0%) patients and presence of antibody was independently 
associated with reduced spine bone density. Functional inhibition of OPG was shown 
in vitro in 3/14 (21.4%) of the positive cases. Case finding of osteoporosis in the 
coeliac cohort was not improved by identification of OPG antibodies.  These results 
are consistent with OPG antibodies being pathological in a small number of patients 




Lay Summary of Thesis 
Osteoporosis, or thinning of the bones, is a common complication of many 
autoimmune diseases but is usually thought to be caused by the underlying disease 
itself. This study describes a patient with autoimmune coeliac and thyroid disease 
who developed very severe osteoporosis due to a protein in the blood that caused 
rapid bone breakdown. The protein was an antibody which blocked the function of a 
key protector of bone called osteoprotegerin. This patient did not respond to 
treatment of his thyroid and coeliac disease, but instead needed a powerful medicine 
to reduce bone breakdown. We have developed a test for this antibody and found 
levels to be raised in some patients attending routine osteoporosis and coeliac disease 
clinics, though in the general population levels of this protein are low. These results 
suggest that antibodies to osteoprotegerin might cause osteoporosis in a small 
number of patients, however it was not possible to show that finding antibodies to 
OPG will help better identify patients with osteoporosis, or influence their response 
to treatment with osteoporosis medicines. Further work will be needed before this 
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Chapter 1: Introduction 
1.1 Epidemiology of osteoporosis 
Osteoporosis is the most common metabolic bone disease in humans and is 
characterised by low bone mass and micro-architectural deterioration of bone tissue, 
which leads to enhanced bone fragility and an increased risk of fracture1. 
Osteoporosis is rare under the age of 50 but becomes progressively more common 
with increasing age, recently estimated in Caucasian populations to affect 11% of 
men and 35% of women above the age of 80 2. Whilst recent estimates of 
osteoporosis suggest an apparent fall in the age-adjusted prevalence of osteoporosis 
in Caucasian populations this effect does not outweigh the increased numbers of 
elderly people with an anticipated increase in the number of people affected by 
osteoporosis of 32% over the next 20 years. The cause of the apparent fall in age-
adjusted prevalence is not clear and does not appear to be explained by increases in 
body weight, use of bisphosphonate therapies or differences in scanning 
technologies2, 3.   
 
The clinical importance of osteoporosis arises from the fact that it is associated with 
an increased risk of fracture, the risk increasing about 2.6 fold for every standard 
deviation decline in bone mineral density4. The cumulative lifetime risk of a fragility 
fracture is estimated to be 53% in a 50 year old woman and 21% in a 50 year old 
man. 5. Fragility fractures represent a major cause of morbidity and mortality, as well 
as an economic burden on society as a whole. Following hip fracture mortality is 
approximately 20% by the end of the first year, with a further 20% of patients 
requiring long term residential care. For society as a whole the cost of osteoporotic 
fracture is estimated at $17.9 billion per annum in the US and £4.3 billion per annum 
in the UK5, 6. Whilst a decline in the age-adjusted prevalence of hip fracture in the 
US appears to parallel the reported fall in hip osteoporosis, once again the absolute 
numbers of hip fractures are still increasing with no improvement in mortality 
following fracture observed reflecting the increased numbers of elderly patients with 




Osteoporosis can be diagnosed accurately and conveniently by dual energy X-ray 
absorptiometry (DEXA) scanning. Osteoporosis has been defined by the World 
Health Organization to exist when levels of bone mineral density (BMD) assessed by 
DEXA scanning at the spine or hip are equal to or less than 2.5 standard deviations 
below the mean value observed in a young healthy reference population. There is a 
consensus on secondary prevention of osteoporotic fracture within the UK, with both 
the National Institute for Health and Care Excellence (NICE) and the Scottish 
Intercollegiate Guidelines (SIGN) recommending that post-menopausal women 
above the age of 50 who have sustained a fragility fracture should be referred for 
bone density scanning and offered treatment if they are identified as having 
osteoporosis8 9. 
 
For primary prevention of osteoporosis there remains considerable debate about 
which individuals to assess for osteoporosis with DEXA scanning, often made more 
urgent by limitations in access to scanners. Current NICE guidelines suggest that a 
fracture risk assessment be performed and an intervention threshold then used to 
select patients for DEXA scanning referral10. The accompanying advice suggests that 
risk assessment would rarely be required below the age of 50, should be considered 
in patients with risk factors above the age of 50 and in all women over 65 years, and 
all men over 75 years of age. No specific intervention threshold is recommended 
however. In the US the National Osteoporosis Foundation does not suggest any risk 
assessment be performed prior to requesting DEXA scanning. The populations 
identified as being at risk of osteoporosis are very similar, though the suggestion is  
that for all men over 70 years of age, it is already reasonable to perform a DEXA 
scan11. SIGN have recently updated their advice and recommend that fracture risk 
assessment be performed above the age of 50 in patients with risk factors. Unlike 
NICE, the SIGN guidance has also suggested a threshold of 10% 10 year fracture 
risk be adopted pragmatically to determine who should be selected for bone density 
scanning, and then offered treatment if identified as having osteoporosis. The 
practical consequences of this advice are currently being worked through. One 
specific concern is that it will not allow the identification of osteoporosis in younger 
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patients who have an inherently low risk of fracture, for example those with coeliac 
disease12.  
 
1.2 Regulation of bone turnover 
1.2.1 Bone modelling and remodelling 
Bone modelling is the process by which skeletal mass is shaped, with the formation 
and resorption of bone occurring on separate bone surfaces13, 14. This is of critical 
importance during bone growth from birth to adulthood, ensuring a mature skeleton 
of appropriate mass and shape. In adulthood bone modelling occurs at a reduced rate 
and mediates the adaption of bone to biomechanical loading. Because the bone 
resorption and formation processes are not coupled this can result in bone loss, for 
example following immobilisation, or bone gain, seen in the dominant wrist of 
experienced tennis players15. Maintenance of healthy bone depends on a process 
termed bone remodelling. This involves both resorption of bone by osteoclasts and 
the laying down of new bone by osteoblasts. This dynamic process allows bone to 
respond to local micro-damage or changes in biomechanical loading in order to 
maintain mechanical integrity of the skeleton. Remodelling occurs at discrete sites 
termed bone remodelling units, with a tightly regulated cycle of resorption and 
formation that in health maintains bone integrity. In adults between the age of 
approximately 21 and 45 years bone resorption and bone formation are closely 
matched leading to little overall change in bone mass or architecture. It is estimated 
that the entire skeleton is reformed over a period of 10 to 20 years. The bone 




Figure 1. The bone remodelling cycle 
Osteoclast precursors are recruited to sites of quiescent bone where they develop 
into bone resorbing osteoclasts and create a resorption pit. Osteoclasts then undergo 
apoptosis and the resorption pit is lined by osteoblast cells that synthesise new bone 
matrix, or osteoid. Over a period of approximately 10 days primary mineralisation of 
osteoid occurs with the deposition of hydroxyapatite crystals, followed by a slower 
secondary mineralisation process. Osteoblasts embedded within bone matrix may 
differentiate into osteocytes, which act as mechanical sensors of bone loading, and 
are the most abundant cell type in bone. Some osteoblasts differentiate into lining 
cells which cover the bone surface.  
 
Systemic regulation of bone remodelling is driven by hormones involved in calcium 
homeostasis, namely parathyroid hormone (PTH), vitamin D and calcitonin, as well 
as by sex steroids most notably oestrogen. PTH is secreted in response to 
hypocalcaemia and mediates its effect on bone by binding directly to osteoblasts and 
bone marrow stromal cells leading to the secretion of macrophage colony stimulating 
factor (M-CSF) and Receptor Activator of Nuclear Factor kappa B beta ligand 
(RANKL)16, indirectly stimulating osteoclast formation and so liberation of calcium 
















reabsorption of calcium and stimulates 1-α hydroxylase activity leading to formation 
of active 1, 25 (OH) vitamin D17. In turn active 1,25 (OH) vitamin D enhances the 
absorption of calcium from the gut, and kidneys, as wells as acting as a feedback 
inhibitor of its own production18. Calcitonin binds directly to receptors on osteoclasts 
leading to inhibition of bone resorption; this pathway has been targeted 
pharmacologically though its physiological significance remains uncertain19. 
Oestrogen acts as a key bone protective hormone with oestrogen receptors expressed 
both in osteoclasts and osteoblasts. For example oestrogen signalling in both 
osteoblasts and osteoclasts has been shown to enhance osteoclast apoptosis mediated 
by FAS signalling, suggesting a role for prolonged osteoclast survival in post 
menopausal osteoporosis20, 21. In addition oestrogen has emerging indirect effects on 
bone mediated by lymphocyte production of inflammatory cytokines and expression 
of RANKL22.  
1.2.2 Determinants of peak bone mass  
During early stages of skeletal growth bone formation predominates over resorption 
until peak bone mass is achieved in early adulthood. Subsequently tight coupling of 
resorption and formation allows maintenance of bone density in a steady state, but 
from the third decade on resorption exceeds formation resulting in a gradual 
reduction in bone density. Adult bone mass is a function of both peak bone mass 
achieved in young adulthood and subsequent adult bone loss23.  
 
Genetic factors play a key role in determining peak bone mass with an estimated 
heritability of between 50 and 80%24. Candidate gene studies have suggested a role 
of estrogen and vitamin D receptor variants whilst acknowledging the significant 
contribution of body weight, hormonal factors, and physical activity25, 26. A recent 
meta-analysis of genome-wide association studies of bone density confined to 
premenopausal women confirmed associations within the WNT16 (encoding 
wingless-type MMTV integration site family, member 16) and ESR1 (encoding 
Estrogen receptor 1) loci27.  WNT signalling is seen as an early component of the 
osteoblastic response to weight bearing exercise in a fashion that is dependent on 
estrogen receptor signalling, highlighting at least one pathway by which these 
diverse genetic and environmental signals interact28, and explaining the benefits that 
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are seen with increased weight bearing exercise in pre-pubertal children29. Most 
genome-wide association studies performed in osteoporosis have looked at older 
women and men in whom it is not possible to determine if the genetic associations 
relate to a deficit in peak bone mass, or subsequent bone loss. Even so the largest 
meta-analysis performed of these studies to date has identified multiple loci encoding 
genes implicated in bone formation in-utero suggesting that even foetal bone 
development contributes to bone density in adulthood 30. 
1.2.3 Causes of increased bone loss in adulthood  
A transient accelerated rate of bone loss is seen in women in the decade following 
menopause, which is followed by a slower continuous rate of bone loss in subsequent 
years31. Oestrogen deficiency plays an important role in both phases of bone loss 
with oestrogen replacement leading to significant improvement in bone density32. 
Sex hormones also play a critical role in male osteoporosis however the dominant 
effect appears to be mediated by oestradiol and the effectiveness and safety of 
testosterone replacement requires further investigation33. Whilst cortical bone, which 
comprises 80% of the adult skeleton, is preserved in women before menopause, 
studies using quantitative computed tomography (CT) have been able to discern 
declines in trabecular bone before menopause, which has been attributed to an 
independent process of increased oxidative stress associated with ageing34, 35. 
Increased bone resorption correlating with increasing levels of parathyroid hormone 
with age is also noted in epidemiological studies and is attributed to nutritional or 
functional deficiency of vitamin D31. 
 
Lifestyle factors contribute significantly to adult bone mass. Smoking and alcohol 
excess, both more common in men, contribute to a reduction in trabecular bone 
mass36. Conversely weight bearing exercise has been shown to improve or at least 
attenuate loss of bone mass in older adults37. 
 
Diverse medical diseases and treatments have adverse effects on bone health, and can 
be identified in up to 64% of men and 50% of pre-menopausal women with 
osteoporosis38. Diseases associated with osteoporosis include hypogonadism, 
hyperthyroidism, hyperparathyroidism, malignancies, gastrointestinal disease and 
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chronic rheumatic disease39. The specific examples of rheumatoid arthritis, coeliac 
disease and inflammatory bowel disease are discussed in more detail in Section 1.4.2, 
1.4.3. and 1.4.4. Drug treatments, notably with corticosteroids, have diverse adverse 
effects on bone health leading to both worsened bone mineral density and increased 
fracture risk40, for example by driving signals of bone resorption in osteoblasts41 as 
well as having direct myopathic effects and influencing the risk of falling42. 
Fundamentally in any individual presenting with osteoporosis there are likely to be 
diverse mechanisms responsible for the development of disease which together have 
led to a relative imbalance of bone resorption over bone formation 
1.3 Cellular regulation of bone turnover 
1.3.1 Bone formation 
In most parts of the skeleton, both in-utero and until skeletal maturity, bone forms 
within a cartilage template in a process termed endochondral ossification43. 
Alternatively in the flat bones of the skull, bone forms directly in a process termed 
intramembranous ossification.   Cartilage is formed by mesenchymal stem cell 
derived chondrocytes capable of secreting the various components of the cartilage 
extracellular matrix, principally collagen type II, aggrecan and hyaluronan43. Mature 
chondrocytes initiate the resorption of the collagen matrix and invasion by 
capillaries. Further degradation of the cartilage matrix is performed by invading 
osteoclasts, with mineralisation of the remaining cartilage septa orchestrated by 
invading osteoblasts resulting in the formation of bone. 
 
Mature bone is formed by mineralisation of an organic matrix secreted by 
osteoblasts. The organic matrix comprises fibrillar proteins such as collagens type I, 
III, V and VI, non-fibrillar proteins involved in the formation and mineralisation of 
the collagen scaffold such as osteopontin, osteocalcin, osteonectin and fibronectin, 
and finally growth factors such as transforming growth factor-beta(TGF-beta)44. The 
most abundant collagen in bone is type 1 collagen which is normally laid down in an 
orderly lamellar pattern of alternately orientated fibrils. Mature bone is comprised 
predominantly (50–70%) of mineral, mostly hydroxyapatite which provides much of 




The adult human skeleton is comprised of 80% dense cortical bone and 20% more 
porous but metabolically highly active trabecular bone13. The relative proportion of 
each varies between different sites; with cortical bone predominating in the shafts of 
long bones but trabecular bone predominant in the vertebrae. Both are made up of 
lamellar bone with mechanical loading thought to mediate the differential 
development into trabecular or cortical bone. In high bone turnover states, the 
lamellar pattern of bone is lost leading to functionally weaker woven bone formation. 
This occurs in disease states such as hyperparathyroidism and Paget’s disease of 
bone13. 
1.3.2 Osteoblasts 
Osteoblasts are derived from pluripotent mesenchymal stem cells which have the 
potential to differentiate into many cell types including adipocytes, myocytes and 
chondrocytes. The expression of Runx2 is an early marker of mesenchymal stem 
cells commitment to an osteoblastic lineage, whilst inhibiting the development of 
adipocytes and chondrocytes45 with subsequent expression of osterix a marker of 
increasing osteoblast commitment46. Runx2 increases the expression of alkaline 
phosphatase and osteocalcin, which are markers of osteoblast activity and hence 
bone formation, though the action of both remains poorly understood. Alkaline 
phosphatase is responsible for hydrolysing mineralisation inhibitors such as 
pyrophosphate, and osteocalcin is also thought to promote mineralisation of bone 
though paradoxically osteocalcin deficient mice have a high bone mass phenotype13. 
 
A number of factors drive the commitment and maturation of mesenchymal stem 
cells into mature osteoblasts (Figure 1.2 – adapted from reference 45). Indian 
hedgehog (HH) protein is secreted by early and prehypertrophic chondrocytes and is 
an essential signal in endochondral ossification47. HH signalling is mediated at least 
in part via parathyroid related protein (PTHrP)48. Notch signalling appears to inhibit, 
and bone morphogenic proteins appears to promote the normal differentiation of 






Figure 1.2. Regulatory signals in osteoblast development.  
Commitment of mesenchymal precursors to osteoblast development is characterised 
by expression of Runx2 and subsequently Osterix. Osteoblast differentiation is 
promoted through signalling by hedgehog proteins (HH) in part mediated by 
parathyroid related protein (PTHrP), bone morphogenic proteins (BMP) and 
wingless proteins (WNT). Fibroblast growth factors (FGF) promote the maturation 
and proliferation of immature osteoblasts. Conversely Notch signalling inhibits 
Runx2 activity and osteoblast differentiation. 
 
Signalling through the WNT and FGF pathways is important in promoting further 
osteoblast differentiation, and conversely dexamethasone promotes mesenchymal 
cell differentiation into adipocytes49.  WNT signalling is mediated through the 
Frizzled (FZD) receptor and its co-receptor LRP5 or LRP6 and results in signalling 




















Figure 1.3 Canonical WNT signalling pathway. WNT ligands bind to a co-receptor 
complex comprising a transmembrane domain of Frizzled receptor (FZD) and either 
co-receptor LRP5 or LRP6. Dishevilled (DSH) and Axin are recruited intracellularly 
forming a complex that inhibits GSK3β. The constitutive activity of GSK3β is 
phosphorylation and hence targeting of β-catenin for proteosomal degradation. 
Following WNT signalling, there is accumulation of cytoplasmic β-catenin ultimately 
allowing translocation to the nucleus and enhanced signalling. 
 
Sclerostin, primarily secreted by osteocytes (Section 1.3.4), plays a key role in the 
maturation and terminal differentiation of osteoblast lineage cells into mature 
osteoblasts mainly through inhibition of WNT signalling45, though its effects may 
also be mediated by suppression of BMP signalling50. A key role in bone health has 
been demonstrated by the study of patients with mutations in components of these 

















associated with an autosomal recessive condition characterised by bony overgrowth 
of the jaw and skull termed van Buchem disease 51, whereas coding mutations of the 
SOST gene result in a similar phenotype termed Sclerosteosis52. Mutations of LRP5 
can cause contrasting phenotypes. A cluster of mutations within LRP5 that result in 
reduced binding by sclerostin are associated with a high bone mass phenotype due to 
enhanced WNT signalling53. Conversely loss of function mutations in LRP5, have 
been shown to result in reduced bone density and pseudoglioma due to loss of WNT 
signalling54. Despite the strong evidence of a direct effect in bone of mutations in 
LRP5 some conflicting reports have been published suggested the effect may be 
mediated by regulation of serotonin synthesis in the gut, though it has been suggested 
that this research was methodologically flawed55, 56. 
1.3.3 Osteoclasts and bone resorption 
Osteoclasts are multinucleated cells derived from haematopoietic stem cell 
precursors. A critical early marker of haematopoietic differentiation along a myeloid 
pathway is PU.1 which is associated with expression of c-fms the receptor for 
macrophage colony stimulating factor (M-CSF)57. PU.1 is also needed for expression 
of the receptor activator of nuclear factor kappa B (RANK) in response to M-CSF 
signalling. The expression of the RANK receptor is further upregulated by RANK 
ligand (RANKL) co-administration58. Signalling by M-CSF and RANKL are 
essential for osteoclast development with deficiency of either factor leading to an 
osteopetrotic phenotype 59, 60. Stimulation of osteoclast precursors by RANKL 
induces the expression of transcription factors such as activator protein 1 (AP1) and 
nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) leading to the expression 
of proteins  required in the fusion of osteoclast precursors such as dendritic cell-
specific transmembrane protein, as well as those required for the resorptive capacity 
of osteoclasts such as cathepsin K and vacuolar ATPase61. Osteoprotegerin (OPG) is 
a decoy receptor for RANKL that blocks both the maturation and activation of 
osteoclasts. The regulatory factors involved  in osteoclast maturation and activation 





Figure 1.4 Essential signals in the differentiation of osteoclasts.  
Expression of the transcription factor PU.1 is an early marker of myeloid 
commitment by haematopoietic stem cells associated with responsiveness to M-CSF.  
Signalling by M-CSF induces RANK receptor expression with stimulation by RANKL 
(co-stimulated by M-CSF and collagen) then driving the expression of osteoclast 
defining transcription factors AP1 and NFATc1. Osteoclasts are recognised by the 
expression of tartrate resistant acid phosphatase (TRAP) and by the presence of a 
ruffled border when activated. OPG, by inhibiting RANKL, blocks the differentiation 
and activation of osteoclasts. 
 
RANKL stimulation triggers the formation of a RANK/TRAF6 complex which 
elicits a number of essential downstream signals including the dimeric transcription 
factors nuclear factor kappaB (NFκB) and AP1 both of which are necessary for 
effective osteoclastogenesis62, 63(Figure 1.5). NFκB is made up of homo or 
heterodimers typically including p50 or p52 subunits and a double deletion of both 
p50 and p52 subunits is associated with the development of osteopetrosis. Deletion 
of either subunit alone does not result in osteopetrosis implying overlapping function 
of the two homologous proteins64. Formation of the RANK/TRAF 6 complex leads 
to phosphorylation of the inhibitor of kappB (IκB) and allows nuclear translocation 
of NFκB . AP1 comprises a dimer of proteins from the Fos, Jun and activating 
transcription factor families with deficiency of c-Fos (which forms a heterodimer 










































A further critical transcription factor downstream of RANK signalling is NFATc1 
which has been shown to be both necessary and sufficient for osteoclastogenesis66. 
NFATc1 regulates its own expression and it appears that a complex of AP1 and 
NFATc1 is required for this autoamplification to occur66. 
 
In addition to NFκB and AP1 signals it is clear that regulation of the intracellular 
Ca2+ levels induced by co-stimulation through immunoreceptor tyrosine-based 
activation motif (ITAM)  containing adaptor proteins DNAX activating protein 12 
(DAP12) and Fc receptor common γ chain (FcR γ) is also required for the  activation 
of NFATc167, 68(Figure 1.5). No ligand has been found for the immunoglobulin-like 
receptors that associate with DAP12, though M-CSF has been shown to generate a 
signal through DAP1269 . Collagen fibres have been shown to signal through the 
osteoclast associated receptor (OSCAR) which is induced by RANKL and associates 
with FcR γ70.   Ultimately NFATc1, in combination with other transcription factors 
directly drives the expression of osteoclast specific genes such as TRAP, cathepsin 









Figure 1.5 Essential signals in osteoclast development. RANKL binding to RANK 
triggers the formation of a RANK/TRAF 6 complex which leads to the nuclear 
targeting of NFκB and the formation of the c-Fos containing transcription factor 
AP1. Co-stimulation via ITAM containing adaptor proteins provides a second signal 
mediated by regulation of intracellular calcium levels. In combination, these events 
drive transcription and autoamplification of the key osteoclast factor NFATc1. 
 
Osteoclasts are uniquely capable of resorbing mineralised tissues, a process that 
requires tight binding of osteoclasts to bone and polarisation of the osteoclast cell 
membrane. The actin cytoskeleton is reorganised to form a ring, which is attached to 
bone via integrin-based structures called podosomes, sealing off a compartment 


















area the osteoclast contains a highly convoluted ruffled border to which acidic 
vesicles are trafficked and which allows the delivery of the components necessary for 
bone resorption. The secretion of hydrogen ions by vacuolar proton ATPase 
transporters can lower the pH within the resorption pit to 4.5 which allows the 
mineral content of the bone matrix to be dissolved13. The organic components of 
bone matrix are digested by secreted enzymes such as cathepsin K, MMP-9 and 
tartrate resistant acid phosphatase13. An active process of reverse vesicular 
trafficking targets the degradation products for release on the opposite membrane 
from the bone surface72 and incidentally facilitates the measurement of breakdown 
products (such as N or C telopeptides of type 1 collagen) that can give an indication 
of bone resorption rate73.  Impairment of osteoclast function caused by inherited 
deficiencies of hydrogen ion secretion are the commonest cause of osteopetrosis in 
humans74, whilst defects in RANK and RANKL have also been identified in 
‘osteoclast poor’ osteopetrosis75. Inherited defects in enzymes such as cathepsin K 
results in a related osteosclerotic condition pycnodysostosis74.  
 
Enhanced induction of osteoclasts by autoantibodies targeting citrullinated vimentin 
have  recently been demonstrated in mice in elegant studies by Schett et al76. This is 
of direct relevance to rheumatoid arthritis in which anti-citrullinated peptide  
antibodies are an early marker of disease and correlate directly with bone resorption. 
It is intriguing to note that osteoclasts express the citrullinating enzyme 
peptidylarginine deaminase potentially leading to a vicious cycle of immune 
mediated activation of osteoclasts, in turn leading to the promotion of enhanced 
autoimmune responses. This work also clearly illustrates that autoantibodies are not 
only biomarkers of disease but can also directly cause pathology. 
1.3.4 Osteocytes and the regulation of bone formation 
Osteocytes play a key role in regulating bone mineralisation and remodelling, and 
function both in an endocrine and paracrine fashion. They are derived from 
osteoblasts that are buried in bone matrix and are the most abundant cell type within 
bone. Osteocytes are connected to each other through a  remarkably extensive 
network of dendritic processes which allow the retention of connections to the 
mineralisation front as well as the bone surface and vasculature77. These processes 
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help osteocytes to function as mechanosensors of bone loading. The mechanisms by 
which mechanical strain mediates bone formation are not well understood though it 
has been shown that conditional osteocytic knock down of polycystin 1 (a gene 
previously established in mechanosensing in renal cilia) results in a failure of the 
anabolic response to loading78. 
 
Osteocytes act in a paracrine fashion to regulate both osteoblasts and osteocytes. 
Sclerostin is a key inhibitor of osteoblast activity and the constitutive expression of 
sclerostin by osteocytes appears critical to suppress bone formation. Mechanical 
loading has been shown to dramatically reduce osteocyte expression of sclerostin 
which in turn promotes new bone formation79.   Osteocytes have also been 
recognised to be a key regulator of osteoclasts, with both healthy and apoptotic 
osteocytes capable of recruiting osteoclasts77. Importantly osteocytes are now 
recognised as the major source of RANKL in the bone microenvironment. This is 
evidenced by the fact that conditional knock out mice in whom osteocytes did not 
express RANKL developed a severe osteopetrotic phenotype 80. This stimulation of 
osteoclasts is presumed to be mediated by RANKL expressed on the dendritic 
processes of osteocytes in response to mechanical stress, though whether this is 
membrane bound or secreted is not currently known. In addition to their influence on 
osteoblast and osteoclast cells osteocytes have also been shown to directly regulate 
the perilacunar space with expression of resorptive enzymes such as cathepsin K and 
TRAP during lactation in mice suggesting that osteocytes are capable of acting in an 
osteoclast-like fashion81. 
 
Osteocytes can also act in an endocrine fashion to regulate renal phosphate and 
calcium handling77. As osteocytes mature they change their pattern of gene 
expression, with reduced expression of alkaline phosphatase and an increase in 
factors such as FGF23, dentin matrix protein 1 (DMP1) and phosphate regulating 
gene with homologies to endopeptidases on the X chromosome (PHEX). DMP1 and 
PHEX are both thought to down regulate FGF23 expression and so maintain renal 
phosphate reabsorption77. Mutations of DMP1 are associated with hypophosphatemic 
rickets in humans82, with mutations of PHEX and DMP1 in mice leading to similar 
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phenotype of osteomalacia with high levels of FGF2383, 84. A role for FGF23 in the 
cardiovascular morbidity associated with renal impairment has also been 
postulated85. 
 
1.3.5 Vascular calcification 
An association between cardiovascular diseases (CVD) and osteoporosis has long 
been recognised though it has commonly been assumed that these were simply co-
existing but independent conditions of increasing prevalence in older people86, 87. 
Epidemiological studies now indicate that both may share a common 
pathophysiological basis. For example, a recent twin study showed that the risk of 
hip fracture was between 2 and 5-fold increased in subjects with various types of 
CVD as compared with controls, suggesting a shared genetic basis to both 
conditions. Vascular calcification is a recognised feature of atherosclerosis, and the 
extent of arterial calcification is generally accepted as a marker of risk for future 
cardiovascular events88. Vascular calcification is typically exacerbated in conditions 
with increased vascular risk such as diabetes, renal impairment and hyperlipidaemia 
but osteoporosis is now also recognised as a regulatory influence89. This is shown in 
several studies that have confirmed an independent association between vascular 
calcification and osteoporosis90-92.  
 
Mineralisation can occur in any fibrillar extracellular matrix, so long as there is 
sufficient phosphate to allow formation of hydroxyapatite, and there is inhibition of 
mineralisation inhibitors, for example the degradation of pyrophosphate usually 
mediated by alkaline phosphatase93.  The walls of muscular arteries contain fibres of 
collagen, and elastin along with abundant vascular smooth muscle cells (VSMC). In 
calcified arteries it has been shown that VSMCs have an osteoblast like phenotype 
with increased expression of alkaline phosphatase, diminished expression of 
mineralisation inhibitors such as matrix Gla protein (MGP) and the ability to support 
mineralisation in vitro94, 95. A great variety of factors have been reported to influence 
this differentiation including inflammatory cytokines such as TGF-beta, platelet 
derived growth factors,  matrix metalloproteinases, high circulating phosphate and 
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calcium, as well as dexamethasone, though the relative physiological importance of 
these factors remains poorly understood95-98. 
 
Vascular calcification is increasingly understood to be an active process with many 
parallels to embryonic bone development99. For example bone morphogenic protein 
2 (BMP) plays a fundamental role in osteoblast differentiation and the formation of 
bone and cartilage 100, 101, but the same protein is upregulated in the endothelium in 
response to inflammatory cytokines resulting in vascular calcification and endothelial 
activation102.  Perhaps unsurprisingly there are a large number of factors that are 
involved in both bone metabolism and vascular calcification, though it remains a 
paradox that too much calcification can occur in the vasculature at the same time as 
there is too little in the bone103.  
 
OPG has been suggested as an important common factor in the development of both 
osteoporosis and vascular calcification, and has been shown to inhibit vascular 
calcification in experimental models104,105. This is supported by evidence from the 
OPG deficient mouse which is characterised by high bone turnover and fracture as 
well as extensive vascular calcification 106. Similarly OPG deficient patients with 
juvenile Paget’s disease who survive into adulthood have been shown to develop 
extensive vascular calcification107. This may be explained by effects on RANKL 
with elevated levels of RANK and RANKL having been identified in atherosclerotic 
lesions where they are associated with increased expression of BMP-2 as well as 
decreased expression of matrix Gla protein (MGP) a key inhibitor of 
mineralisation108. Several investigators have looked for evidence of associations 
between circulating levels of OPG and/or RANKL, cardiovascular disease and 
osteoporosis109-112. The results of these studies have paradoxically shown an 
association between high circulating OPG levels and low RANKL levels with 
vascular calcification. Attempts to rationalise this finding have suggested these 
factors act in a paracrine rather than endocrine fashion to affect cellular function113.  
An alternative mechanism independent of RANKL has also been suggested. OPG 
acts as a decoy receptor for TNF related apoptosis inducing ligand (TRAIL) and both 
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TRAIL and OPG have been identified in atherosclerotic plaques, with TRAIL also 
shown to enhance the mineralisation of VSMCs in-vitro114.  
 
Many other factors have also been implicated in both bone metabolism and vascular 
calcification though a full discussion of these factors is beyond the scope of this 
thesis. Oestrogen has a critical bone protective effect, and has also been shown to 
protect against vascular calcification, possibly by inhibiting the effects of RANKL 
on BMP-2 and MGP expression in vascular smooth muscle cells108. Vitamin K 
activates MGP by carboxylation and deficiency of vitamin K has been implicated in 
both vascular calcification and osteoporosis115, 116 . Finally PTH and vitamin D exert 
a permissive effect on vascular calcification by regulating the availability of 
phosphate and calcium, but have also been shown to have direct effects in the 
vasculature themselves117.   
 
1.3.6 Receptor activator of NFκB pathway 
The RANK pathway was identified in the late 1990s as the key regulator of 
osteoclast differentiation and function (see also Section 1.3.3)118, 119. The RANK 
receptor encoded by the TNFRSF11A gene is a member of the tumour necrosis 
factor (TNF) receptor super family which is expressed on osteoclast precursors and 
dendritic cells. RANKL encoded by the TNFSF11 gene is a member of the TNF 
superfamily that  is expressed both on the cell membrane and as a soluble ligand 
(sRANKL) formed by cleavage of RANKL from the cell membrane, and also 
capable of stimulating RANK120.  OPG encoded by the gene TNFRSF11B and also a 
member of the TNF receptor superfamily lacks a transmembrane domain and acts as 
a decoy receptor for RANKL and was identified as a potent inhibitor of bone 
resorption by blocking the interaction of RANKL with RANK121.   
 
The RANK/RANKL/OPG signalling axis is now recognised as a critical pathway in 
osteoclast differentiation and bone resorption. It is central to the cross talk between 
osteoclasts and osteoblast lineage cells; as bone marrow stromal cells mature into 
osteoblasts their expression of RANKL reduces, and secretion of OPG increases, 
down regulating osteoclast activity122.  Osteoblasts and mesenchymal-derived 
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precursors are considered the major source of OPG though this is based primarily on 
in vitro work 123, 124.  As discussed earlier, whilst bone marrow stromal cells can 
express RANKL, it is now osteocytes that are recognised as the primary source of 





Figure 1.6: Role of the receptor activator of nuclear factor kappa B (RANK) 
pathway in osteoclast development. RANKL expressed by osteocytes, bone marrow 
stromal cells or T lymphocytes induces differentiation and activation of osteoclast 
precursors via RANK and subsequent activation of NFκB. sRANKL is derived by 
cleavage from the cell membrane.  OPG, a soluble inhibitor of RANKL, inhibits the 
binding of RANK by RANKL. 
 
Genetic studies confirm the critical role of RANK/RANKL/OPG in bone 
homeostasis. Meta-analysis of genome wide association studies into osteoporosis has 
shown that genetic variation at the TNFSF11, TNFRSF11A and TNFRSF11B loci 
(encoding RANKL, RANK and OPG respectively) as well as downstream signalling 

















also been described in association with mutations in these genes. Complete 
deficiency of OPG in humans causes “juvenile Paget’s disease” which is a rare 
disease characterised by high bone turnover, bone deformity and multiple fractures 
126. This is confirmed in mouse models where deficiency of OPG also causes severe 
osteoporosis and multiple fractures 106. Activating mutations of the TNFRSF11A 
gene which encodes RANK have been identified as the cause of the rare bone 
dysplasias, familial expansile osteolysis and expansile skeletal hyperplasia127, 128. 
Conversely deficiency of RANK or RANKL causes osteopetrosis due to defects in 
osteoclast function75. 
 
In addition to its role in the regulation of bone, genetic studies in mice have shown 
that RANK/RANKL signalling also plays a critical role in thymic development, as 
well as maintaining tolerance to autoreactive T cells129, 130.  Exploring cross talk 
between the immune system and bone cells has emerged as a new field of study 
termed osteoimmunology131. RANKL is expressed on both bone marrow stromal 
cells and lymphocytes132, 133, thereby representing an intriguing link between bone 
homeostasis and immune regulation. Activated T cells express RANKL directly and 
this mediates bone loss and joint destruction that can be blocked by administering 
recombinant OPG134. Similarly in rheumatoid arthritis, blockade of RANKL has 
been shown to impede the development of bone erosions135.  
 
T cell expression of RANKL, as well as the osteoclast stimulatory effects of 
inflammatory cytokines such as tumour necrosis factor α and interferon are likely to 
contribute to the development of osteoporosis that is seen in many autoimmune 
conditions136. Equally B cells have been shown to produce OPG in response to 
stimulation of CD40 137 and by some estimates constitute the major source of OPG 
within the bone marrow138. It is possible that this B cell derived OPG could act as a 
homeostatic regulator of the osteoclastogenesis that is driven by immune activation, 
though no role for B cell produced OPG in physiological bone loss has been 
identified; specifically no exacerbation of ovariectomy induced bone loss was found 




Although many factors have been shown to regulate osteoclastogenesis including 
interleukin-1(IL-1), TGF beta, TNF, IL-6, 1,25 vitamin D3 and parathyroid hormone 
(PTH), the effects of these agents on osteoclast activity has been shown at least in 
part to be mediated by alteration of the RANK signalling pathway 140. For example 
the importance of oestrogen deficiency to post-menopausal osteoporosis can be 
partially explained by oestrogen’s demonstrated ability to stimulate OPG production 
by osteoblasts141. 
 
Investigators have looked for evidence of associations between circulating levels of 
OPG and/or sRANKL and post-menopausal osteoporosis but paradoxically have 
found high circulating OPG levels and low sRANKL levels in patients with 
osteoporosis142. Rationalising this difference many authors have emphasized the 
paracrine rather than endocrine action of these factors on cellular function, or 
alternatively suggested that this is a compensatory mechanism attempting to restore 
bone homeostasis. It is important to recognise that OPG and sRANKL are produced 
by diverse cell types hence the circulating levels may bear little correlation with the 
bone microenvironment143-145 and that there exists significant variability within 
currently available assays for sRANKL144. Equally in inflammatory disease a 
paradoxical association between low sRANKL levels or high circulating OPG levels 
and osteoporosis has been found110, 143 again casting doubt on the biological 
significance of circulating OPG and sRANKL, and demonstrating that despite the 
key importance of this pathway it cannot be readily exploited to provide a biomarker 
for osteoporosis. 
1.3.7 Osteoprotegerin 
OPG is formed as a protein of 401 amino acids containing four tandem cysteine rich 
domains that have homology to other members of the TNF receptor superfamily and 
that mediate the binding of RANKL, as well as a C-terminal dimerisation domain 146. 
In addition the protein encodes a 21 amino acid N-terminal signal peptide that is 
cleaved prior to secretion of a final protein of 380 amino acids. OPG has been shown 
to undergo N-linked glycosylation and cysteine linked dimerization yielding a 
secreted dimer with a molecular mass of 110kDa, though under reducing conditions 





Figure 1.7 Structure of osteoprotegerin 
1.4 Complications of autoimmune disease 
1.4.1 Osteoporosis in autoimmune disease 
Osteoporosis is a recognised complication of autoimmune diseases such as coeliac 
disease147, inflammatory bowel disease148, and inflammatory rheumatic diseases 
including rheumatoid arthritis149. The pathogenesis is complex involving direct 
effects of local and systemic inflammation, indirect effects mediated through 
conventional risk factors for osteoporosis, as well as drug treatment effects 
particularly with corticosteroids. Inflammation has been shown to have a direct effect 








which are correlated with levels of RANKL or increased RANKL/OPG ratio in 
rheumatoid arthritis, coeliac disease and inflammatory bowel disease150, 151. Indirect 
effects on bone density may arise from an association of autoimmune disease with 
smoking and female gender, as well as the potential impact of disease on body mass 
or mobility147, 152.   
More recently evidence of direct autoimmune stimulation of bone loss has been 
identified in the work of Schett, who has demonstrated that autoantibodies can 
recognise antigens expressed by osteoclasts and directly stimulate osteoclast activity 
both in-vitro and in-vivo76. 
 
1.4.2 Rheumatoid arthritis 
Rheumatoid arthritis is a systemic inflammatory disorder characterised by 
polyarticular and deforming arthritis, which is frequently associated with the 
development of autoantibodies to citrullinated proteins. Anti-citrullinated protein 
antibodies typically develop in genetically susceptible individuals with exposure to 
environmental triggers such as smoking or bacterial stimuli153. An increased risk of 
fracture is observed in patients with rheumatoid arthritis after correction for 
conventional risk factors such as smoking, which is attributed both to complications 
of the disease and use of corticosteroids149. Both local and systemic inflammation 
result in bone loss with chronic localised inflammation leading to characteristic peri-
articular erosions and systemic inflammation also associated with reduced bone 
mineral density154, 155. Effective management of rheumatoid arthritis, particularly 
with more potent biological therapies, has shown improvements in local bone 
erosions although systemic osteoporosis remains an issue in rheumatoid arthritis155, 
156.  
1.4.3 Coeliac disease 
Coeliac disease is one of the most common autoimmune disorders with a prevalence 
estimated at 1% of the UK population157. It is characterised by a gluten sensitive 
enteropathy and by the development of autoantibodies to transglutaminase. 
Osteoporosis is the commonest complication affecting 20–50% of newly diagnosed 
patients147 with an associated increased relative risk of hip fracture of 1.43 158. 
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Reduced bone density in coeliac disease is usually considered a consequence of 
malabsorption, and a correlation with the severity of villous atrophy has recently 
been shown159. The consequences of malabsorption are diverse with effects on body 
mass, as well as reduced absorption of vitamin D and calcium. Vitamin D and 
calcium deficiency in turn cause secondary hyperparathyroidism leading to increased 
bone turnover. Equally vitamin D deficiency results in muscle weakness and an 
increased risk of falling160. The severity of  osteoporosis however correlates poorly 
with symptoms of disease suggesting that malabsorption alone is not the only factor 
implicated in reduction of bone density 161.  
 
Despite the high prevalence of coeliac disease and the significant morbidity 
associated with osteoporosis, there is currently no clear guideline to suggest which 
patients with coeliac disease should be targeted for bone mineral density scanning 
either at diagnosis or on follow up. 
1.4.4 Thyroid disease 
Osteoclasts and osteoblasts are a target of thyroid hormones as well as thyroid 
stimulating hormone (TSH), with an increase in the turnover of bone associated with 
thyroid hormone excess, as well as suppression of TSH162-164. Untreated 
hyperthyroidism is associated with lowered bone mineral density and an increased 
risk of fracture165. Even within the normal range higher levels of T3 and T4 hormone 
have been associated with reduced bone mineral density and increased fracture 
risk166.  In the short term there is evidence that treatment of hypothyroidism with 
thyroxine replacement is associated with a reduction in bone density which suggests 
it is prudent to use the lowest dose of thyroxine replacement required to suppress 
thyroid stimulating hormone167. 
1.4.5 Inflammatory Bowel Disease 
The inflammatory bowel diseases (IBD) are immune mediated conditions 
characterised by chronic, relapsing inflammation involving the large bowel 
(ulcerative colitis) or the entire gastrointestinal tract (Crohns’ disease). IBD is 
commonly complicated by the development of osteoporosis with estimates for the 
frequency of this complication varying between 17 and 41%168. In turn IBD is also 
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associated with an increased risk of fracture169. Conventional risk factors for reduced 
bone density have been shown to predict lowered bone density in IBD such as 
reduced body mass index 148, cumulative steroid exposure170and smoking171. It 
remains unclear whether disease specific factors such as gut inflammation are also 
risk factors for the development of osteoporosis172. 
1.4.6 Development of autoantibodies 
The fundamental role of the immune system is to discriminate self from non-self and 
stringent mechanisms are in place to delete or render anergic self-reactive 
lymphocytes. Despite this, autoimmune diseases are common amongst western 
populations with pathological auto-reactive antibodies long recognised in conditions 
as diverse as autoimmune haemolytic anaemia, myasthenia gravis, and neonatal 
lupus (with antibodies directed against red blood cells, the acetyl-choline cell surface 
receptor and Ro and La nuclear antigens respectively)173. More recently antibodies 
directed against endogenous cytokines, that are capable of functional inhibition, have 
been identified as an emerging cause of immunosuppression itself174.  
  
Extracellular self-antigens typically induce a state of anergy in autoreactive B cells 
that have escaped clonal deletion in the bone marrow; by contrast sequestered 
intracellular antigens have been demonstrated to promote autoreactive B cell 
development175. Post translational modification of proteins is an established 
mechanism in autoimmune disease by which this process of tolerance can be 
overcome, for example citrullination in rheumatoid arthritis153. Environmental 
factors are thought to contribute to this process, in the example of rheumatoid 
arthritis smoking and periodontitis are the most compelling 176. In addition, the 
genetic makeup of patients who develop autoimmune disease appears to predispose 
to development of self-reactive immune responses. This can be restricted to specific 
epitopes by inheritance of human leukocyte antigen alleles as in the ‘shared epitope’ 
of rheumatoid arthritis177. Alternatively an unrestricted tendency to autoimmunity 
and autoantibody generation may be seen with inherited deficiencies of key 
regulatory factors as seen in Mendelian disorders of immunodysregulation and 
polyendocrinopathy178, 179. Despite recent advances in understanding, the mechanism 
of immune tolerance breakdown remains unclear in the majority of cases. 
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1.5 Identification of autoantibodies 
A number of techniques are available for the identification of autoantibodies173. 
1.5.1 Immunofluorescence 
Immunofluorescence is a widely used technique in which antibodies that cross react 
to sections of human tissue or cultured cells are identified by the binding of a 
secondary fluorescent labelled antibody. Though convenient, the results of this 
technique may be limited by the quality and availability of substrate as well as the 
need for an experienced interpreter.  
1.5.2 Immunoblotting 
A more specific technique for the detection of autoantibodies is thought to be 
immunoblotting, in which multiple proteins from a tissue or cell culture of interest 
are first separated out by gel electrophoresis, next transferred onto a membrane and 
finally probed with serum to identify specific autoreactive antibodies. An advantage 
of this approach is that the immunoreactive protein spots can be directly cut out and 
the protein identified, commonly now by mass spectrometry. This technique however 
may lack sensitivity due to the potential denaturing of the protein of interest prior to 
interaction with antibody. The technique may also lack specificity due to 
unanticipated interactions between antibodies and commonly found antigens within 
cell lysates. In one elegant exploratory paper looking for autoantibodies directed at 
cell membranes, a large number of intracellular antigens were identified 
unexpectedly. The authors attribute this to non-specific binding and noted that many 
of these same antigens have recently been suggested as novel autoantigens by 
immunoblotting in a diverse range of autoimmune disorders180.  
1.5.3 Enzyme-linked immunosorbent assay 
Enzyme-linked immunosorbent assays (ELISA) provide a much more convenient 
mechanism for the screening of multiple samples for autoantibodies. In this 
technique a small quantity of protein is bound to a solid surface which is then washed 
over with serum. Cross-reacting antibodies are then themselves bound by enzyme-
linked secondary antibodies allowing for an objective measure of recognition to be 
made, typically by measurement of a colour change reaction. Although 
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standardisation of results between assays can be challenging, ELISA tests allow for 
the analysis of multiple samples with objective results. 
1.5.4 Array based technologies 
High throughput technologies are emerging that will facilitate the screening of 
multiple samples against a large numbers of proteins and should ensure both high 
sensitivity and specificity. These include protein micro-arrays as well as bead based 
immunoassays. Already such technologies are facilitating the identification of novel 
autoantibodies181 
1.6 Aims of the current study 
This work arises from the investigation of a patient with severe high bone turnover 
osteoporosis who was identified as having autoimmune thyroid and coeliac disease 
but whose osteoporosis deteriorated despite appropriate treatment of these 
conditions. This presentation led to the hypothesis that neutralising autoantibodies to 
the bone protective cytokine OPG may have developed in view of the autoimmune 
diathesis present, as well as the severe high bone turnover state analogous to that 
seen in patients with inherited deficiency of OPG182 . This led to the further 
hypothesis that autoantibodies to OPG may play a pathogenic role in other patients 
with osteoporosis, in particular those with concomitant autoimmune disease. This 
study has aimed to test these hypotheses with the following specific goals; 
 
 Establish if immunoglobulins isolated from the index patient are capable of 
recognising OPG in-vitro 
 Establish if identified OPG autoantibodies are functional ie capable of 
inhibiting OPG activity in-vitro 
 Develop an assay for OPG autoantibodies to facilitate the screening of patient 
cohorts, as well as building/accessing biobanks of serum from suitable patient 
groups 
 Establish if the presence of OPG autoantibodies within different cohorts of 
patients is associated with reduced bone mineral density, and if so whether 
this is independent of conventional risk factors for osteoporosis. As a 
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secondary study the potential impact of OPG autoantibodies on vascular 
calcification has been investigated. 
 
To summarise the structure of the thesis, characteristics of the index patient himself 
as well as the results of preliminary assays developed to detect and assess 
functionality of OPG antibodies in serum are presented in Chapter 3. A variety of 
approaches to measuring and assessing functionality of OPG antibodies were 
considered and are described within Chapter 2: Materials and Methods. A particular 
focus of this work has been to develop a high throughput assay for OPG antibodies in 
order to allow the screening of distinct patient cohorts for the presence of OPG 
autoantibodies. The reproducibility of the immunoprecipitation and ELISA assays 
used to identify OPG autoantibodies is discussed in Chapter 4, as well as the 
influence of serum factors on the performance of the ELISA. The characteristics of 
patients with OPG antibodies identified in a general population study (the Orkney 
complex diseases cohort -ORCADES) are presented in Chapter 5. Cohorts of patients 
attending the osteoporosis service and coeliac patients attending the gastroenterology 
department have been recruited over the course of the study and the results of 
screening these cohorts, as well as an established cohort of inflammatory bowel 
disease patients, are presented in Chapters 6 and 7. Whilst the main focus has been to 
establish whether the presence of OPG antibodies is associated with reduced bone 
mineral density, the possible clinical utility of measuring OPG antibodies in these 






Chapter 2: Materials and Methods 
Within this section the protocols that were developed to identify and characterise 
antibodies to OPG are described in detail. The source of the reagents used is listed 
alphabetically in Appendix A1. Apparatus used is detailed in Appendix A2 and the 
constituents of the solutions used are listed in Appendix A3. The results of 
preliminary experiments developing an ELISA assay for OPG antibodies are 
presented in this section; this includes details of a prototype indirect ELISA which 
was not taken forward, as well as iterations of a direct ELISA the results of which are 
presented in subsequent sections. Exploratory studies using a number of different cell 
lines to demonstrate functional activity of OPG antibodies which were not taken 
forward are described separately in Appendix A4.  
2.1 Immunoprecipitation assay for osteoprotegerin antibodies 
The ability of serum from the index patient to recognise OPG was first demonstrated 
using a modification of a standard immunoprecipitation assay. The principals of the 










Figure 2.1 Immunoprecipitation assay for OPG antibodies  
Recombinant OPG is added to patient serum, allowing immune complexes to form in 
the presence of OPG antibodies (1). Serum immunoglobulins are pulled down by 
addition of excess protein G coated agarose beads (2). Unbound OPG is washed out 
in patients without OPG antibodies by sequential washes, but retained in the 
presence of OPG antibodies (3). Retained OPG is subsequently demonstrated by 
Western blot using a commercial anti-OPG antibody. 
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2.1.1 Immunoprecipitation assay 
A working solution of recombinant homo-dimeric full length OPG (R&D systems) 
was made in 5% bovine serum albumin (BSA) to minimise non-specific binding. The 
stock solution of OPG was typically made at a concentration of 25ug/ml with a 
working solution made up by adding 7.5μlof OPG stock to 3ml of 5% BSA. In the 
final protocol, 2μl of serum was added to 200μl of OPG working solution (ie a 1 in 
100 dilution of serum in a solution containing 12.5ng OPG). These samples were 
incubated for 1 hour at 37o C whilst being shaken vigorously. Meantime protein G 
coated agarose beads (Calbiochem) were pre-incubated with 5% BSA. Typically 
390μl of agarose beads was added to 2.61ml of 5% BSA and mixed end over end for 
at least 10 minutes), with 230μl of this solution added to each treatment Eppendorf. 
Eppendorf tubes were centrifuged at 1400rpm for 3 minutes and 200μl of supernatant 
removed to leave 30μl of beads per tube. 
 
Immunoprecipitation of immune complexes was performed by adding 200μl of 
serum/OPG solution to each treatment eppendorf, resuspending the beads by briefly 
vortexing and incubating for 1 hour at 37o C. Beads were resuspended periodically 
by further brief vortexing. Subsequently each eppendorf was spun at 14000rpm for 1 
minute and the supernatant removed. The samples were resuspended in 200μl of 
warm phosphate buffered saline (PBS), with this wash step repeated five times to 
remove unbound OPG. Finally the bead pellet was resuspended in 30µl of sample 
loading buffer (Appendix 3.1) and incubated at 90o C for 5 minutes.  
 
Following brief centrifugation, the supernatant was either frozen for later analysis or 
analysed immediately by gel electrophoreses and Western blot. 
2.1.2 Gel electrophoresis 
Gel electrophoresis was performed using CriterionTM XT BioRad (12% Bis-Tris) pre-
cast gels, which were placed into a vertical electrophoresis tank filled with 
electrophoresis running buffer (Appendix 3.1). Samples from the immunoprecipitation 
assay were already made up in sample loading buffer (Appendix 2.1) to a final volume 
less than 50μl. All samples were heated at 90°C for 5 minutes and loaded carefully 
into the well. A Kaleidoscope pre-stained standard and a Magic Marker XP western 
32 
 
standard were used to identify molecular weights. Gels were run at constant voltage of 
200V for 45 minutes.  
2.1.3 Electrophoretic transfer 
This procedure allows the recovery of proteins from the polyacrylamide gel to a solid 
protein-binding membrane. The gel was removed from the pre-cast gel cassette and 
immersed into transfer buffer (Appendix 3.1) for 5 minutes. Meanwhile, a 
polyvinyliden difluoride membrane (PVDF membrane - Hybond-P) was cut to the 
size of polyacrylamide gel, immersed in 100% methanol and then allowed to 
equilibrate in transfer buffer for 5 minutes. A blotting sandwich was prepared with 
the following successive layers: pre-soaked extra thick blot paper, membrane, 
polyacrylamide gel and pre-soaked extra thick blot paper. The sandwich was 
orientated to ensure that the negatively charged proteins were moved out of the 
polyacrylamide gel and transferred across to the membrane. The transfer was carried 
out using a Biometra transfer machine at a constant current of 90mA for 1 hour 20 
minutes. 
2.1.4 Immunostaining and antibody detection 
The PVDF membrane was incubated at room temperature for 1 hour in blocking 
solution of 5% (w/v) bovine serum albumin in TBST (Appendix 3.1) to ensure 
blocking of non-specific binding sites. Once completed, the membrane was washed 
in TBST for 30 minutes, while changing the buffer every 10 minutes. Membranes 
were incubated overnight at 4C with continuous agitation, with a primary 
monoclonal antibody to OPG (Abcam) at a concentration of 1:2000 in 5% BSA in 
TBST. The membrane was washed three times in TBST for 15 minutes and 
incubated with an anti-mouse secondary antibody at a concentration of 1:5000 in 5% 
w/v dried non-fat milk in TBST for 1 hour at room temperature. Membranes were 
again washed three times with TBST. To visualise immunoreactivity, the Pierce 
SuperSignal® West Dura Extended Duration chemiluminescent detection system 
was used and the signal was detected on a Syngene Genegnome Bio Imaging 





Membranes were stripped of bound antibodies by incubation in stripping buffer 
(Appendix 3.2) for 5 minutes at 50C. Equal loading of the samples was assessed by 
probing the blot with peroxidase conjugated goat anti-human antibody (Jackson) at a 
1/5000 dilution in 5% BSA for 1 hour. Immunolabelled bands were again detected 
using Pierce Supersignal chemiluminescence detection system. 
2.2. Assays of functional inhibition by OPG antibodies 
A number of cellular models were investigated to see if they might be able to 
demonstrate functional inhibition of OPG by the patient’s serum. A potential high 
throughput functional assay of OPG antibodies was investigated using the 
AlphaLISA bead-based protocol (Perkin Elmer). This is a proximity assay of protein 
interactions, in which a signal is emitted when coupled beads are brought together by 
linked protein pairs, in this case recombinant OPG and RANKL. Relatively weak 
enhancement of background signalling was observed however with increasing 
concentrations of OPG and RANKL, as well as an inconsistent dose response despite 
trials of a number of blocking buffers. In view of the high cost of the reagents this 
was not pursued (further details in Appendix A4.1). 
 
The generation of osteoclast like multi-nucleated cells from RAW264.7 cells has 
been reported in response to RANKL stimulation183. These cells have been reported 
to express tartrate resistant acid phosphatase (TRAP) which can readily be measured 
by direct staining of the osteoclast cells or potentially by analysis of the culture 
supernatant, and this assay had promise as a more physiological assay of OPG 
function. No expression of TRAP in RANKL stimulated RAW cells was detected in 
preliminary experiments exploring this assay and in view of the assay complexity 
this approach was not pursued (further details in Appendix A4.3). RAW264.7 cells 
expressing the secreted alkaline phosphatase (SEAP) gene under the transcriptional 
control of an  NFκB response element (IML-120 Imgenex) were obtained, but these 
were found to be unresponsive to RANKL (further details in Appendix A4.3).  
 
Finally human embryonic kidney 293 cells (HEK 293) stably transfected with a 
NFκB luciferase reporter construct (Panomics RC0014) were examined. Although 
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these cells are thought to be embryonic kidney cell in origin, they were shown to 
respond to RANKL in a dose-dependent fashion (Figure 2.2).  
Figure 2.2 Dose response to RANKL in HEK293 NFκB luciferase cells. 
A linear dose response to 50ng/ml or 100ng/ml RANKL was demonstrated (diamonds 
– Medium) with suppression of signalling demonstrated by addition of OPG 
100ng/ml (squares – OPG100ng/ml). Results shown are means ± standard deviations 
of triplicate experiments.  
 
Based on these experiments 100ng/ml RANKL is expected to give robust activation 
of reporter gene expression. Importantly this effect is abrogated by the addition of 
equimolar human recombinant OPG providing a direct measure of OPG function. 
Based on these results, an assay demonstrating functional inhibition of OPG by 











































Figure 2.3 Functional assay for osteoprotegerin antibodies 
First recombinant OPG is incubated with immunoglobulins purified from the 
patients’ sample. This with equimolar RANKL was added to a cell line stably 
transfected with an NFκB luciferase response element which had been shown to 
respond to RANKL in a dose dependent manner. The luciferase response measured 
gives a measure of the functional inhibition of OPG.  
 
2.2.1 Purification of immunoglobulins 
Two techniques were utilised to purify immunoglobulins from serum samples. The 
first used protein G coated agarose beads (Pierce Protein G spin columns) to pull 
down serum immunoglobulins, the second utilised a proprietary filtration gel which 
depletes non-immunoglobulin components of serum (Melon™ Gel IgG Spin 
Purification Kit). 
 
For both systems, all steps of the immunoglobulin purification were performed at 
room temperature, with buffers also equilibrated to room temperature. All 
centrifugation steps were performed on a micro-centrifuge set to 5,000g (8,000rpm) 
for 1 minute.  
 
After an initial spin to remove storage solution, Protein G spin columns were 
equilibrated by addition of 400μl binding buffer (Pierce Protein G IgG Binding 
Buffer 21019) and brief mixing. Columns were centrifuged again and the flow 
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through discarded. This step was repeated once. 250µl of serum sample was mixed 
with an equal volume of binding buffer and added to the column for a 10 minute 
incubation at room temperature with end over end mixing. After centrifugation the 
columns were washed three times by adding 400µl binding buffer and centrifugation. 
For collection of the purified immunoglobulins, the spin columns were placed in 
collection tubes containing 40μl of neutralisation buffer (1M Tris ph 7.5-9). 400µl of 
IgG Elution buffer (Pierce IgG Elution Buffer 21004) was added to each column, 
mixed gently then centrifuged with the collected solution making the first elution 
fraction. Second and third elution fractions were collected in the same fashion. The 
protein content of the elution fractions was estimated using standard protein 
concentration assay (Section 2.2.2). Spin columns were regenerated by adding 400µl 
elution buffer and centrifuging for 1 minute. This step repeated three times. Resin 
then washed several times in storage solution and stored at 4˚C. Columns could be 
used up to 10 times without significant loss in binding capacity. 
 
This protocol generated approximately 6mg/ml purified immunoglobulins from the 
positive control though lower levels of antibody were typically seen with other 
patient or volunteer samples. Overnight mixing of serum samples in the spin columns 
showed enhanced protein retention with the immunoglobulin yield increasing from 
2.21mg/ml to 5.05mg/ml facilitating equivalent immunoglobulin treatment in the 
functional studies. 
 
For the melon gel purification, the bottle containing the purification support was 
swirled to obtain an even suspension before 500μl aliquots of the gel were dispensed 
into spin columns using a cut pipette tip. Spin columns were placed in micro centrifuge 
tubes and an initial spin performed to remove storage solution. Two washes were then 
performed using 300μl of purification buffer with brief centrifugation for 10 seconds 
and discarding of the flow-through. A bottom cap was then placed on the columns. 
50μl of serum sample was added to 450μl of melon gel purification buffer and added 
to the column. A top cap was placed on the column prior to incubation for 5 minutes 
at room temperature with end-over-end mixing. The bottom cap was removed from 
the column, and the top cap loosened prior to re-inserting the spin column in the 
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collection tube. The purified sample was then collected after a final spin for 1 minute. 
The antibody was then either used directly or stored and the used Gel Support 
discarded. 
2.2.2 Measuring protein concentration 
The protein concentration was determined using the bicinchoninic acid (BCA) Pierce 
protein assay. A standard curve was generated using supplied standard concentrations 
of bovine BSA (1,000ug/µl to 5ug/µl). In a fresh 96-well plate, 10μl of each 
concentration standard and protein samples (1:10 and 1:20 diluted in water) were 
plated in duplicate. 200μl of copper (II)-sulfate (diluted 1:50 with BCA) were added 
in each well and incubated for 10 minutes at 37oC. The absorbance was measured at 
562nm on a plate reader and the protein concentration in each sample was calculated 
from the BSA standard curve. 
2.2.3 NFκB Reporter Assay 
HEK 293 cells stably transfected with an NFκB luciferase reporter (Panomics 
RC0014) were maintained in d-minimum essential solution (d-MEM) with 1% 
Penicillin/Streptomycin/Glutamine and 10% Foetal calf serum (FCS). Cells were 
harvested once a confluent layer of cells was seen. Incubation with 1/500 agromycin 
was performed every five cycles to maintain purity of cells.  
Prior to assay, the medium was removed and cells rinsed with 10ml of warm PBS. 
Cells were suspended by trypsinisation (2ml trypsin added to adherent cells). Total 
volume made up to 10ml of supplemented d-MEM then liberated cells were spun 
down and made up to 3ml supplemented d-MEM. Cells counted in modified 
Neubauer cell counter and resuspended to give final concentration of 500,000 
cells/ml (ie in order to give 50,000 cells/well with addition of 100μl of cells to each 
well of a 96-well plate. Cells were plated out overnight and prior to assay serum 
starved in 100μl of d-MEM with 2% cytokine free tissue culture medium (TCH 
solution –MP Biomedicals) for 2 hours 
 
All assays were performed in sextuplet in 96-well black-out plates to minimise 
transference of signal. Sufficient treatments for all cells was made up at 10 times 
concentration for administration in final volume of 10μl serum deplete d-MEM per 
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well. A pre-incubation was performed of the patient serum (final concentration 1/40 
dilution) with human recombinant OPG (final concentration 100 to 400ng/ml) in a 
water bath at 37˚C with shaker on for 20 minutes. Subsequently human recombinant 
RANKL (final concentration 100ng/ml) was added to each sample for a further 20 
minutes, again in the water bath at 37˚C. 
 
10μl of each treatment was added directly to cells and incubated for minimum of 3 
hours (optimum approximately 7 hours) at 37˚C. 10μl alamar blue was added with 
treatment to assess cell viability. 
 
During cell stimulation, Steady Glo reagent (Promega) was equilibrated to room 
temperature. To minimise use of reagents, 50μl sample was typically removed before 
addition of 50μl Steady Glo reagent. Cells were left for 5 minutes to lyse then read 
immediately on plate reader. To correct for cell viability, the luciferase reading was 
divided by the alamar blue reading for final result. 
2.3 Enzyme linked immunosorbent assay 
In view of difficulties in quantifying the immunoprecipitation assay, a high 
throughput ELISA for OPG antibodies was developed. Two fundamental approaches 
were assessed: an indirect assay in which serum OPG antibodies compete with the 
signal from labelled anti OPG antibodies, and a direct assay in which OPG 





2.3.1 Indirect ELISA for OPG antibodies 
An indirect ELISA-based assay for OPG antibodies was developed using the 
principals shown in Figure 2.4. In preliminary experiments, a rabbit biotinylated 
polyclonal antibody to human OPG (AbCam, Ab18068) was used at a concentration 










Figure 2.4 Principals of indirect ELISA for OPG antibodies 
Recombinant human OPG adsorbed to the base of 96-well plates is used as a capture 
antigen. OPG antibodies found in serum would be expected to bind to OPG in 
proportion to their serum concentration. A labelled secondary antibody against OPG 
was used to measure the levels of unbound OPG and hence give an indirect measure 
of serum levels of OPG antibodies  
 
A standard curve was created by addition of a murine monoclonal anti human OPG 
(Abcam, Ab140491) at a concentration of to 1,600 ng/well. Results of a preliminary 
experiment are shown in Figure 2.5. Serum from the index patient was shown to 
substantially compete with the labelled antibody, reducing the colour that developed 
in these wells when streptavidin linked horse radish peroxidase was added. Since the 
level of absorbance seen with addition of serum fell below the limit of the standard 
curve it was not possible to attempt any quantification of patient serum OPG 
antibody concentration in this experiment. 
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Figure 2.5 Preliminary competitive ELISA experiment  
The principal of the assay is confirmed with decreasing level of signal seen with 
increasing concentration of the competing monoclonal antibody ( mAb, standard 
curve ♦) though complete suppression of the signal could  not be achieved despite 
greatly increasing the concentration (note logarithmic scale for concentration of 
competing mAb). A greater suppression of signal is seen with addition of patient 
serum than with the highest concentration of murine anti-human OPG. 
 
A number of further experiments were performed in an attempt to optimise this 
assay, varying both the concentration of OPG (to optimise the number of binding 
sites) and the concentration of the labelled polyclonal anti-OPG antibody (to 
optimise competition for OPG). Results of a dose ranging experiment are shown 
(Table 2.1). In this experiment, concentrations of plated OPG between 5ng/well to 
20ng/well were used, as well as concentrations of labelled anti-OPG antibody from 
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 OPG conc/well (ng) 
PAb conc/well (ng) 20 15 10 5 
0 0.23 0.21 0.20 0.21 
0.1 0.25 0.24 0.23 0.21 
0.2 0.27 0.26 0.26 0.24 
0.4 0.34 0.32 0.31 0.27 
0.8 0.48 0.45 0.44 0.34 
1.6 0.68 0.66 0.64 0.48 
5.0 1.43 1.35 0.90 0.61 
 
Table 2.1 Dose ranging experiment demonstrating reduced levels of signal with 
decreasing concentrations of OPG used as a capture antigen, as well as increasing 
levels of signal with increasing labelled polycloncal antibody to OPG (pAb)  
 
Only a relatively modest increase in signal is seen when increasing from 15 to 
20ng/well of OPG so for ongoing experiments 15ng/well OPG was selected. A 
relatively high background signal is seen even in the absence of specific labelled 
polyclonal antibody. A variety of blocking buffers were assessed but were not able to 
reduce the background signal seen (data not shown).  
 
Finally an unlabelled rabbit polyclonal antibody to OPG (Abcam, ab9986), 2.5 to 
1,280ng/well) was used for the standard curve to negate the possibility that the 
epitope specificity of the monoclonal antibody rendered it impossible to completely 
suppress the signal from the labelled polyclonal antibody. This antibody was able to 
suppress signal at relatively low concentrations, though once again complete 






Figure 2.6 Inhibition by polyclonal OPG antibody  
 
Based on these experiments the optimised protocol comprised 15ng OPG per well 
plated out overnight and then blocked in 1% BSA. Serum was added at a dilution of 
1:2.5 and incubated for 1 hour at 37˚C. A standard curve was created using serial 
dilutions of the polyclonal antibody to OPG. Biotinylated polyclonal antibody to 
OPG was added at a concentration of 0.1ng/ml to each well and this was incubated 
for 1 hour at 37˚C. Following a further wash, optical density was read after addition 
of substrate. Results are shown in Figure 2.7. A reduction in absorbance is seen with 
addition of the serum from our index patient that is greater than that seen with a 
negative control, providing proof of principal. The absolute fall in signal intensity 
seen is relatively modest suggesting it would be very difficult to use this assay to 




















































Figure 2.7 Suppression of signal seen with increasing concentration of competing 
polyclonal antibody to OPG. The sample from our index patient showing suppression 
of signal but a relatively modest suppression of signal intensity by 1/3 suggests that 
the dynamic range of the assay is likely to be insufficient to demonstrate suppression 











































2.3.2 Principals of a direct ELISA for OPG autoantibodies 
A direct capture ELISA for antibodies to OPG was developed by modification of the 
indirect ELISA protocol. Once again recombinant OPG was used to coat an ELISA 
plate, but this time patient serum samples were added directly, with the addition of 
labelled anti-human immunoglobulin G giving a direct measure of the presence of 
autoantibodies. The same polyclonal rabbit antibody to OPG (Abcam, ab9986) was 
used to create a standard curve, taking advantage of a cross reactivity of the labelled 
anti-human IgG with rabbit antibodies. The principals of a direct capture ELISA for 










Figure 2.8 Principals of direct ELISA for OPG antibodies 
Recombinant human OPG adsorbed to the base of 96-well plates is used as a capture 
antigen. OPG antibodies found in serum would be expected to bind to OPG in 
proportion to their serum concentration. A labelled secondary antibody against 
human immunoglobulin directly measures the quantity of OPG antibodies. 
 
In a dose ranging experiment, OPG concentrations between 1 and 15ng/well were 
utilised to coat the plate, and serum was added in doubling dilutions from 1 in 40, to 
1 in 640 (see Table 2.2). Unsurprisingly a dose response is seen both with increasing 
concentration of OPG and with increasing concentration of serum.  
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OPG concentration used to coat plate (ng/well) 
1.0 2.5 5.0 10 15 
Negative control 
1 in 40 1.055 0.973 0.931 0.993 1.009 
1 in 80 0.680 0.711 0.683 0.731 0.723 
1 in 160 0.634 0.597 0.621 0.610 0.622 
1 in 320 0.442 0.452 0.446 0.452 0.489 
1 in 640 0.363 0.353 0.331 0.349 0.369 
 
Positive control 
1 in 40 1.507 1.859 2.060 2.240 2.264 
1 in 80 1.185 1.406 1.735 1.971 2.008 
1 in 160 0.963 1.121 1.507 1.695 1.914 
1 in 320 0.621 0.833 1.087 1.287 1.495 
1 in 640 0.459 0.524 0.725 0.908 1.029 
 
Table 2.2 Optimisation of conditions for direct OPG ELISA 
Plate reader absorbance values (arbitrary units) are shown with increasing 
concentration of OPG used to coat ELISA plates both for a sample known to be 
negative for OPG (Negative control) and serum from the index case (Positive 
control). Effects of serial dilutions of both samples was also explored to identify 
conditions that would optimally discriminate positive from negative samples. 
 
Relatively high background signal is seen with the negative control, which was 
attenuated with increasing dilution of serum, whilst maintaining a similar ratio of 
positive to control signal at all dilutions. Attenuation of the signal seen with the 
positive control is seen with increasing dilutions however (Table 2.3).  On the basis 
of these experiments a final dilution of 1 in 1,000 was typically used to prevent non-







Serum sample and dilution 
Negative control Positive control 
1: 640 1: 1,280 1: 2,560 1: 640 1: 1,280 1: 2,560 
Repetition 1 0.151 0.115 0.074 2.070 1.574 0.943 
Repetition 2 0.161 0.113 0.076 2.104 1.530 0.896 
Mean 0.156 0.114 0.075 2.087 1.552 0.920 
Standard deviation 0.007 0.001 0.001 0.024 0.031 0.033 
 
Table 2.3 Effect of serum dilution on direct OPG ELISA 
Plate reader absorbance values (arbitrary units) are shown with varying dilutions of 
a sample known to be negative for OPG antibodies(negative control), as well as 
serum from the index case (positive control). Results of duplicate experiments are 
shown. 
 
An inherent difficulty with this approach is that no human antibody to OPG is 
commercially available, and so the primary antibody used to generate a standard 
curve is necessarily from a different species than that in the assayed samples (ie a 
commercial polyclonal antibody raised in rabbit to OPG was used to form a standard 
curve initially). As a result there will be an inherent difference in the affinity of the 
labelled secondary antibody for the primary antibody in the assayed samples 
compared to the standard curve. This potentially introduces error both within assays, 
for example at differing concentrations of sample, and between assays, for example 
if the affinity of the reaction is differentially affected by environmental factors.  
 
Initially this was accepted as an unavoidable hazard and a first iteration of the ELISA 
using a rabbit polyclonal antibody to derive a standard curve was used (referred to 
throughout thesis as ELISA I – protocol given in Section 2.3.4). Results from a 
number of populations are reported with this assay. Subsequently a generous 
donation of serum from the index patient meant that there was sufficient serum to use 
to derive a standard curve in all the assays that we intended to run, thereby avoiding 
this problem altogether.  From this point on serial dilutions of index patient serum 
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were used to create a standard curve, with an arbitrary value of 100 units assigned to 
the absorbance reading obtained by a sample of serum from the index patient. This 
iteration of the assay is referred to as ELISA II (protocol given in Section 2.3.6). 
Both protocols utilise similar conditions to coat the plates, assay samples and 
measure levels of antibody however in ELISA I a normal range for the assay was 
derived from a small cohort of healthy volunteers within the department, and for 
ELISA II a larger cohort of healthy volunteers taken from the ORCADES population 
was used to derive a normal range (standardization of assays described in detail in 
Section 2.3.3 and Section 2.3.5).  
 
2.3.3 Standardisation of ELISA I 
A linear standard curve was produced using serial dilutions from 5 to 500pg/μl of a 
rabbit polyclonal antibody to OPG (Figure 2.9).  This allows a quantification of the 
signal obtained for assayed samples, which since they were typically measured at a 
1/1000 dilution yielded final antibody concentrations measured in ng/μl. A signal 
that is close to the background signal is seen with the negative control and 
approximately ten fold increases in signal with the positive control suggesting that 






Figure 2.9 Indicative standard curve for direct OPG antibody ELISA I illustrating 
also the value of serum from index case (black square) and a sample from healthy 
volunteer (asterix). Standard curve for the assay was derived from increasing 
concentrations of rabbit polyclonal antibody to OPG between 5 and 500ng/µl. Plate 
reader absorbance is close to background for sample negative for OPG antibodies, 
with enhanced signal seen with serum from index case. 
 
Whilst a linear standard curve was originally fitted to the data a plateau effect was 
observed that was non-linear. The plate reader software included a spline analysis 
function to determine concentration more accurately in this situation. A sample 
standard curve including standard deviations for each reading and showing spline 











































Figure 2.10 Standard curve of ELISA 1 showing spline and linear fit 
 
In order to generate a normal range and so allow categorisation of the presence of 
raised titres of OPG antibody, serum was obtained from 20 healthy volunteers of 
known normal bone density working within the department of medical physics, or 
the Institute of Genetics &Molecular Medicine. Volunteers were of average age 48 
(±7), average BMI 23.75 (±5) and 14/20 female (70%). The distribution of OPG 
antibodies within the healthy volunteer cohort is illustrated in Figure 2.11. Mean 
OPG antibody titre was 19.39 ng/µl (±23.94). A threshold was chosen of mean plus 3 
standard deviations equivalent to 91.21 ng/µl which lies above the 100th percentile 

























































Figure 2.11 Frequency distribution of OPG antibodies in 20 healthy volunteers with 
normal bone density using ELISA I. Dotted line represents the threshold used to 
describe positive OPG antibodies derived from the mean plus three standard 
deviations (91 ng/µl). 
 
 
2.3.4 Protocol for ELISA I 
In subsequent results sections where this iteration of the assay are used (with a 
standard curve based on commercial-labelled OPG antibody) the assay is referred to 
as ELISA I, with this protocol now described in detail. Human recombinant OPG 
(R&D Systems) was reconstituted to prepare an OPG stock solution of 100ug/ml by 
adding 250μl of 0.2um filtered PBS to 25ug lyophilised powder. Reconstituted OPG 
was stored in the same vial at 4oC for later use. OPG stock (100 ng/μl) was diluted to 
0.3ng/μl using 16μl stock + 5,319μl of coating buffer per plate. Coating buffer 
(Sigma) is prepared by dissolving 1 capsule in 100ml distilled water. 
 
50μl aliquots of the diluted OPG solution were added to all wells of a Costar high-

















plate was sealed with a plate sealer and incubated at 4oC for approximately 24 hours 
(±1 hour). 
 
The plate was washed seven times in TBST wash buffer (Appendix 3.3) and dried 
thoroughly. Plate was blocked by addition of 300μl of 1% BSA blocking buffer (1g 
BSA in 100ml TBST) to each well, and incubated at 24oC for 2 hours. After incubation, 
the plate was washed seven times and dried thoroughly. 
 
To create a standard curve, a non-biotinylated polyclonal rabbit antibody to OPG was 
used (Abcam ab9986) from a stock solution at 500ng/µl. Briefly 3 µl of stock was 
added to 7,797µl of buffer giving a concentration of 192pg/ µl with doubling 
dilutions used down to 3pg/µl. 50μl of sample was added to each well to give a 
standard curve of 9.6ng down to 0.15ng per well. 
 
Serum was obtained from the index case and unselected patients after giving informed 
consent. Positive control serum from the index case was used at a dilution of 1 in 6,000, 
negative control serum and serum under investigation was used at a dilution of 1 in 
2,000. Dilutions were prepared in a standard micro-titre plate and used at a final 
volume of 50μl added to each plate. The well contents were mixed by gently tapping 
the plate for approximately 1 minute. The plate was then re-covered and incubated at 
37oC for 1.5 hours. 
 
After incubation, the plate was washed eight times and dried thoroughly. Secondary 
peroxidase conjugated anti-human detection antibody (Jackson) was diluted 
1:40,000 and added at a volume of 100μl per well. The plate was re-covered and 
incubated at 24oC for 1.5 hours. 
 
Colour development: After incubation, the plate was washed eight times and dried. To 
each test well of the plate 100μl of tetramethylbenzidine (TMB) substrate solution 
(Sigma) was added and the plate was incubated at 24oC for 20 minutes to permit colour 
development (plate was covered with foil to protect from direct light). 100μl of TMB 
stop solution (KPL) was then added to each well of the plate. Optical density for 
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samples in all wells was measured at 450nm within 30 minutes of adding the stop 
solution. An automated spline analysis (using plate reader software) was used to 
determine the sample concentrations. 
2.3.5 Standardisation of ELISA II 
As discussed in 2.3.2, and following a generous donation of serum, serial dilutions of 
serum from the index patient were used to generate the standard curve for the 
ELISA. A value of 100 relative units (RU) was adopted for serum from the index 
patient. A sample standard curve generated by the plate reader is shown in Figure 
2.12. There is saturation of signal with increasing concentration of positive control 
serum, with a logistic curve chosen to best fit the standard curve. Positive samples 
that fell on the non-linear part of the curve were re-analysed after dilution.  
 
Figure 2.12 Standard curve utilising serial dilutions of index case serum. An 
arbitrary value of 100 units is assigned to neat serum such that the starting dilution 
of 1/2500 is assigned a value of 0.04, from which doubling dilutions were derived to 
generate a standard curve. Samples are assayed at 1/1000 dilution but final 
























Serial dilutions of index patient serum (Relative units)




Typically readings for patient samples generated results that were greater than the 
lowest dilutions of the standard curve using index serum, suggesting that non-
specific serum effects were still influencing readings in healthy patients. 101 samples 
from healthy volunteers taken from the ORCADES cohort and with known normal 
bone mineral density were used to generate a reference range for the ELISA II assay. 
The mean reading obtained was 3.45 RU (±3.62) with a threshold of 14.31 RU 
adopted of the mean of healthy volunteers plus three standard deviations which 
would be expected to exclude the vast majority of negative samples. Since the results 
from these volunteers did not follow a strictly normal distribution (Figure 2.13) this 
threshold corresponded to a 98th percentile for healthy volunteers. In view of the 
arbitrary nature of this threshold, all analyses were also repeated using the absolute 
titre of OPG antibody. 
 
Figure 2.13 Frequency distribution of OPG antibodies in healthy volunteers with 
normal bone density measured using ELISA II. Dotted line represents the threshold 








OPG antibody concentration in healthy controls (RU)
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2.3.6 Protocol for ELISA II 
The second iteration of the direct ELISA assay using positive control serum to 
provide a standard curve is referred to as ELISA II. In a minor modification to the 
protocol the plates were not dried after coating with OPG lest this influence protein 
integrity. As before, human recombinant OPG (R&D Systems) was reconstituted to 
prepare an OPG stock solution of 100μg/ml by adding 250μl of 0.2um filtered PBS 
to 25ug lyophilised powder. Reconstituted OPG was stored in the same vial at 4oC 
for later use. OPG stock (100ng/μl) was diluted to 1ng/μl using 99μl stock + 9801μl 
of coating buffer per plate. Coating buffer (Sigma) is prepared by dissolving 1 
capsule in 100ml distilled water.  
 
100μl of diluted OPG is added to all wells of a Costar high-binding micro-titre plate 
(Corning), giving a final total of 100ng OPG per well. The plate was sealed with a 
plate sealer and incubated at 4oC for approximately 24 hours (±1 hour). Subsequently 
the wells are washed twice with 200μl/well of wash buffer for 5 minutes. 
 
200μl/well of 3% BSA blocking buffer is then added to each well for 1 hour at room 
temperature (3g of BSA added to 100ml of PBS). In this time a standard curve of 
positive control serum is prepared from a fresh aliquot of the index serum This is 
diluted 1 in 100 in binding buffer, with further dilutions taken to give 300μl of the 
positive control at dilutions of 1/2,500, 1/5,000, 1/10,000, 1/20,000, 1/25,000 and 
1/50,000. An arbitrary value of 100 units was assigned to neat positive serum, 
yielding a standard curve from 0.04 down to 0.002 units. Samples falling below the 
lower limit of the standard curve are assigned 0 for further analysis. Samples to be 
analysed were diluted 1/1000 in binding buffer (typically 2μl of the sample is added 
to 198μl of binding buffer, with a second dilution step of 30μl added to 270μl of 
binding buffer). 
 
Blocking solution is removed from each well and the samples added at a volume of 
100μl/well, and incubated for 1 hour at room temperature. After incubation, the plate 
was washed five times with 200μl/well of wash buffer. Secondary peroxidase 
conjugated anti-human detection antibody (Jackson) was diluted 1:20,000 and added 
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at a volume of 100μl per well. The plate was re-covered and incubated at room 
temperature for 1 hour. 
 
Colour development: after incubation, the plate was washed five times. To each test 
well of the plate, 100μl of TMB substrate solution (Sigma) was added and the plate 
was incubated at 24oC for 30 minutes to permit colour development (plate was 
covered with foil to protect from direct light). 100μl of TMB stop solution (KPL) 
was then added to each well of the plate. Optical density for samples in all wells was 
measured at 450nm within 30 minutes of adding the stop solution, with a reference 
wavelength of 640nm. An automated four parameter analysis (using plate reader 
software) was used to determine the sample concentrations. 
 
2.4 Commercial assays of OPG and RANKL 
Commercial ELISA assays for both free (Biomedica) and total (Biovendor) RANKL 
as well as OPG (Biomedica) were purchased and utilised according to 
manufacturers’ instructions. Unless otherwise stated all reaction steps were carried 
out at room temperature 
2.4.1 Human Ampli-sRANKL ELISA (free RANKL) 
A commercial ELISA assay for total free sRANKL was used according to 
manufacturer’s instructions (Biomedica BI-20452). Standards and control were 
reconstituted by adding 700μl of deionised water to each and leaving for at least 15 
minutes. All reagents and samples (undiluted) were brought to room temperature 
prior to assay. Wash buffer was prepared by adding 50ml of the supplied stock 
Washbuffer to 950ml distilled water and this was stored at room temperature until 
required. 100μl of the standards and the control were pipetted in duplicate into 
respective wells. Additionally, 100μl of the serum samples to be tested was added to 
the respective wells. For the duplicate sample, 10μl of the same serum samples were 
added to the desired wells and in these wells 90μl of wash buffer had already been 




To each well (including the blank), 100μl of solution AB (green cap) was added and 
the plates swirled gently to mix. Plates were sealed tightly and incubated overnight 
with vigorous shaking. 
 
After incubation, wells were aspirated and washed five times with 300μl of wash 
buffer. Remaining wash buffer was removed by tapping onto paper towels after the 
last wash. 
 
200μl CONJ solution (Amber cap) was added into each well, the plates were sealed 
tightly and incubated for 1 hour (no shaking). After incubation plates were washed 
five times. Amplifier A and B were squeezed into clean troughs, then 100μl 
Amplifier A (Blue cap) was added to each well. Subsequently, 100μl Amplifier B 
(Red cap) was added to each well and the plate incubated for 25 min (no shaking). 
 
At this point the pink/red colour had developed substantially and so the plate was 
read quickly at 490nm. The highest standard had an optical density value of 
approximately 2.0 and the blank a value of less than 0.2. Therefore, the reaction was 
stopped by addition of 50μl STOP solution (White cap) to each well. The absorbance 
at 490nm, with reference of 630nm was then immediately measured. 
2.4.2 Human sRANKL ELISA (total RANKL) 
A commercial ELISA assay for total human sRANKL was used according to the 
manufacturer’s instructions (Biovendor RD193004200R). The master standard and 
the high and low quality controls were reconstituted with dilution buffer using the 
volumes stated on the Certificate of Analysis just prior to assay. These were left for 
15 minutes with gentle shaking.  
 
The following standards were prepared using the reconstituted master standard. 
Serum samples were diluted by adding 2.5μl sample to 247.5μl of dilution buffer. 
100μl of Standards, Controls, Dilution buffer (Blank) and Samples were pipetted (in 
duplicate) into the appropriate wells. Due to low volumes for serum samples only 
90μl was used per well. Plate was incubated at 2–8 oC overnight with shaking at 
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approximately 300 rpm. Biotin labelled antibody was brought to room temperature 
overnight 
 
Wash solution was diluted by adding 100ml of concentrate to 900ml of distilled 
water, using 350μl of this wash solution the wells of the plates were washed five 
times. After the final wash, plates were tapped onto paper towels to dry. 
 
100μl of biotin labelled antibody was added to each well and the plates incubated for 
1 hour with shaking (300rpm). Wells were washed five times, then 100μl of 
Streptavidin-horse radish peroxidase (HRP) Conjugate was added to each well. The 
plates were incubated for 1 hour with shaking. Wells were again washed five times 
then 100μl of Substrate solution was added to each well. The plate was covered with 
foil to protect from light and incubated for 25 minutes. 
 
The colour development was stopped by addition of 100μl of stop solution. 
Subsequently, the absorbance at 450nm was determined (with a reference of 630nm). 
The blank OD 450 value was subtracted from 450nm readings as was the reading at 
630 nm (subtracted from the 450nm value). 
 
2.4.3 Human OPG ELISA 
A commercial assay for human OPG was utilised according to manufacturer’s 
instructions (Biomedica, BI-20403). The master standard and the high and low 
quality controls were reconstituted with dilution buffer using the volume stated on 
the Certificate of Analysis, just prior to assay. These were left for 15 minutes with 
gentle shaking (without allowing to foam). 
 
Assay standards were prepared as below: the prepared standards and the 
reconstituted high and low controls were further diluted three fold with dilution 
buffer (100μl standard and 200μl of dilution buffer). Serum samples were similarly 
diluted three fold (100μl sample and 200μl of dilution buffer). 100μl of the diluted 
Standards, Controls, Dilution buffer (Blank) and Samples (in duplicate) were 
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pipetted into the appropriate wells. Plates were incubated for 1 hour with shaking at 
approximately 300 rpm. 
 
Wash solution was diluted by adding 100ml of concentrate to 900ml of distilled 
water. Subsequently, the wells were washed three times with 350μl of the prepared 
wash solution. After the final wash plates were inverted onto paper towels to dry. 
100μl of Biotin labelled Ab was added to each well and the plates incubated for 1 
hour with shaking (300rpm). Wells were washed three times then 100μl of 
Streptavidin-HRP Conjugate was added to each well and the plates incubated for 30 
minutes with shaking. Wells were washed three times then 100μl substrate solution 
was added to each well. The plates were covered with foil to protect from light and 
incubated for 10 minutes. Colour development was then stopped by the addition of 
100μl of stop solution. The absorbance at 450nm (with a reference of 630nm) was 
determined. After subtracting the blanks absorbance values from the 450nm values, 
the 630nm reading was also subtracted from that at 450nm. 
 
2.5 Assessment of vascular calcification on lateral image DEXA 
DEXA scanning was performed using a Hologic QDR4500 densitometer. Whilst CT 
scanning is the gold standard for assessing vascular calcification a simple scoring 
system based on the lateral lumbar spine image obtained at DEXA scanning has been 
shown to have reasonable agreement with CT, and offers great advantages in terms 
of safety and convenience184.  
 
A simple semi-quantitative 8-point scoring system has been derived based on 
assessments of the anterior and posterior aortic wall on the lateral image DEXA of 
lumbar vertebrae (L1–L4), with each wall scored between 0 to 4 (Figure 2.14). High 
correlation was found between this score and a more detailed 24 point score (r=0.98, 
p<0.0001) and the latter score was in turn shown to have a sensitivity of between 
56% and 71%, and specificity between 80% and 63% when compared to varying 
thresholds of CT determined aortic calcification184. The 24-point score is also 
calculated based on the extent of calcification observed adjacent to the lumbar 

















Figure 2.14 Vascular calcification scoring of lateral image DEXA scan   
A score of 0 is given if there is no calcification, 1 if the extent of calcification is equal 
to or less than the height of one vertebra, 2 if calcification is greater than one 
vertebra but equal to or less than the height of two vertebrae and so on. (a)Sample 
image from ORCADES showing extensive vascular calcification. (b)In this example 
the anterior aortic wall scores 2 and posterior wall 3 giving a total score of 5.  
 
on whether there is no calcification (0), calcification involves less than 1/3 of the 
vertebral height (1), calcification involves between 1/3 and 2/3 of the vertebral height 
(2) and calcification involving more than 2/3 of the vertebral height (3). Both anterior 
and posterior aortic walls are scored to give a maximum possible score of 24. Vascular 
calcification was assessed in patients from a general population cohort who had 
undergone DEXA scanning as part of the ORCADES study (described in detail in 
Section 2.3.3) using this method. 
 
Similarly a semi-quantitative technique has been described to detect prevalent 








2.6 Study populations 
A number of different populations were studied in the course of this thesis and the 
details of how each has been derived are listed here. A summary of the 
characteristics available for analysis in each cohort is given in table 2.4.  
 
Characteristic ORCADES Coeliac OP IBD 
Age     
Gender     
Height     
Weight     
Spine BMD T-score      
Spine BMD Z-score      
Hip BMD T-score     




    
Co-morbidities     
Current smoker     
Alcohol 
(units/week) 
    
Serum ALP, Ca     
Additional disease 
specific factors 





















2.6.1 ORCADES cohort 
The Orkney Complex Disease (ORCADES) study is a population-based study for 
health research, designed to identify genetic risk factors for complex diseases 
(Orkney Research Ethics Committee approval - 27/02/2004). Exceptionally high 
recruitment has yielded a cohort of 2000 healthy volunteers whose grandparents 
originated from the Orkney Islands (from a total population of 12000). The study is 
cross-sectional in nature. The average age is 53 years (range 18–100 years), and 
approximately 42% are male. Up to 200 different traits have been measured in each 
individual. Bone mineral density assessed by DEXA is available in 1,578 patients. 
Data are also available on subjects’ medical and surgical history, medication, family 
history, diet, smoking, alcohol, physical activity, angina, claudication, lung 
symptoms and socio-economic status.  All participants are flagged at Information 
Statistics Division (NHS Scotland) for deaths and hospital admissions allowing 
prospective analysis of the value of biomarkers in predicting major health events. A 
bank of stored plasma, serum and whole blood was made available by Dr James 
Wilson. I played no part in the recruitment of these patients, though assisted in the 
cataloguing of the approximately 2000 samples.  
2.6.2 Osteoporosis Cohort 
All patients attending the osteoporosis service at the Western General Hospital in 
Edinburgh, including the index case, were invited to contribute a blood sample to 
support ongoing research. Appropriate approval from the local research ethics 
committee (reference 04/S1102/41) was in place to recruit patients attending the 
clinic, though an amendment was agreed to allow direct recruitment of patients that 
had previously attended the department in addition. BMD measurements were 
performed in line with routine clinical care. At time of DEXA scanning detailed 
information on risk factors for osteoporosis was recorded including patient 
demographics, body mass index (BMI), lifestyle factors and calcium intake (a copy 
of the questionnaire is given in Appendix A5). 
2.6.3 Coeliac and Inflammatory Bowel Disease Cohorts 
A cohort of patients with coeliac disease was recruited over the course of this study 
with approval of local research ethics committee (reference 10/S1402/33). All 
62 
 
patients attending coeliac disease clinics across Lothian were invited to give serum 
samples. BMD measurements were performed in line with routine clinical care. At 
time of DEXA scanning detailed information on risk factors for osteoporosis was 
recorded including patient demographics, BMI, lifestyle factors and calcium intake. 
Specific permission has been obtained for ongoing surveillance of these patients for 
complications obtained by record linkage. The Inflammatory Bowel Disease cohort 
samples had been collected already under the supervision of Professor Jack Satsangi 
from patients attending gastroenterology clinics in NHS Lothian. Results from this 
cohort have been previously published, with extensive phenotype data obtained by 
case note review148. 
2.7 Statistical Analysis 
Two-tailed independent student t-tests were applied for between group comparisons 
of normally distributed data.  Results are displayed as mean ± standard deviation 
(SD).    A Mann Whitney U test (MWU) was applied when the variables were not 
normally distributed, with results given as median (interquartile range IQR). 
Comparison of proportions was performed using the Chi-square test of 
independence, or Fishers Exact test for categorical variables where expected values 
in any cell of the contingency table are less than 5, with results displayed as 
frequency (percentages). Linear regression modelling was performed to identify 
significant predictors of bone density at the spine and the hip, with model variables 
entered either as categorical variables such as sex, or continuous variables such as 
age, weight, height or OPG antibody concentration.  Regression diagnostics were 
performed in minitab with the distribution of response variables and residuals of the 
models visually inspected, and tested for normality using the Anderson-Darling test. 
Histograms of model variables were visually inspected to identify outliers and assess 
for normality. Correlation testing for non-normally distributed data was performed 
using Spearman’s rank test on SPSS. All p-values of <0.05 were considered 
significant. 
 
Statistical analysis was performed using Minitab version 16 (Minitab Inc., 
Pennsylvania, US) or the Statistical Package for Social Services version 19 (SPSS 
IBM Corp, NY State, US).  
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Chapter 3: Severe osteoporosis due to neutralising 




Osteoporosis is a recognized complication of coeliac disease which is generally 
considered to be secondary to malabsorption of calcium, vitamin D and other 
nutrients. This study describes the occurrence of severe osteoporosis in a patient with 
coeliac disease who had developed neutralising antibodies to OPG.  
3.1.2 Patient, Methods and Results 
 A 40 year old man presented with severe osteoporosis with a BMD T score at the 
lumbar spine of -6.6; a low trauma fracture of the clavicle and raised biochemical 
markers of bone turnover about 20 times the normal range. Investigations revealed 
evidence of coeliac disease and primary hypothyroidism but other causes of 
osteoporosis were excluded. He was advised on a gluten-free diet, and prescribed 
calcium and vitamin D supplements as well as thyroxine replacement, but the 
osteoporosis progressed with further bone loss and the development of fragility 
fractures of the spine and humerus. Good compliance with his gluten free diet was 
confirmed on a repeat duodenal biopsy. On further investigation, autoantibodies to 
OPG were detected in the patient’s serum by an immunoprecipitation assay and the 
immunoglobulin fraction from patient’s serum blocked the inhibitory effect of OPG 
on RANK signalling in vitro.  No evidence of OPG autoantibodies was found in 10 
controls or 14 patients with hypothyroidism but autoantibodies to OPG were detected 
in 3/15 unselected patients with coeliac disease. 
3.1.3 Conclusion 
These studies demonstrate the presence of neutralising autoantibodies to OPG in a 
patient with high bone turnover osteoporosis, and raise the possibility that OPG 




3.2 Case report 
A 40-year-old Caucasian man, previously in good health, presented with a low 
trauma fracture of the left clavicle sustained in a trial of strength with his 13-year-old 
son. He had no previous history of fracture despite having played rugby during his 
20s and 30s. DEXA performed using a Hologic QDR4500 densitometer detected low 
levels of BMD with a T score of –6.6 at the spine (L1–L4) and –2.9 at the femoral 
neck. Routine investigations showed an elevated total alkaline phosphatase (ALP) 
(2610U/L; normal 25-120U/L), an elevated serum phosphate (2.36mmol/L; normal 
0.8–1.4mmol/L) but normal serum calcium, albumin, urea and electrolytes, liver 
function tests and full blood count. Isoenzyme studies showed that the raised ALP 
was of bony origin. Serum PTH was low (8ng/L; normal 10–65ng/L), and serum 
25(OH)D was 33nmol/L (normal 25–150nmol/L). A short synacthen test was 
normal. He was screened for primary hypothyroidism since he had experienced cold 
intolerance and lack of energy over the 12 months prior to presentation. Serum free 
thyroxine was <5pmol/L (normal 10–20), TSH was raised (>65 mU/L; normal 2-
5mU/L) and anti-thyroid peroxidase antibodies were detected (243u/ml; normal 0–
82u/ml). Tests for TSH receptor blocking antibodies186 were negative. Serum 
testosterone and gonadotrophins were normal. He was commenced on L-thyroxine 
100mcg daily, but ALP levels increased further to 3595U/L and hypercalcaemia 
developed (2.8mmol/L; normal 2.1–2.6mmol/L). At this point serum PTH and 
1,25(OH)2D3 were undetectable and urinary calcium/creatinine ratio was elevated 
(4.78; normal <0.5) consistent with a resorptive mechanism of hypercalcaemia187. 
The hypercalcaemia resolved with intravenous rehydration. A transiliac bone biopsy 
was performed without tetracycline pre-labelling. This showed high bone turnover 
and woven bone (Figure 3.1a); the extent of osteoid seams was increased but 
thickness was normal (Figure 3.1b). Investigations were performed to exclude occult 
malignancy including bone marrow biopsy, CT scan of chest, abdomen and pelvis 
and measurements of serum PTH-related protein but the results were normal. A 
radionuclide bone scan showed a generalised increase in tracer uptake but no focal 
lesions (Figure 3.1c). Titres of transglutaminase IgA antibodies were raised (101u/L; 
normal 5-30u/L) and occult coeliac disease was confirmed by small bowel biopsy. 
65 
 
Treatment was commenced with a gluten-free diet, ergocalciferol 10,000 units daily 

















Figure 3.1 Clinical and histological features of the patient  
Panel a. Photomicrograph of transiliac bone specimen stained with haematoxylin 
and eosin showing the increase in osteoclast numbers (red arrows) and osteoblast 
numbers (blue arrows). Woven bone is present throughout the biopsy as evidenced 
by the irregular cement lines. The inset shows a higher power view, illustrating the 
irregular cement lines. Panel b. Photomicrograph of transiliac bone specimen 
stained with toluidine blue illustrating increased extent of osteoid seams of normal 
thickness. Panel c. Radionuclide bone scan showing generalised increase in tracer 
uptake, but no focal lesions.  Panel d. Radiograph of the lumbar spine showing 
osteopenia and multiple vertebral compression fractures 
 
a period of 6 months, but the osteoporosis deteriorated with an 8% decrease in spine 
BMD to a T-score of -7.1 (Figure 3.2a). He suffered a low trauma fracture of the left 




the fact that repeat duodenal biopsy showed normalisation of bowel histology and 
serum 25(OH)D3 levels were normal (68nmol/L). Serum OPG was measured by 
ELISA (Biomedica, Oxford Biosystems, Oxford UK) on two occasions 
approximately 4 weeks apart and levels were 0.78 and 0.47pmol/L respectively 
(normal 0.14–130). Serum total RANKL levels measured by ELISA (Apotech, 
Epalinges, Switzerland) at the same time points were 0.152 and 0.143nmol/L 
respectively (normal 0–10). 
Urinary deoxypyridinoline(DPD)/creatinine values were measured at this point and 
were about 20 times above the upper limit of normal (93nmol/mmol creatinine; 
normal 2.3–5.4). Alkaline phosphatase normalised following treatment with a gluten-
free diet, calcium and vitamin D, but urinary DPD remained grossly elevated.  
 
3.3 Differential diagnosis 
A number of potential diagnoses were considered. An inherited form of osteoporosis 
was excluded by the late onset of the disease and the fact that the patient had never 
previously sustained a fracture despite leading an active lifestyle, for example 
regularly playing rugby whilst in his 20s. Osteoporosis and osteomalacia are known 
complications of coeliac disease due to malabsorption and the effects of calcium and 
vitamin D deficiency161, 188. The severity of the osteoporosis and dramatic elevation 
in bone turnover observed in this patient is out of keeping with that usually observed 
in coeliac disease however 161, 188, 189, and the patient’s failure to respond to a gluten-
free diet, and calcium and vitamin D supplements, argued strongly against coeliac 
disease as the primary cause of the bone disease. Whilst extensive seams of osteoid 
were observed on his bone biopsy these were of normal thickness, unlike the 
thickened osteoid seams expected in osteomalacia. It would be most unusual for a 
patient with osteomalacia to develop hypercalcaemia, and again the patient failed to 
respond to effective therapy for osteomalacia.  
 
Fibrogenesis imperfecta ossium (FIO) was also considered since it presents in 
adulthood with fragility fractures and a mineralisation defect190. The clinical features 
in our patient were quite distinct from those described in FIO however, which is 
characterised by trabecular thickening on radiographs, accumulation of thick osteoid 
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on bone biopsy and a poor response to treatment. It was difficult to reconcile the 
development of autoimmune hypothyroidism with his high bone turnover state since 
increased TSH  would be expected to suppress bone turnover164. We therefore 
speculated that the patient might have developed inhibitory antibodies to the TSH 
receptor. We looked for evidence of such antibodies using the methods of Minich et 
al186 but these results were negative.  
The severity of the bone disease and clinical deterioration despite treatment of the 
coeliac disease and supplementation with calcium and vitamin D was matched only 
by the remarkable recovery that occurred in response to treatment with the potent 
inhibitor of osteoclastic bone resorption, zoledronic acid. These observations 
underscored the importance of elevated bone turnover as the primary cause for this 
patient’s osteoporosis and would be compatible with an acquired defect of OPG. This 
coincided with the development of autoantibodies against thyroid peroxidase and 
tissue transglutaminase.  
 
The high turnover osteoporosis, elevation in ALP and fragility fractures were 
consistent with the reported phenotype seen in mice with targeted inactivation of the 
gene encoding OPG 106 and in humans with juvenile Paget’s disease who have 
inactivating mutations in OPG 126, 182. Further studies were therefore initiated to 
determine the cause of the increase in bone turnover focusing on the possibility that 
he might have developed neutralising antibodies to OPG, in view of the high bone 
turnover and autoimmune diathesis. 
3.4 Identification of OPG autoantibodies 
The patient’s serum immunoprecipitated OPG, reflected by appearance of a strong 
band at 55Kd on the Western blot (Figure 3.2 a and b, arrows lane 2). Sera from 10 
healthy controls and 14 patients with primary hypothyroidism yielded negative 
results (representative blot shown Figure 3.2 panel a), but 3/15 samples from patients 
with coeliac disease yielded positive results, albeit with lower intensity than the 
index case (Figure 3.2 panel b, lanes 10-12). Equal loading of the samples was 
confirmed by probing the same blots for total immunoglobulin (lower half of each 
panel, labelled anti human IgG). The immunoprecipitation assay was repeated in the 
presence of gliadin, but this had no effect on the ability of the index patient’s serum 
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to immunoprecipitate OPG suggesting that the OPG autoantibodies did not cross 




Figure 3.2 Identification of OPG antibodies by immunoprecipitation 
Figure 3.2a The top panel shows the presence of autoantibodies directed against 
OPG in the patient’s serum (lane 2- arrow), reflected by the detection of a strong 
~55 Kd band on western blot by an anti-OPG antibody following 
immunoprecipitation. Lane 1 shows a negative control. Samples from healthy 
controls (lanes 3-10) showed no evidence of OPG antibodies. Figure 3.2b again 
shows a robust ~55Kd band recognised by anti-OPG antibody following 
immunoprecipitation by patient serum (lane 2). In addition 3/15 samples from 
patients with coeliac disease also showed the 55Kd band consistent with anti-OPG 
antibodies (lanes 9–12). In each case the lower panel is stained for immunoglobulin 
and confirms equal loading of the gel. The result shown is representative of three 
independent experiments. Molecular weight markers of 80, 60 and 50kDa are shown 
(lane MWM). 
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3.5 Functional inhibition of OPG by patient immunoglobulins 
The ability of immunoglobulins purified from the index patient’s serum to overcome 
the activity of OPG was next assessed in a cellular assay.  Immunoglobulins were 
purified on protein G spin columns to avoid any non-specific serum effects on the 
cells and a final dilution of 1 in 40 used (Methods 2.2.1). Functional inhibition of 
RANKL signalling by OPG was demonstrated in a HEK293 cell line stably 
expressing a NFκB luciferase reporter (protocol described in detail in Methods 2.2.3) 




Figure 3.3 Functional inhibition of OPG by patient serum 
Patient serum, but not control serum abrogates the inhibitory effect of 100ng/mL 
OPG on RANKL stimulated NFκB activation in HEK293 cells. Addition of 400ng/mL 
OPG (indicated +++) overcame the inhibition. *** p<0.001 from vehicle; ## 
p<0.01 from RANKL and from RANKL+ OPG + patient serum. The result is 
representative of three independent experiments. 
 
The addition of RANKL to the cell line at a concentration of 100ng/ml caused robust 





















































RANKL - + + + + - -
OPG - - + + +++ - -
Serum - - Control          Index case Index case Control       Index case
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OPG at a concentration of 100ng/ml in the presence of the immunoglobulin fraction 
from control serum, but in the presence of immunoglobulins purified from the index 
case’s serum, the inhibitory effect of OPG was lost. Addition of OPG at a higher 
concentration (400ng/ml) overcame the inhibition. Addition of immunoglobulin 
fractions from the patient and a control in the absence of RANKL had no significant 
effect on reporter gene expression. 
 
3.6 Progress of index case 
 
Following his bone biopsy which confirmed severe high bone turnover osteoporosis 
he was treated with three monthly infusions of zoledronic acid which normalised his 
markers of bone turnover (Figure 3.4). Following the first infusion, serum calcium 
decreased to 1.91mmol/L and this was accompanied by an elevation in PTH to 163 
ng/L and 1,25(OH)2D3 to 992pmol/L(normal 15–150pmol/L). No symptoms of 
hypocalcaemia were reported. Subsequently, serum calcium, PTH, 1,25(OH)2D3, 
ALP and urinary DPD/creatinine ratio returned to normal. When he was reviewed 42 
months after the original presentation, no further clinical fractures had occurred; his 
height had remained stable and there was no evidence of progression of the vertebral 
fractures; the spine BMD T-score had increased to –1.7, the femoral neck T-score to 

































Figure 3.4. Bone density, biochemical markers and response to treatment 
Panel a) Lumbar spine and femoral neck BMD at presentation and in response to 
treatment.  Lumbar spine BMD (LS-BMD) decreased by about 8% despite an 
extended period of treatment with a gluten-free diet, calcium and vitamin D (grey 
bar), but BMD progressively increased at both the spine and femoral neck (FN-
BMD) following treatment with zoledronic acid (arrows). Panel b) Urinary DPD and 
ALP levels at presentation and in response to treatment.  Serum ALP levels 
decreased from over 3000U/L to about100 U/L 
 
 
The index patient has remained under regular follow up since his initial presentation. 
He has kept in good health overall with no further fractures. Bone turnover has 

































































































presentation, a minor rise in ALP was noted associated with non-specific symptoms 
of arthralgia and malaise for which he received an infusion of 5mg zoledronate 
(Aclasta) that was effective in alleviating symptoms and restoring normal ALP. At 
this time he was also screened for the presence of vascular calcification with a CT 
scan of chest/abdomen/pelvis which revealed mild calcification in the carotid, 
abdominal and iliac arteries. After a further 2 years he once again developed minor 
elevation of ALP and on this occasion in view of the mechanism of his disease, as 
well as the known association of OPG deficiency with vascular calcification, the 
decision was made to switch his treatment to subcutaneous denosumab (Prolia). This 
is a monoclonal antibody blocking RANKL and was given in the usual osteoporosis 
treatment regime of 60mg every 6 months for a period of 2.5 years. Over this time he 
developed modest elevation of ALP and symptoms of arthralgia and malaise that 
responded only temporarily to denosumab injections. At his most recent attendance 




Figure 3.5 ALP levels in index case from presentation to most recent attendance. 
Treatment pulses of iv zoledronate indicated by vertical arrows, 6 monthly 































The remarkable improvement that was seen in BMD has been maintained over the 
last five years of follow up (Figure 3.6). An ELISA assay for OPG antibodies has 
been developed (full details of the protocol in Section 2.3.5: ELISA II) and using this 
assay in frozen serum samples from a variety of time points it is interesting to note 
that high levels of antibody are maintained throughout this time. Indeed the highest 
level is seen on the most recently obtained sample.  
 
 
Figure 3.6 Time course of bone density up to present day. Lumbar spine bone density 
T scores are marked with black squares (▪), Hip bone density T scores with black 
diamonds (♦) and levels of OPG antibody by ELISA (right hand scale in arbitrary 
units) in grey circle (●). 
3.7 Summary and Discussion 
The patient described here presented in adulthood with severe, high turnover 
osteoporosis associated with subclinical coeliac disease and autoimmune 
hypothyroidism. The patient had circulating antibodies to OPG and immunoglobulins 
purified from the patient’s serum, but not control sera, abolished the inhibitory effect 
of OPG on RANKL-induced NFκB signalling in vitro, consistent with the presence 
of neutralising antibodies to OPG. No evidence of circulating antibodies to OPG was 
found in sera from 10 healthy controls and 14 patients with autoimmune 






































































This is the first report of a bone disease occurring in association with the 
spontaneous development of antibodies to OPG. Whilst one patient has been 
described in whom treatment with a recombinant immunoglobulin Fc region-OPG 
construct led to the development of autoantibodies to the fusion protein, this did not 
result in a clinical illness 191. The mechanism by which OPG antibodies developed in 
the patient described here remains unclear, but autoantibodies to other circulating 
proteins have been reported to develop in patients with autoimmune disease 192 
which is also the case here. 
 
The patient described is unusual in many respects. His osteoporosis was extreme 
with bone density T score falling to a nadir of -7.1 in the spine and multiple vertebral 
fractures resulting in height loss of 6cm. Very high bone turnover was confirmed 
both on bone biopsy and in marked elevation of calcium, alkaline phosphatase and 
urinary deoxypyridinoline. Unlike many patients with coeliac disease there was no 
improvement in his bone density with a gluten-free diet and calcium and vitamin D 
replacement, yet his response to treatment with the anti-resorptive zoledronate 
(Aclasta) was astonishing. This raises the possibility that the identification of OPG 
antibodies in other coeliac patients might justify a more aggressive approach to the 
management of osteoporosis in these patients. 
 
Another lesson is in the very high level of OPG antibody observed in the most recent 
sample assayed from the index patient. Whilst it is possible that the delay in 
processing the stored samples may have led to sample degradation, these samples 
were all stored at -80˚C and it would normally be assumed that antibodies are stable 
in such conditions. This demonstrates at least that for some patients antibody persists 
even after treatment of associated autoimmune conditions. In turn, the persistence of 
OPG antibodies in the index case raises a number of cautions in interpreting the 
clinical significance of OPG antibodies. Firstly the response to treatment in the index 
case occurred despite persistently high OPG antibody levels. This does suggest that 
care must be taken in interpreting the association of BMD with presence of OPG 
antibodies in patients that have received anti-resorptive therapies. Such difficulties 
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are likely to make it more difficult to demonstrate an association between bone 
density and OPG antibodies in patients who have received treatment. This will be of 
most relevance in an osteoporosis cohort, though could attenuate associations seen in 
the coeliac populations too. It emphasises the importance of building a prospective 
cohort of patients in order to properly assess the evolution of bone disease associated 
with OPG antibodies.  
 
The immunoprecipitation assay also demonstrated the presence of anti-OPG 
antibodies in 3/15 coeliac patients studied. Whilst these observations raised the 
possibility that OPG antibodies might contribute to the pathogenesis of osteoporosis 
in coeliac disease more generally, the observations should be interpreted with caution 
since BMD is a complex trait which is influenced by many genetic and 
environmental factors. Overall these findings justify further research to determine if 
OPG antibodies are associated with the development or severity of osteoporosis in 
patients with autoimmune disease or in ‘idiopathic’ osteoporosis, and in turn whether 






Chapter 4: Performance of assays for OPG antibodies  
4.1 Abstract 
4.1.1 Introduction 
Neutralising antibodies to OPG have recently been identified using an 
immunoprecipitation assay and subsequently an ELISA. The suitability of these 
assays for population screening has not been characterised.  
4.1.2 Materials and Methods 
The immunoprecipitation assay uses the patient serum itself to precipitate 
recombinant OPG, with the protein then visualised by chemiluminescence on a 
Western blot (see Materials and Methods Section 2.1). An ELISA was developed 
using membrane bound OPG as a capture antigen. Two protocols were established 
the first using a commercial antibody to OPG to provide a standard curve (ELISA I - 
Section 2.3.3), and the second using serial dilutions of serum from the index case to 
derive a standard curve (ELISA II – Section 2.3.5). Full details of the patient 
populations screened are given in Section 2.6. 
4.1.3 Results 
A coefficient of variation of 50% was observed using the immunoprecipitation assay. 
An ELISA for OPG antibodies showed improved convenience of use, though still 
significant variation. ELISA I had an intra-assay variability of 11.1% and inter-assay 
variability of 30.4% in a cohort of 600 patients. ELISA II showed similar 
performance with an intra-assay variability of 12.9% and inter-assay variability of 
21.8% in a cohort of 192 patients. Circulating OPG and RANKL do not affect the 
assay though repeated freeze thaw cycles do reduce assay reproducibility.  
   
4.1.4 Conclusion 
The immunoprecipitation assay was not suitable for population screening. The 
ELISA showed improved reproducibility and convenience. Whilst there remains 




4.2 Reproducibility of immunoprecipitation assay 
OPG antibodies were first identified using an immunoprecipitation assay in which 
the test serum itself immunoprecipitates recombinant OPG from solution, and then a 
commercial anti-OPG antibody is used to label any precipitated protein on a Western 
blot. Using this approach, serum from patients with coeliac disease (n=46), multiple 
sclerosis (n=20), rheumatoid arthritis (n=10), thyroid disease (n=14) and severe 
osteoporosis (n=10) were screened for the presence of OPG antibodies 




Figure 4.1 Identification of OPG antibodies by immunoprecipitation from patients 
with coeliac disease (a) and multiple sclerosis (b). OPG immunoprecipitated by 
serum from the index case (highlighted by arrow) was used as a positive control in 
each set of samples assessed. Protein loading was assessed by reprobing with 
labelled antibody against human immunoglobulin (lower part of image).  
 
Using this technique, evidence of OPG precipitation was seen in serum from 15/46 
(33%) patients with coeliac disease, 2/10 (20%) patients with rheumatoid arthritis, 
Ab: anti human OPG
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1/10 (10%) patients with hypothyroidism and 8/10 (80%) patients with severe 
osteoporosis (defined as having bone mineral density T score less than -3.5).  
 
Whilst the technique has an attractive simplicity in concept there are substantial 
difficulties in interpreting these results. A weak positive band of OPG was often 
observed in the negative control in the absence of serum and despite pre-incubation 
of the agarose beads with albumin (Figure 4.1 a, first column) indicative of non-
specific binding of OPG by the agarose beads. This effect appears attenuated by use 
of a serum sample from a patient known to be negative for OPG antibodies (Figure 
4.1 b, first column) but still raises the possibility of false positive tests using this 
technique.  Despite standardisation of the protocols for protein loading and transfer, 
as well as duration of chemiluminescence exposure, the observed intensity of bands 
seen is highly variable undermining attempts at quantification of the signal seen (as 
seen in the arrowed bands in 4.1a and 4.1b). Expressing band intensity as a 
percentage of the signal seen in the positive control and with correction for protein 
loading was attempted but marked variability in the band intensity measured was 
seen. The inter-assay coefficient of variation in 10 coeliac samples was measured at 
48%, with no improvement in the coefficient of variation (CV) observed by 
increasing the number of replicates to five. Hence although these results give an 
indication of OPG recognition, it is difficult to provide any confident estimate of 
prevalence of OPG antibodies. 
4.3.1 Co-efficient of variation  of ELISA protocol I 
Serum from the index patient was included on every ELISA plate to act as a positive 
control, alongside serum from a patient known to be negative for OPG antibodies. 
The results of these quality control standards, as well as illustrative results for a 
sample of intermediate positivity are given in Table 4.1. Samples were analysed in 
duplicate wells, and on duplicate plates. In preliminary experiments very reasonable 
intra-assay variability of between 1 and 4% was noted for all quality controls, but a 





Stratification OPG Ab 
ng/µl (Rep 1) 
OPG Ab 




 CV % 
Low 28.9 (±1.1) 34.1 (±1.1) 3.9, 3.3 11.6 
Medium 227.6 (±0.7) 317 (±12.3) 0.31, 3.87 23.3 
High 364 (±5.7) 490 (±1.7) 1.57, 0.36 20.9 
 
Table 4.1 The effect of OPG antibody titre on coefficient of variation in ELISA 
protocol I. Assays were performed in duplicate on consecutive days. 
4.3.2 Effect of freeze thaw cycles on ELISA I performance 
The effects of repeated freeze thaw cycles on the results of OPG ELISA I were 
analysed in samples from the IBD cohort. Table 4.2 shows the baseline concentration 
of OPG antibody in a negative control, a weakly positive sample and serum from the 
index case. There is evidence of some degradation of the signal with repeated freeze 
thaw cycles which appears more marked in the sample with the lowest concentration 
of OPG antibody.  
 
Stratification OPG Ab (ng/µl)  % change d1 to d2 % change d2 to d3 
Low 37.5 (±13.4) -9.040 -60.173 
Medium 227.5(±0.7) +39.560 -19.0551 
High 376.9(±32.4) +31.464 -19.8789 
 
Table 4.2 The effect of repeated freeze thaw cycles on the measured OPG antibody 
concentration using ELISA I. Assays were performed in duplicate on consecutive 
days with overnight freezing at -80ºC. 
 
A further illustration of the adverse effects of multiple freeze thaw cycles was 
obtained by comparison of results in 38 samples that were sent to another lab for 
analysis of bone turnover markers. In this process samples underwent three freeze 
thaw cycles as well as being kept at 4˚C whilst being analysed. Comparison was 
made between samples analysed directly on defrosting of an original aliquot with 
these degraded samples. No correlation between the measured concentrations of 
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antibody were seen (Figure 4.3, R2 =1%, p=0.552). A significant increase in the 
mean OPG antibody concentration was observed in the degraded samples (mean 
OPG antibody concentration 56.28 ± 33.122ng/µl compared to 29.94 ± 25.45ng/µl, 
p<0.001) which may represent contamination of the samples.  
 
Figure 4.3 Effects of multiple freeze thaw cycles. No correlation observed between 
concentration of OPG antibody detected by ELISA I after repeated freeze thaw 
cycles. Most samples are below the threshold for a positive OPG antibody (marked 
by dotted line). 
4.3.3 Effect of circulating RANKL/OPG on OPG antibody ELISA I 
It is clearly possible that circulating OPG in the serum samples could compete with 
the capture OPG used in the assay, or that circulating sRANKL might recognise 
bound OPG and also interfere in the assay. To investigate this possibility we used a 
commercial ELISA for serum OPG and sRANKL to test a selection of serum 
samples for OPG and RANKL concentrations (Methods Section 2.4.1 to 2.4.3) 
Neither increasing OPG nor RANKL concentrations were associated with a 














































non-significant trend to increasing levels of OPG antibody in those samples with 
increased serum OPG concentrations was observed (Figure 4.4a, p=0.068) and with 
increased levels of total RANKL (Figure 4.4b, p=0.033). 
 
Figure 4.4 Correlation of OPG antibody concentration (ELISA I) with serum levels 
of circulating OPG (a) or total RANKL (b) 
 
One commercial ELISA for free sRANKL uses OPG as a capture antigen 
(Biomedica BI-20452). A number of samples in this assay had very low, or even 
undetectable levels including serum taken from the index case which suggests that 
there might be interference by OPG antibodies on the performance of this ELISA. 


























































Figure 4.5 Correlation of OPG antibodies measured by ELISA I with serum levels of 
free RANKL. 
 
No trend of any significance is observed in these samples (p=0.568). This is perhaps 
unsurprising given that most of the samples have low levels of OPG antibodies, but 
from this data it can be concluded that OPG antibodies are not a common cause of 
low or undetectable free RANKL in this assay.  
4.3.4 Comparison of serum and plasma with ELISA I 
Samples of plasma and serum samples taken at the same visit from 20 patients 
attending the rheumatology department were compared. The mean OPG Ab 
concentration measured did not differ significantly between the two samples (mean 
concentration in serum samples 60.2 ± 71.7ng/μl compared  to plasma samples 51.8 
± 70.3ng/μl, p=0.265). A highly significant correlation between the values obtained 
in plasma and serum was seen (r2=80.9%, p<0.001, Figure 4.6) suggesting that both 
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Figure 4.6 Correlation of OPG antibody concentration measured by ELISA I in 
plasma and serum. 
 
4.4 Coefficient of variation of ELISA protocol II 
 
In the revised version of the ELISA serum from the index patient was again included 
on every ELISA plate to act as a positive control, alongside serum from a patient 
known to be negative for OPG antibodies. The results of these quality control 
standards, as well as an illustrative result for a sample of intermediate positivity are 
given in Table 4.3. Samples were analysed in duplicate wells, and on duplicate 
plates. For positive samples a reasonable intra-assay CV of 1.1 to 8.2% is noted, and 
improved inter-assay CV of 11.5 to 12.7%. Higher variation is noted in the negative 
control sample presumably reflecting a greater influence of non-specific signal, and 
the inherent increase of CV with reduced mean sample values.   
 
  































Stratification OPG Ab 
ng/µl (Rep 1) 
OPG Ab 




 CV % 
Low 8.3 (±0.6) 6.7 (±1.1) 7.2, 16.4 15.1 
Medium  30.3(±1.5) 25.3(±2.1) 5.0, 8.2 12.7 
High  90.7(±1.2) 106.7(±1.2) 1.3, 1.1 11.5 
 
Table 4.3 The effect of OPG antibody titre on coefficient of variation in ELISA 
protocol II. Assays were performed in duplicate on consecutive days. 
 
4.5 Summary of ELISA characteristics 
For reference a summary of the characteristics of the two iterations of the ELISA 
assay are presented in Table 4.3. 
 
Characteristic ELISA I ELISA II 
Standard curve Polyclonal rabbit anti OPG Dilution of serum from 
index case 
Units ng/µl RU (relative units) 
Threshold for positive 
sample 
91ng/ul 14.3 RU 
Value of positive 
control 
364 to 490 ng/ul 90.7 to 106.7 RU 
(Standard 100RU) 
Intra-assay CV  Low 3.3 to3.9% 
High 0.36 to 1.6% 
Low 7.2 to 16.4% 
High 1.1 to 1.2% 





Table 4.3  Summary of characteristics of ELISA protocols I and II. 
 
4.6 Discussion  
Whilst the immunoprecipitation has an attractive simplicity in concept in practice 
there was high variability in the intensity of bands despite attempts to standardise the 
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assay, as well as concerns about false positive signals. Increased signals were seen in 
a small number of patients with severe osteoporosis as well as in the coeliac patients 
tested but it is difficult to quantify the levels of OPG antibody in these populations 
given the limitations of the assay.  In practical terms since it takes 48 hours to 
perform the assay in just 10 samples it would never be a suitable assay to use in 
screening of large populations and in view of all these limitations attention turned to 
developing a high throughput and quantifiable assay. 
 
Initially an indirect ELISA approach was adopted using commercial labelled anti-
OPG antibodies to provide a signal that test serum samples would compete out. Proof 
of principle was established with clear suppression of signal seen with serum from 
the index case (Section 2.3.1). A standard curve was constructed using unlabelled 
commercial anti OPG but even with very high levels of this antibody complete 
suppression of the background signal could not be achieved. Unfortunately even after 
optimisation of the concentrations of OPG, and the quantity and type  of primary 
antibody used, it became clear that this assay would lack the dynamic range needed 
to identify any but the most strongly positive of test samples.  
 
Subsequently a direct ELISA was developed. Using the lessons learned from the 
indirect assay, an assay was developed that was able to show greater than 10 fold 
increase in signalling with the positive control over negative serum samples, and 
appeared much more promising to use  as a screening tool. No direct effect of serum 
OPG or sRANKL levels on the performance of the ELISA was observed. The 
performance of the assay did appear to be affected by repeated freeze thaw cycles 
with substantial variability observed already after one, and particularly after two, 
freeze thaw cycles. An apparent increase in the concentration of antibody seen after 
freeze thaw may simply reflect day to day variability in the assay performance seen 
particularly with predominantly negative samples, but does raise concerns about 
interpretation of results in such samples. As a result samples were only analysed after 




A major challenge has been ensuring reproducibility of results using the direct 
ELISA. Refinements were made to the number of washes, the temperature and 
timing of labelling steps, the coating protocol as well as the plate reader algorithm 
itself. After optimisation ELISA I showed good intra-assay variability of 
approximately  0.4 to 3.9% but higher inter-assay variability of 11.6 to 20.9%. With 
the additional serum from the index case it was possible to create a standard curve 
using human immunoglobulin which avoids any criticism that having separate 
species of immunoglobulin in the test wells and the standard curve might have 
generated, as well as potentially removing a further cause in variation in day to day 
performance. In terms of reproducibility this assay performed similarly with average 
intra-assay CV of 1.1 to 16.4% and inter-assay CV of 11.5 to 16.1% overall. 
 
There is an inherent difficulty in assaying predominantly negative samples. Results 
are more likely to be influenced by non-specific effects and there is an inherent 
inflation of CV as absolute values near zero. Consequently whilst it remains an 
aspiration to develop an assay capable of demonstrating excellent reproducibility in 
all samples, it is more realistic to aim to achieve reproducibility in the positive 
samples. Here results are more encouraging with the most recent results showing 
intra-assay variability of 1.1 to 1.2 % only and inter-asssay variability of 11.5%. In 
view of this observed variability all samples were measured on two separate days and 
assayed in duplicate.  
 
High background levels of signalling were seen in both the direct and indirect assays 
for OPG. Whilst purification of immunoglobulins from the samples attenuated this 
effect so too did sample dilution, and for simplicity the latter approach was adopted. 
With either approach, there is some possible loss of sensitivity. The possible effects 
of circulating RANKL and OPG were assessed. There was no evidence of reduced 
OPG antibody detection in association with increased levels of these cytokines, with 
if anything, a trend to increased OPG antibody concentrations seen with increased 
levels of OPG and RANKL. This observation makes it most unlikely that circulating 
cytokines are having a significant effect on the performance of the assay (an 
87 
 
inherently plausible conclusion given the very low concentrations of circulating OPG 
and RANKL in human serum).  
 
Importantly a positive ELISA result does not reveal the affinity or epitope specificity 
of the antibody identified. An attempt was made to develop a screening assay that 
would simultaneously allow identification and functional assessment but this proved 
unsuccessful (proximity bead based assay discussed in Appendix A4.1). 
Consequently whilst the direct ELISA results are useful for hypothesis generation in 
the populations screened, this information should ideally also be combined with a 
separate assessment of the functional activity of such antibodies. 
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Chapter 5: Prevalence and correlation with bone traits 
of OPG antibodies in a general population cohort 
5.1 Abstract 
5.1.1 Introduction 
Cardiovascular diseases (CVD) and osteoporosis frequently co-exist, and 
epidemiological studies suggest both may share a common pathophysiological basis. 
OPG has been suggested as a link between these conditions (Section 1.3.4). 
Neutralising antibodies to OPG might play a pathogenic role in both osteoporosis 
and cardiovascular disease. 
5.1.2 Materials and methods 
Plasma was obtained from participants of the ORCADES study who have already 
been assessed extensively for CVD and osteoporosis (Section 2.6.1). OPG antibodies 
were identified using ELISA I (Section 2.3.4). Samples of serum from 20 volunteers 
with normal bone density were used to define a normal range (Section 2.3.3). 
Vascular calcification on the lateral DEXA image was scored according to validated 
methodology (Section 2.5).  
5.1.3 Results 
Raised levels of OPG antibody were found in 14/864 (1.6%) of the ORCADES 
population, similar to levels seen in healthy controls. No significant association 
between presence of OPG antibody and bone density or turnover was observed, but 
significantly higher vascular calcification scores were observed even after adjustment 
for age and sex. 
5.1.4 Conclusions 
OPG antibodies did not contribute significantly to osteoporosis in this population 
cohort. The association of OPG antibodies with vascular calcification is intriguing 





5.2 Prevalence of OPG antibodies in ORCADES population 
An analysis was performed on 864 plasma samples taken from the ORCADES 
cohort using ELISA I. Analysis of the OPG antibodies was performed either taking 
the absolute level of OPG antibody as a continuous variable, or alternatively treating 
the presence of antibodies to OPG as a categorical variable. In the latter analysis 
presence of OPG antibody was defined as a titre of OPG antibody by ELISA greater 
than the mean OPG antibody level in healthy controls plus three standard deviations 
(91ng/µl). Within this cohort the prevalence of OPG antibodies was low at 1.6% 
(n=14) with the small sample size limiting the study’s power to detect any effect. No 
significant difference in the titre of OPG antibody was observed between cases and 
controls (controls median OPG antibody level 23.7 (IQR 23.5), ORCADES cohort 
median OPG Ab level 27.3 (IQR 20.7), p=0.11). Characteristics of participants in the 
ORCADES study are presented in Table 5.1.   
Characteristic High antibody level 
(n=14) 




Age 59(±11.6) 56(±14.0) 0.35 
Sex 7 male(50%) 357 male(42%) 0.24 
BMI 27.42 (±4.8) 28.15(±14.0) 0.98 
Spine BMD Z score 0.33(±1.7) 0.44(±1.5) 0.72 
Hip BMD Z score 0.40(±1.1) 0.56(±1.1) 0.77 
Spine BMD T score -0.68 (±1.8) -0.47(±1.5) 0.66 
Hip BMD T score -0.34(±1.2) -0.12 (±1.1) 0.71 
Bone turnover (CTX) 
(n=350) 
0.56 (±0.32) 0.56(±0.32) 0.99 
Table 5.1 Characteristics of ORCADES participants by OPG antibody status 
No significant differences were observed between participants with or without OPG 
antibodies (p values represent 2 sided student T test for continuous, or Chi square test 
for categorical variables). Similarly no association between OPG antibody titre and 




5.3 Regression modelling within ORCADES population 
Linear regression modelling was performed with the response taken as Z scores of the 
spine and hip. Age, weight, height and OPG antibody concentration were included as 
continuous variables with sex included as a categorical variable (female sex assigned 
value of 0, male sex 1). Possible correlations between these factors and the 
concentration of OPG antibody were explored with no significant correlations 
observed (Table 5.2). Since OPG antibody concentration is not normally distributed a 
Spearman’s rank correlation coefficient was calculated for the continuous variables. 
Very similar OPG antibody concentration levels were observed in both women 
(median concentration 27.8, interquartile range 20.3) and men (median concentration 
25.6, interquartile range 21.1) with a MWU test suggesting there was no significant 
difference (p=0.19). 
 
FACTOR Spearman’s rho P value 
Age (yrs) 0.052 0.13 
Weight (kg) -0.04 0.3 
Height (cm) -0.04 0.3 
Table 5.2 No correlation observed between key variables and OPG antibody 
concentration 
 
Linear regression modelling was then performed using Z scores of the spine and hip 
as the response variable, with the full results of univariate and multivariate modelling 
given in table 5.3. Univariate regression analysis within the ORCADES population 
found no association with either spine bone density Z-score (p=0.86) or hip bone 
density Z-score (p=0.86) with the presence of OPG antibodies (Figure 5.1).   
Multivariate regression analyses against BMD scores revealed expected significant 
associations for sex, age, height and weight, however there was still no association 
with OPG antibody titre in this analysis either at the spine (p=0.86) or the hip 
(p=0.66).  
 
Although plasma was available in further participants of the ORCADES cohort, 
given the low prevalence of antibody in the population there was estimated not to be 
sufficient power to detect an effect. Even had we extended the analysis to all 1,584 
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available participants this is estimated to give only 41% power to detect a difference 
of 0.5 SD in bone density or turnover and this was not pursued.  
 
 
FACTOR Analysis Outcome β co-
efficient 
SE P value 
Age Univariate Spine Z score 0.0305 0.0036 <0.001 
Gender Univariate Spine Z score 0.184 0.0522 <0.001 
Weight Univariate Spine Z score 0.020 0.0027 <0.001 
Height Univariate Spine Z score -0.006 0.0039 0.12 
OPG Ab Univariate Spine Z score -0.0003 0.0020 0.86 
 
Age Multivariate Spine Z score 0.0318 0.0034 <0.001 
Gender Multivariate Spine Z score 0.5647 0.0614 <0.001 
Weight Multivariate Spine Z score 0.0312 0.0029 <0.001 
Height Multivariate Spine Z score 0.0230 0.0043 <0.001 
OPG Ab Multivariate Spine Z score -0.00045 0.0027 0.865 
 
FACTOR Analysis Outcome β co-
efficient 
SE P value 
Age Univariate Hip Z score 0.0126 0.0027 <0.001 
Gender Univariate Hip Z score 0.08718 0.0376 0.021 
Weight Univariate Hip Z score 0.02146 0.00189 <0.001 
Height Univariate Hip Z score 0.0004 0.0028 0.88 
OPG Ab Univariate Hip Z score -0.0003 0.0020 0.86 
 
Age Multivariate Hip Z score 0.0138 0.0024 <0.001 
Gender Multivariate Hip Z score 0.4617 0.0425 <0.001 
Weight Multivariate Hip Z score 0.0316 0.0020 <0.001 
Height Multivariate Hip Z score 0.0226 0.0030 <0.001 
OPG Ab Multivariate Hip Z score -0.00076 0.0017 0.66 







Figure 5.1 Univariate regression analysis reveals no association between OPG 
antibody concentration measured using ELISA I and spine BMD Z-score (a) or hip 
BMD Z-score (b). Threshold for positive OPG antibody status illustrated by dotted 
vertical line, and value seen in index case indicated by arrow.  



























OPG Ab concentration ng/µl
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In this and subsequent figures, results from the index case are illustrated (but not 
included in analysis) to allow approximate comparison between the two iterations of 
the ELISA). In a separate analysis no association was observed between OPG 
antibody titre and bone turnover markers (p=0.95) on either univariate or 
multivariate analyses. 
 
5.4 Association of OPG antibodies with vascular calcification in 
ORCADES cohort 
Vascular calcification was scored on the lateral image DEXA scan in all ORCADES 
participants that had undergone scanning and found to be present in 144/1578 
(9.1%). The average calcification score of these participants was 2.6 (±1.6) based on 
an 8-point score, or 5.4 (± 4.07) based on a 24-point score. A regression analysis of 
the 24 point score against the 8 point score confirmed a highly significant correlation 
between the two (p<0.001) with an R2 of 96.1% confirming that these two scores 
correspond closely. 
 
OPG antibodies were measured by ELISA in plasma from a subgroup of 859 patients 
from the ORCADES cohort in whom lateral DEXA images were available. Within 
this group 91 cases (10.6%) had vascular calcification present with mean 
calcification scores of 2.7 (± 1.6) using the 8-point score and 5.6 (±4.0) using the 24-
point score.  
 
The titre of OPG antibody correlated significantly with presence of aortic 
calcification (p=0.015), although this effect was attenuated in a regression analysis 
including age and sex as covariates (p=0.08). Unsurprisingly age was a strong 
predictor of vascular calcification (p<0.001) though sex is not significant (p=0.368). 
Use of either the 8 or 24-point calcification scores substantially strengthened the 
observed association between OPG antibodies and vascular calcification. In this 
analysis significance is maintained even after adjustment for age and sex with p 





Analysis based on a categorical definition of antibody positivity (defined as levels of 
OPG antibody greater than the mean of healthy controls plus 3 standard deviations) 
similarly revealed highly significant differences in both the 8-point calcification 
score (mean score in antibody positive 1.3±2.6 vs 0.27±0.94, p<0.001) and the 24-
point scores (mean score in antibody positive 2.64±5.5 vs 0.56±2.0, p<0.001) (Figure 
5.2). Significance was maintained on a multivariate regression analysis including age 
and sex as covariates for both the 8-point score (p<0.001) and 24-point score 
(p=0.001) with presence of OPG antibodies. 
 
Figure 5.2 Vascular calcification grouped by presence or absence of OPG 
antibodies. Significantly higher calcification scores are seen in OPG antibody 
positive individuals. Scores based on an 8 point scoring system are shown in empty 
diamonds (panel a), and scores based on a 24 point scores are shown in filled 
diamonds (panel b). Means displayed as horizontal grey bar. 
 














































































Results of screening the ORCADES population cohort for the presence of OPG 
antibodies identified raised levels of autoantibodies to OPG in approximately 1.6% 
of the general population. The level that was set within the healthy control cohort as 
a threshold to define the presence of antibody was essentially arbitrary, and the 
absolute level measured in the ORCADES samples was correspondingly arbitrary. 
However the detection of any level of antibody to a circulating endogenous cytokine 
such as OPG in a healthy population is in itself surprising, and does raise an 
important issue about the frequency with which self-tolerance is breached in healthy 
populations. There is a single prior reference to OPG antibodies in the very specific 
context of a trial involving recombinant Fc-OPG fusion molecule191where it was 
quite reasonably assumed that the presence of the carrier protein, or some alteration 
in the conformation/post translational modification of expressed OPG itself allowed 
the development of an autoimmune response. It is intriguing that further examples  
have been recently reported of diverse clinical syndromes associated with the 
development of autoantibodies against self-antigens with the suggestion that this is 
such a widespread phenomenon that it makes more sense to consider diseases 
associated with autoantibodies to be a greatly exaggerated but fundamentally normal 
physiological occurence193 . In keeping with this concept, a number of beneficial 
roles of naturally occurring antibodies with the capacity to recognise self-antigens 
have been recently described194.  
 
Within the ORCADES population, no association was seen between levels of OPG 
autoantibody and either lowered bone density or with markers of bone turnover, 
which would suggest that these antibodies do not have any adverse clinical effect, or 
if present any such effect is too small to be detected. Contradicting the notion that 
these antibodies are benign however was the observed significant association 
between vascular calcification and the presence of OPG autoantibodies. This could 
simply be a chance observation and it will require replication, however there is 
biological plausibility for a pathological role since OPG has been suggested as a 
possible common factor in the development of vascular calcification and 
osteoporosis (discussed in detail in Section 1.3.5). A simple explanation for this 
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association would be that calcium liberated by excess bone turnover had been 
deposited in the vasculature. This is difficult to reconcile with the normal bone 
turnover observed in these patients, though possibly the vascular calcification could 
represent evidence of a preceding and transient episode of increased bone turnover 
for which a compensating physiological response had been generated. Such 
responses could be immunological suppression of pathological neutralising antibody 
or an increase in levels of OPG itself. Alternatively there could be a direct role of 
OPG antibodies on the vasculature independently of an effect on bone density. This 
data is equally consistent with OPG antibodies being an epiphenomenon of vascular 





Chapter 6: Prevalence and correlation with bone traits 
of OPG antibodies in patients with osteoporosis  
6.1 Abstract 
6.1.1 Introduction 
Neutralising antibodies to OPG have previously been described in a patient with 
severe osteoporosis who responded dramatically to treatment with bisphosphonate 
therapy. It is not known if OPG antibodies influence the risk of ‘idiopathic’ 
osteoporosis or its response to treatment. 
6.1.2 Materials and methods 
Serum was obtained from patients attending the osteoporosis service in Lothian, who 
completed lifestyle questionnaires at time of bone density scanning (Section 2.6.2). 
Prevalence of OPG antibodies was assessed in 315 patients by ELISA (Section 2.3.5 
ELISA protocol II). Serum from healthy volunteers with normal bone density was 
used to define a normal range. Follow up bone density scans were available in 78 
patients allowing treatment response to be evaluated. 
6.1.3 Results 
Raised levels of OPG antibodies were found in 37/315 (11.7%) of osteoporosis 
patients and titres of OPG antibodies were significantly higher than in age-matched 
non-osteoporotic controls. Within this cohort the presence of OPG antibodies was 
not associated with lower bone density. Serum calcium and ALP were raised but not 
serum CTX in patients with OPG antibodies. No difference in treatment response 
was observed between patients with and without OPG antibodies. 
6.1.4 Conclusions 
OPG antibody levels were higher in patients with osteoporosis consistent with a 
pathological role in a subset of these patients; however the presence of OPG 




6.2 Prevalence of OPG antibodies in osteoporotic cohort 
Serum samples were analysed from 315 patients attending the osteoporosis clinic by 
ELISA II (Section 2.3.6). In this cohort, 37/315 patients (11.7%) were found to have 
raised titres of OPG antibody as defined by levels greater than the mean plus 3 
standard deviations of 101 healthy controls (14.3 RU). The titre of OPG antibodies 
was significantly raised when compared to healthy controls even after adjusting for 
age (median OPG antibody level 3.3 RU (IQR 4.0) in cases compared to 2.0 RU 
(IQR 4.5) in controls, p=0.01) (Figure 6.1) 
 
 
Figure 6.1 OPG antibody concentration in osteoporosis patients and age-matched 
controls. Significantly raised concentration of OPG antibody measured by ELISA II 
are seen in patients with osteoporosis. 
 
The characteristics of these patients are given in Table 6.1. No significant differences 
were present between the groups as defined by OPG antibody status. No difference 




























Characteristic High antibody level 
(n=37) 




Age 69.5 (±12.8) 68.7 (±12.5) 0.70 
Sex 5 male (13.5%) 58 male (20.1%) 0.38 
BMI 24.1 (±6.2) 24.5 (±5.0) 0.61 
Current smoker 6/37 (16%) 51/278(18%) 1.00 
Calcium intake  926mg (±384) 845mg (±502) 0.34 
Autoimmune disease 8/37 (21%) 50/278 (18%) 0.65 
Spinal fracture  6/37 (16%) 65/278 (23%) 0.41 
Spine BMD T score -2.97 (±1.16) -2.99 (±1.28) 0.94 
Spine BMD Z score -1.03 (±1.29) -1.27 (±1.40) 0.33 
Hip BMD T score -2.76 (±0.87) -2.43 (±0.95) 0.08 
Hip BMD Z score -1.03 (±0.87) -0.82 (±1.01) 0.24 
 
Table 6.1 Characteristics of osteoporosis patients by defined by OPG antibody status  
6.3 Regression analyses in the osteoporotic cohort 
No significant correlations between age, weight, height and OPG antibody 
concentration within the osteoporosis cohort were identified using Spearman’s rank 
correlation coefficient (Table 6.2). Similarly no significant difference in the OPG 
antibody concentration between women (median concentration 3.4, interquartile range 
4.6) and men was observed (median concentration 3.3, interquartile range 2.4) with a 
MWU test non-significant (p=0.57). 
FACTOR Spearman’s rho P value 
Age (yrs) 0.096 0.09 
Weight (kg) 0.006 0.92 
Height (cm) -0.004 0.95 
Table 6.2 No correlation observed between key variables and OPG antibody 
concentration by ELISA II 
Linear regression modelling was performed with the response taken as Z scores of 
the spine and hip. Age, weight, height and OPG antibody concentration were 
included as continuous variables with sex included as a categorical variable (female 
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sex assigned value of 0, male sex 1. Results of univariate and multivariate analyses 
against BMD Z scores are shown in table 6.3 with expected associations of age, 
gender and weight, though no association was seen between OPG antibody 
concentration or height, and BMD Z scores at either spine or hip. 
 
FACTOR Analysis Outcome β co-efficient SE P value 
Age Univariate Spine Z score 0.0496 0.0060 <0.001 
Gender Univariate Spine Z score 0.3608 0.1009 <0.001 
Weight Univariate Spine Z score 0.0240 0.0060 <0.001 
Height Univariate Spine Z score -0.0130 0.0085 0.13 
OPG Ab Univariate Spine Z score 0.0060 0.0075 0.42 
 
Age Multivariate Spine Z score 0.0540 0.0055 <0.001 
Gender Multivariate Spine Z score 0.5262 0.1090 <0.001 
Weight Multivariate Spine Z score 0.0410 0.0056 <0.001 
Height Multivariate Spine Z score 0.0038 0.0096 0.70 
OPG Ab Multivariate Spine Z score 0.0043 0.0060 0.48 
 
FACTOR Analysis Outcome β co-efficient SE P value 
Age Univariate Hip Z score 0.0272 0.0043 <0.001 
Gender Univariate Hip Z score 0.2983 0.0705 <0.001 
Weight Univariate Hip Z score 0.0149 0.0042 <0.001 
Height Univariate Hip Z score -0.0085 0.0058 0.15 
OPG Ab Univariate Hip Z score -0.0008 0.0053 0.88 
 
Age Multivariate Hip Z score 0.0315 0.0042 <0.001 
Gender Multivariate Hip Z score 0.4659 0.0806 <0.001 
Weight Multivariate Hip Z score 0.0270 0.0042 <0.001 
Height Multivariate Hip Z score 0.0078 0.0070 0.27 
OPG Ab Multivariate Hip Z score -0.0015 0.0045 0.74 
 
Table 6.3 Regression modelling of predictors of BMD Z scores of the spine and hip 
in the osteoporosis cohort. Age, sex and weight are significantly associated with 
BMD but in this analysis neither height nor OPG antibody concentration are 
significantly associated. 
 
Similarly univariate analysis of OPG antibody showed no association with spine T 
score (p=0.80) or hip T score (p=0.63), as well as multivariate analysis including 
age, sex and BMI also not showing any association with spine T score (p=0.46) or 





Figure 6.2 Association of BMD and OPG antibody in osteoporosis cohort.  
Univariate regression analysis revealed no significant association between OPG 
antibody concentration by ELISA II and spine BMD T-score (a) or total hip BMD T-
score (b). Values for index case are shown to illustrate that in this cohort some 
samples approached levels of OPG antibody seen in index case. 
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6.4 Analysis of disease response in OPG antibody positive 
patients 
The phenotype information that is held on the patients recruited to this study is 
currently being extended to include drug prescribing data, fracture data and results of 
biochemistry investigations. At the time of preparation of this manuscript, this data 
was available in 225 patients that had given a serum sample for assessment of OPG 
antibody. OPG antibodies were present in 31/225 (13.8%) and the baseline 
characteristics of these patients are given in Table 6.4.  
Characteristic OPG Ab positive 
(n=31) 
OPG Ab negative 
(n=194) 
p value  
Spine BMD 0.71 (±0.14) 0.71  (±0.14) 0.97 
Total Hip BMD 0.67 (±0.14) 0.68 (±0.13) 0.56 
Fem Neck BMD 0.56 (±0.10) 0.58 (±0.10) 0.36 
FRAX major 
fracture 
23.55 (±17.6) 20.27 (±11.3) 0.19 
FRAX hip fracture 12.31 (±15.3) 9.10 (±9.14) 0.11 
Number of vertebral 
fractures 
1.61 (±2.32) 1.13 (±1.51) 0.13 
Serum Calcium 2.44 (±0.20) 2.37 (±0.12) 0.02 
Serum ALP 99.71 (±29.67) 87.12 (±31.07) 0.04 
Serum   
25(OH)Vitamin D 
51.19 (±39.23) 54.06 (±42.94) 0.78 
CTX (n=104) 0.22 (±0.25) 0.22 (±0.25) 0.96 
 
Table 6.4 Baseline characteristics of OPG antibody positive patient in osteoporosis 
cohort. 
 
Once again no difference was observed in the BMD at any site between cases and 
controls. No difference in any individual component of the FRAX score, nor in the 
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consequent calculated fracture risk was seen, nor in the number of vertebral fractures 
seen. OPG antibody patients were found to have significantly higher serum calcium 
and ALP compatible with increased bone turnover; though in the subset of these 
patients for whom serum CTX data is available this marker was not different 
between cases and controls.  
 
A subset of 78 patients has undergone repeat bone density scanning since recruitment 
allowing a preliminary assessment of treatment response to be made. Characteristics 
of these patients are shown in Table 6.3. Of these patients 27 were treated with a 
bisphosphonate (13 alendronate, 4 risedronate and 10 zoledronate) and 22 treated 
with PTH therapy (20 teriparatide and 2 preotact).  
Patients treated with strontium ranelate, hormone replacement therapy, calcium and 
vitamin D alone or in whom prescribing information was incomplete were not 
included. The average duration of follow up was 3.15 (±2.28) years. 
 
As might be expected, the greatest improvements in BMD were observed in the 
lumbar spine, and with teriparatide therapy. Significantly greater BMD 
improvements were seen with teriparatide treatment compared to bisphosphonate 
therapy. No significant change in either measure of hip BMD was observed within 
either treatment arm. Adjustment for the duration of treatment appeared to 
substantially improve the sensitivity of this analysis, with significantly greater effects 
of teriparatide shown in the lumbar spine over bisphosphonate in all comparisons 
performed (effects assessed in all treated patients, and subgroup analyses of patients 
with high or low OPG antibody status). No significant difference in response to 
either PTH or bisphosphonate treatment was seen between low or high OPG 
antibody status patients suggesting that presence of OPG antibody does not predict 
treatment response (Table 6.5).  
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 vs PTH (all) 0.119 0.001 0.128 0.116 0.313 0.386 
BP (low OPG) 
vs BP (high OPG) 0.095 0.098 0.286 0.198 0.67 0.366 
PTH (low OPG) vs 
PTH (high OPG) 0.293 0.442 0.255 0.194 0.877 0.904 
BP (low OPG) vs 
PTH (low OPG) 0.679 0.042 0.185 0.111 0.458 0.681 
BP (high OPG) vs 
PTH (high OPG) 0.017 0.007 0.543 0.481 0.480 0.398 
 
Table 6.5 Change in BMD over time. ΔBMD calculated by subtracting the baseline 
BMD value from the BMD reading on the return visit (ie a positive value represents 
a gain in BMD).  ΔBMD/time is calculated by dividing the ΔBMD by the time (in 
years) between baseline and follow-up scan. 
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6.5 Discussion  
The prevalence of OPG antibodies in the osteoporosis cohort was estimated at 11.7% 
(ELISA protocol II) with the titre of OPG higher than in age-matched controls. These 
patients were no more likely to have autoimmune disease and overall had very 
similar demographic characteristics to patients without OPG autoantibodies. The 
higher level of OPG autoantibodies is consistent with a pathogenic role for OPG 
antibodies in a proportion of patients with osteoporosis, though also with antibodies 
being an epiphenomenon of osteoporosis.  
 
It remains a striking observation that over 11% of patients attending the clinic were 
found to have autoantibodies to OPG and a number of preliminary analyses of the 
characteristics of disease in these patients have been carried out. Serum calcium and 
ALP were noted to be significantly raised in these patients which echoes the 
markedly elevated bone turnover observed in the index case. There is an 
inconsistency in that the results of serum CTX were not found to be raised and these 
results must be interpreted with some caution. Even if it is established that patients 
with OPG autoantibodies have higher bone turnover this does not necessarily infer 
that they will respond to antiresorptive therapy in the dramatic fashion seen in the 
index case. The number of patients in whom treatment response data are available at 
present is very small but no trend is seen to a better response in OPG antibody 
positive patients compared to OPG negative to bisphosphonate, or indeed a 
differential response to PTH treatment. This analysis will need to be repeated with 
larger numbers of patients, and it would be of particular interest to observe the 
effects of more potent bisphosphonates such as zoledronate and denosumab.  
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Chapter 7: Prevalence and correlation with bone traits 




Osteoporosis is a recognised complication of coeliac disease and inflammatory 
bowel disease (IBD). It is not known if autoantibodies to OPG contribute to the 
pathogenesis of osteoporosis in coeliac disease or IBD.  
7.1.2 Materials and Methods 
Serum samples were obtained from patients attending gastroenterology disease 
clinics in Lothian with bone density scanning performed in line with routine clinical 
practice (Section 2.6.3). OPG antibodies were identified by ELISA, with the IBD 
cohort assessed using ELISA protocol I (Section 2.3.3) and the coeliac patients using 
ELISA protocol II (Section 2.3.5). Serum from volunteers with normal bone density 
was used to define a normal range. 
7.1.3 Results 
Raised levels of OPG antibody were seen in 14/282 (5.0%) patients with coeliac 
disease and this was associated with reduced spine BMD. Functional inhibition of 
OPG was shown by 3/14 (21.4%) of the OPG antibody positive samples. No 
improvement in case finding was shown by inclusion of OPG antibodies into a risk 
prediction score for osteoporosis. Raised levels of OPG antibodies were found in 
5/141 (3.5%) of IBD patients with the presence of antibodies associated with reduced 
bone density Z-scores of the hip. This result was confounded by features of increased 
disease severity in OPG antibody positive patients. 
7.1.4 Conclusion 
Results are consistent with a pathological role of OPG antibodies in a proportion of 
patients with coeliac disease. Whilst similar trends were observed in the IBD cohort 
the association with BMD is confounded by features of increased disease severity. 
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7.2 Prevalence of OPG antibodies in patients with IBD 
Levels of OPG autoantibody were measured using ELISA I in a cohort of 141 
patients with IBD in whom stored serum samples was available. The titre of OPG 
antibody was not significantly higher in the cases (median concentration 23.1 ng/µl, 
IQR 25.1) than in controls (median concentration 23.0 ng/µl, IQR 37.0); p=0.08 
MWU) (Fig 7.1). 
 
 
Figure 7.1 OPG antibody levels in IBD patients and controls. The concentration of 
OPG antibody is not significantly raised in IBD patients (n=141) when compared to 
healthy controls (n=20). OPG antibodies measured using ELISA protocol 1, with a 
threshold of mean plus three standard deviations indicated by the grey dotted line, 
and the median value in each cohort by a horizontal grey bar.  
 
A total of 5/141 (3.5%) of the IBD patients had elevated levels of OPG 
autoantibodies as defined by values >3 SD above the mean in 20 healthy controls (91 




































based on 2 sided student T test for continuous variables, and Chi square or Fishers 
Exact test for categorical variables. Lower hip BMD Z-scores were associated with 
presence of OPG antibodies, though the difference in spine BMD Z-scores was not 
statistically significant. This association was potentially confounded by features of 
more severe disease with a younger age of onset, and non-significantly lower BMI in 
cases with OPG antibodies.  
 
Characteristic High antibody level 
(n=5) 




Age 44(±17.2) 46(±14.6) 0.36 
Sex 2(40%) 61(43%) 1.00 
BMI 22.2(±2.37) 25.1(±4.3) 0.07 
Age of onset 18(±7.2) 32.6(±14.5) 0.01 
Crohns disease 5/5(100%) 88(65%) 0.17 
Spine T score -1.4(±0.97) -0.93(±1.3) 0.39 
Spine Z score -1.05(±0.97) -0.48(±1.3) 0.17 
Hip T score -1.8(±0.14) -0.63(±1.1) 0.07 
Hip Z score -1.6(±1.06) -0.39(±0.94) 0.01 
 
Table 7.1 Characteristics of OPG antibody positive patients in IBD cohort 
7.3 Regression analyses in patients with IBD 
Linear regression modelling was performed with the response taken as Z scores of the 
spine and hip. Age, weight, height and OPG antibody concentration were included as 
continuous variables with sex included as a categorical variable (female sex assigned 
value of 0, male sex 1).  
 
Possible confounding was investigated by looking at Spearman’s correlation 
coefficient between age, weight, height and age of onset of inflammatory bowel 
disease with OPG antibody concentration (Table 7.2). Within this cohort age of onset 
of inflammatory bowel disease was significantly associated with the concentration of 
OPG antibody as measured by ELISA I. No significant correlations between age, 
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weight, height and OPG antibody concentration within the IBD cohort were identified 
however. Similar concentrations of OPG antibody were observed in women (median 
concentration 22.7, interquartile range 24.7) and men (median concentration 26.7, 
interquartile range 25.4) with a MWU test non-significant (p=0.58). 
FACTOR Spearman’s rho P value 
Age (yrs) -0.10 0.24 
Weight (kg) -0.06 0.51 
Height (cm) 0.02 0.77 
Age of onset IBD -0.25 <0.05 
Table 7.2 No correlation observed between key variables and OPG antibody 
concentration by ELISA I 
Further modelling was then performed using Z score of the spine as the response 
variable, with the full results of univariate and multivariate modelling given in table 
7.3. Univariate regression analyses revealed significant associations for sex, age, 
weight and age of onset of IBD. Significance for all these factors was maintained on 
multivariate analysis with the exception of age of onset. No association was seen 
between OPG antibody concentration and spine Z score. 
FACTOR Analysis Outcome β co-efficient SE P value 
Age Univariate Spine Z score 0.0190 0.007 0.01 
Gender Univariate Spine Z score 0.2838 0.109 0.01 
Weight Univariate Spine Z score 0.0192 0.008 0.02 
Height Univariate Spine Z score -0.0045 0.012 0.71 
OPG Ab Univariate Spine Z score -0.006 0.004 0.16 
Age of onset Univariate Spine Z score 0.0160 0.007 0.03 
 
Age Multivariate Spine Z score 0.0185 0.008 0.02 
Gender Multivariate Spine Z score 0.6087 0.146 <0.001 
Weight Multivariate Spine Z score 0.0243 0.009 0.01 
Height Multivariate Spine Z score 0.0317 0.017 0.07 
OPG Ab Multivariate Spine Z score -0.0046 0.004 0.29 
 
Age Multivariate Spine Z score 0.0223 0.011 <0.05 
Gender Multivariate Spine Z score 0.6029 0.147 <0.001 
Weight Multivariate Spine Z score 0.0251 0.009 0.01 
Height Multivariate Spine Z score 0.0304 0.018 0.09 
OPG Ab Multivariate Spine Z score -0.0054 0.005 0.25 
Age of onset Multivariate Spine Z score -0.0055 0.011 0.63 




The same analysis was performed using hip BMD Z score as the response variable 
(Table 7.4). In these analyses weight is consistently and highly significantly 
associated with hip Z score. The presence of OPG antibodies was significantly 
associated with hip BMD Z scores on univariate analysis (p=0.01) (Figure 7.2). On 
multivariate analysis including age, sex, height and weight, significance remained 
(p=0.025), and was demonstrated also for hip T score (p=0.046). However, this result 
was confounded by features of more severe disease in these patients including a 
significantly lower age of disease onset such that if age of onset was included in a 
multivariate analysis then significance was lost for the association of hip Z score and 
OPG antibody (p=0.08). 
FACTOR Analysis Outcome β co-efficient SE P value 
Age Univariate Hip Z score 0.0041 0.006 0.49 
Gender Univariate Hip Z score 0.1347 0.0865 0.12 
Weight Univariate Hip Z score 0.0233 0.006 <0.001 
Height Univariate Hip Z score 0.0018 0.010 0.85 
OPG Ab Univariate Hip Z score -0.0092 0.003 0.01 
Age of onset Univariate Hip Z score 0.0119 0.006 0.04 
 
Age Multivariate Hip Z score 0.0009 0.006 0.9 
Gender Multivariate Hip Z score 0.2984 0.112 0.01 
Weight Multivariate Hip Z score 0.0290 0.007 <0.001 
Height Multivariate Hip Z score 0.0054 0.013 0.69 
OPG Ab Multivariate Hip Z score -0.0076 0.003 0.02 
 
Age Multivariate Hip Z score -0.0083 0.008 0.32 
Gender Multivariate Hip Z score 0.3090 0.112 0.01 
Weight Multivariate Hip Z score 0.0274 0.007 <0.001 
Height Multivariate Hip Z score 0.0077 0.014 0.57 
OPG Ab Multivariate Hip Z score -0.0062 0.003 0.08 
Age of onset Multivariate Hip Z score 0.0107 0.009 0.22 








Figure 7.2 Association of BMD and OPG antibody in IBD cohort. Univariate 
regression analyses revealed no association between OPG antibody concentration by 
ELISA I and spine BMD Z-score (a) but a significant association between femoral 
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7.4 Prevalence of OPG antibodies in patients with coeliac disease 
Serum samples were analysed from 282 patients with coeliac disease recruited 
through gastroenterology clinics in Lothian using ELISA II (Section 2.3.6). The 
concentration of OPG antibodies was significantly raised when compared to levels 
seen in healthy age matched controls (Figure 7.4). The median OPG antibody level in 
coeliac cases was 4.0 RU (IQR 4.6) compared to a median of 2.6 RU (IQR 3.1) in the 
controls. 
 
Figure 7.3 Raised concentrations of OPG antibody by ELISA II are seen in a coeliac 
cohort compared to age matched controls. Threshold for positive antibody status 
indicated by horizontal dotted line. 
 
A reference range was derived from the mean plus three standard deviations of 
concentrations seen in 101 volunteers with normal BMD (14.3RU). Within the 
coeliac cohort, 14/282 patients (5.0%) were found to have raised levels of antibody 
(defined as greater than the mean plus 3SD of levels seen in 101 volunteers of 




























elevated titres of OPG antibody. The characteristics of patients with raised or normal 
levels of antibody within this cohort are given in Table 7.5.  
 
Characteristic High antibody 
level (n=14) 




Age 56.2 (±15.8) 55.5 (±15.0) 0.85 
Female 8/14 (57%) 199/268 (74%) 0.16 
Bisphosphonate (ever) 4/14 (29%) 39/268(14%) 0.25 
Steroid use (ever) 1/12 (8%) 16/251 (6%) 0.56 
Ca/D (ever) 10/13 (77%) 122/252 (48%) 0.05 
BMI 25.7 (±4.0) 25.7 (±4.8) 0.87 
Number of raised TTG 
results since diagnosis 
1.6(±3.2) 0.7 (±1.1) 0.33 
Months since diagnosis 
of CD 
118 (±116) 103 (±114) 0.58 
Current smoker 1/12(9%) 27/251 (12%) 1.00 
Alcohol (units/week) 8.9 (±10.4) 5.3(±8.3) 0.27 
Spine BMD T-score 
(n=254) 
-2.00 (±1.2) -1.05 (±1.3) 0.02 
Spine BMD Z-score 
(n=254) 
-1.12 (±1.39) -0.10 (±1.2) <0.01 
Hip BMD T-score 
(n=254) 
-1.36 (±0.99) -1.01 (±1.10) 0.29 
Hip BMD Z-score 
(n=254) 
-0.38 (±0.84) -0.03 (±0.97) 0.24 
  
Table 7.5 Characteristics of OPG antibody positive patients in coeliac cohort. Bone 
density data was only available in 254 patients. p values represent results of 2-tailed 
student T test for normally distributed continuous data, or Mann-Whitney U test 




No significant differences between patients with raised OPG antibody levels and 
those with normal levels were observed in terms of conventional risk factors for 
osteoporosis, namely age, sex, BMI, smoking, alcohol consumption or use of steroid 
medication. Significantly lower BMD at the spine was observed in patients with high 
OPG antibody levels (both T-score and Z-score). Whilst numerically lower bone 
density was seen at the hip, this was not statistically significant. 
 
This difference was not contributed to by treatment effects since a greater proportion 
of patients in the high OPG antibody group were receiving bone active treatments 
both bisphosphonate therapy and combined vitamin D and calcium (the latter 
narrowly failing to reach statistical  significance p=0.051).  
 
7.5 Regression analyses in patients with coeliac disease 
Prior to performing linear regression possible associations between the variables of 
interest and OPG antibody by ELISA II in the coeliac cohort were explored. 
Spearman’s rho was calculated for the continuous variables age, weight and height. 
No significant correlation was seen between any of the factors analysed and OPG 
antibody concentration by ELISA II (Table 7.6). Very similar concentrations of OPG 
antibody were seen in women with median concentrations 4RU (IQR 4.5), and in men 
median concentrations 4RU (IQR 5.1 ) with no significant difference on Mann 
Whitney U test (p= 0.78) 
FACTOR Spearman’s rho P value 
Age (yrs) 0.01 0.86 
Weight (kg) -0.04 0.54 
Height (cm) 0.07 0.28 
Table 7.6 Correlation analysis of OPG antibody concentration in coeliac patients 
Linear regression modelling was then performed with the response taken as Z scores 
of the spine and total hip. Age, weight and height were included as continuous 
variables with sex included as a categorical variable (female sex assigned value of 0, 
male sex 1). On univariate regression analysis the titre of OPG antibody was 
significantly associated with spine BMD T-score (p=0.005) and Z-score (p=0.006), 
though not total hip T-score (p=0.10) or Z-score (p=0.17) (Table 7.7 and Figure 7.4). 
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The result was consistent when analysed by OPG antibody status with significant 
association maintained with spine T-score (p=0.021) and Z-score (p=0.006), but not 
total hip T-score (p=0.34) or Z-score (p=0.24). A multivariate analysis of OPG 
antibody concentration which included age, sex, height and weight as covariates, 
found significant associations with spine T score (p=0.004) and spine Z-score 
(p=0.015), though again no association was seen with total hip T score (p=0.13) or 
total hip Z-score (p=0.31). Expression as a categorical variable did not change this 
analysis; association with T-score of the spine (p=0.03) and Z-score of the spine 
(p=0.03) was maintained, though again no association was found with either hip T-
score (p=0.34) or hip Z-score (p=0.45). In a further sensitivity analysis the OPG 
antibody concentration was log transformed but statistical significance for the 
association of OPG antibody and spine BMD Z score was maintained on both 
univariate and multivariate analysis (p<0.05). 
FACTOR Analysis Outcome β co-efficient SE P value 
Age Univariate Spine Z score 0.0122 0.005 0.02 
Gender Univariate Spine Z score 0.2848 0.08 0.001 
Weight Univariate Spine Z score 0.0227 0.005 <0.001 
Height Univariate Spine Z score 0.0009 0.009 0.92 
OPG Ab Univariate Spine Z score -0.0461 0.016 0.005 
 
Age Multivariate Spine Z score 0.0154 0.005 <0.005 
Gender Multivariate Spine Z score 0.5150 0.099 0.58 
Weight Multivariate Spine Z score 0.0271 0.006 <0.001 
Height Multivariate Spine Z score 0.0173 0.011 0.131 
OPG Ab Multivariate Spine Z score -0.0436 0.016 0.015 
 
FACTOR Analysis Outcome β co-efficient SE P value 
Age Univariate Hip Z score 0.0001 0.004 0.98 
Gender Univariate Hip Z score -0.1197 0.073 0.10 
Weight Univariate Hip Z score 0.0289 0.004 <0.001 
Height Univariate Hip Z score 0.0107 0.008 0.17 
OPG Ab Univariate Hip Z score -0.0185 0.013 0.17 
 
Age Multivariate Hip Z score -0.0044 0.004 0.30 
Gender Multivariate Hip Z score -0.0113 0.067 0.09 
Weight Multivariate Hip Z score 0.0326 0.005 <0.001 
Height Multivariate Hip Z score -0.0144 0.008 0.08 
OPG Ab Multivariate Hip Z score -0.0134 0.012 0.27 






Figure 7.4 Association of BMD and OPG antibody in coeliac cohort. Univariate 
regression analyses revealed significant association between OPG antibody 
concentration by ELISA II and spine BMD Z-score (a) but no significant association 
with total hip BMD Z-score (b). Values for index case shown for illustrative purposes 
only. 































A number of coeliac disease specific factors were also analysed. A numerically 
greater number of raised TTG antibody tests and longer disease duration were seen in 
patients with raised OPG antibody concentrations, but neither difference was 
statistically significant. There was a suggestion that higher titres of OPG antibody 
were observed in patients in the early part of their disease, rather than in established 
disease, though it is not possible to draw firm conclusions from this small sample. 
Specifically of the 14 samples that are positive for OPG antibody the mean disease 
duration of the highest 7 samples, was significantly shorter than that in the lowest 7 
samples (mean duration of disease 46.1 months (± 70.6 months) in highest OPG 
antibody patients, compared to mean duration of disease 189.9 months (± 112 
months) in the lowest OPG antibody patients (Figure 7.5a, p<0.01  MWU test). 
Within this small cohort the duration of disease however was not a significant 
predictor of OPG antibody concentration either on univariate regression (Figure 7.5b, 
p=0.09, data log transformed to ensure a normal distribution of disease duration) or 







Figure 7.5 Mean disease duration is shorter in those OPG antibody positive patients 
with the highest titre, compared to those with the lowest titre (a) however disease 
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7.6 Assessment of functional activity of OPG antibodies 
All samples identified as having raised levels of OPG antibody in the coeliac cohort 
have also been assessed for their ability to inhibit OPG function using the 
methodology described in Section 2.2.3.   
   
Figure 7.6 Assessment of OPG inhibition by serum samples negative for OPG 
antibodies (coeliac samples 1-2) and samples known to be positive for OPG antibodies 
(coeliac samples 3 to 11). Levels of NFκB activation were compared to that observed 
in cells treated with both RANKL and OPG alone (RANKL/OPG + +, third column). 
Significantly increased signalling compared to this background level, is seen in serum 
from the index case which was used as a positive control, as well as samples 7 and 11. 
*represents p<0.05, ** represents p<0.01. Results are means plus SD of triplicate 
samples. The ELISA OPG Ab value for each serum sample analysed is displayed above 
each sample (inset columns in light blue, dotted line representing threshold for positive 
OPG antibody) suggesting there is no simple correlation between titre of OPG 





































































RANKL + - + + + + + + + + + + + + +
OPG - + + + + + + + + + + + + + + 
Serum - - - Index      1       2        3        4        5        6       7        8        9       10     11
Case Coeliac samples 1-11
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Three of the 14 positive samples screened showed significant inhibition of OPG 
similar if not greater than that shown by serum from the index case. Overall there 
was substantial variation in the extent of inhibition of OPG function demonstrated in 
the samples from coeliac patients. No significant correlation between the level of 
OPG antibody and the extent of inhibition was observed (Pearson correlation 
coefficient 0.33, p=0.23). In turn this implies that the affinity or specificity of the 
antibody may play a more important role in antibody function than absolute titre.  
7.7 Clinical utility of testing for OPG antibodies in coeliac disease 
The results presented so far demonstrate that OPG antibodies are found more 
commonly in coeliac disease and correlate with reduced BMD. In order to translate 
this knowledge into improvements in the management of coeliac disease it will be 
necessary to show that the identification of OPG antibodies can help in either the 
identification or in the treatment of osteoporosis. Despite the frequency with which 
osteoporosis complicates coeliac disease, there are no reliable models that can 
predict the development of osteoporosis195 and an exploratory study was performed 
to see if OPG antibodies might be of value in osteoporosis risk prediction. 
7.7.1 Utility of the FRAX tool in predicting osteoporosis in coeliac 
disease 
A number of fracture risk assessment tools have been developed that can aid in the 
management of patients at risk of osteoporosis, and which have recently been 
advised for use in selecting patients for bone density scanning (see Section 1.1) . The 
FRAX algorithm, developed by the World Health Organization, is the most widely 
available, and incorporates clinical risk factors that include causes of secondary 
osteoporosis such as coeliac disease (Figure 7.6) 196. Based on these variables a 10-
year probability of hip fracture and major osteoporotic fracture is generated as well 
as management advice on whether patients should be given empirical treatment, be 





Figure 7.7 Screenshot of the FRAX risk assessment tool displaying the 10 year major 
osteoporotic and hip fracture probabilities for a patient with characteristics of the 
index case. The National osteoporosis guidelines group (NOGG) guidance in this 
example was to measure BMD. 
 
Within the cohort of 282 patients with coeliac disease, there were 254 in whom BMD 
scans had been performed. Patients that had not received a bone density scan were 
necessarily excluded from further analysis. Of note the excluded patients had a 
significantly shorter duration of disease prior to recruitment (median 5 months 
compared to 254 months, MWU test p<0.01) as well as having been recruited more 
recently (median recruitment date 481 days into the study, rather than 276 days, 
MWU test p=0.05) suggesting that one reason for their not having a scan was simply 
that they had not yet been appointed. The excluded patients were significantly 
younger however (average age 39.7±16.1 years compared to 57.2±14.7 years, 
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p<0.01) suggesting that they are also less likely to have osteoporosis and this limits 







Age at DEXA (yrs) 65.3 (±12.1) 52.1 (±14.6) <0.001 
Sex (Female) 36/45 (80.0%) 153/209 (73.2%) 0.45 
Weight, kg 62.7 (±8.8) 71.9 (±14.7) <0.001 
Height, cm 1.61 (±0.08) 1.66 (±0.08) <0.001 
History of low 
trauma fracture  
13/45 (28.9%) 52/209 (24.9%) 0.58 
Parental hip fracture 1/45 (2.2%) 18/209 (8.6%) 0.21 
Current smoker 7/45 (15.6%) 21/209 (10.0%) 0.30 
History of 
glucocorticoid use  
6/45 (13.3%) 11/209 (5.2%) 0.09 
Alcohol, 
>3units/week 
0/45 (0%) 14/195 (6.7%) 0.14 
FRAX major fracture 18.4 (±11.3) 10.1%(±8.1) <0.001 
FRAX hip fracture 7.80 (±7.61) 2.69 (±4.27) <0.001 














Table 7.8 Distribution of FRAX risk prediction variables in coeliac patients 
depending on osteoporosis status 
 
Of the patients that had received a scan 45/254 (17.7%) had osteoporosis based on 
the WHO classification of BMD T score ≤ -2.5. The distribution of risk factors used 
in the FRAX algorithm between patients with or without osteoporosis is displayed in 
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Table 7.8 (p values based on 2-sided student T test for continuous variables or 
Fishers exact test for categorical variables).  
 
Age, height and weight are statistically different between cases and controls. The 
patient details were entered into the online FRAX tool (data entry performed 
September 2014) to generate 10-year estimates of major fracture and hip fracture 
risk, as well as the NOGG management advice (treat, measure BMD or offer lifestyle 
advice only). BMD data were not included since utility in predicting osteoporosis 
was to be assessed. Patients with osteoporosis were identified as being at highly 
significantly greater risk of fracture and were more likely to be recommended for 
active management (Table 7.3). 
 
The utility of the NOGG guidance and FRAX fracture prediction scores in predicting 
osteoporosis within the coeliac cohort were analysed using Receiver Operating 
Characteristic (ROC) analysis. Of these, the FRAX fracture prediction scores both 
yielded a fair result, though the NOGG guidance was a poor test (Table 7.9).  
 
Prediction variable  Area under curve Std Error 95% CI 
NOGG guidance 0.61 0.047 0.52-0.70 
FRAX Major 
Fracture 
0.741 0.043 0.66-0.82 
FRAX Hip Fracture 0.767 0.041 0.68-0.85 
 
Table 7.9 ROC curve analysis of the FRAX tool output variables in predicting the 
presence of osteoporosis 
 
To illustrate this, if the NOGG guidance to measure or treat are both taken as an 
indication for bone density scan referral, this yielded a test with a sensitivity for 
osteoporosis of 89% but a specificity of only 20.6%. Alternatively use of a FRAX 
major fracture risk score of ≥10% (which is the proposed threshold for bone density 
scan referral under the forthcoming SIGN guidelines) yielded a sensitivity of only 
73.3% and a specificity of 64.1%. These results suggest that there are significant 
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shortcomings in the currently available risk assessment tools, and justify a re-
evaluation of the predictors of osteoporosis in coeliac disease. 
7.7.2 Utility of the QFracture tool in predicting osteoporosis 
The QFracture algorithm is an alternative to FRAX which has been derived and 
validated in large UK primary care patient cohorts utilising the records of over 4.5 
million patients197. The current revision of QFracture incorporates 26 risk factors, has 
been validated in patients aged between 30 and 100, and can generate a risk of hip or 
any osteoporotic fracture over 1 to 10 years. Malabsorption is included in the risk 
equation for all fractures, but is not included in the hip fracture equation. All the 
inputs used in FRAX are also included in QFracture, with QFracture utilising a 
graded score for smoking and alcohol to reflect levels of consumption. Unlike FRAX 
there is no option within QFracture to input BMD. The distribution of additional risk 
factors found within the coeliac patient cohort is shown in Table 7.10 (p values 







Depression 0/45 (0%) 3/209 (1.4%) 1.0 
Cancer 3/45 (6.6%) 13/209 (6.2%) 1.0 
Asthma 1/45 (2.2%) 2/209 (0.96%) 0.47 
Cardiovascular 
disease 
5/45 (11.1%) 9/209 (4.3%) 0.08 
Endocrine disorder 3/45 (6.6%) 6/209 (2.9%) 0.20 
Falls 5/45 (11.1%) 23/209 (11%) 1.0 
Hormone 
replacement 
2/45 (4.4%) 10/209 (4.8%) 1.0 
Rheumatoid arthritis 3/45 (6.6%) 4/209 (1.9%) 0.12 
Type 1 diabetes 1/45 (2.2%) 0/209 (0%) 0.17 
Caucasian ethnicity 44/45 (97.8) 207/209 (99%) 0.44 
Table 7.10 Additional risk factors utilised in the QFracture algorithm 
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Whilst none of these factors reached statistical significance this is not surprising 
given the small numbers of patients with each individual condition. Across all 
medical conditions, with the exception of depression, an absolute higher prevalence 
was seen in the osteoporotic patients, consistent with the results reported in the 
derivation of QFracture. Whilst dementia, residence in institutional care, epilepsy, 
chronic liver disease, type II diabetes, Parkinson’s disease and renal failure are 
components of this score there were no patients with these conditions identified by 
the patient completed questionnaire. 
 
Open source software generating the QFracture scores is freely available online and 
this was used to generate both 5 and 10 year risk scores, for both all fractures and hip 
fractures (download performed November 2014). The algorithms were verified by 
comparison with the output from the online tool. The only discrepancies noted were 
instances in which the all fracture model generated a lower score than the hip 
fracture model. In these cases in order to avoid logical absurdity the online tool 
appears to raise the all fracture score so that it is brought in line with the hip fracture 
score. The utility of the QFracture scores in predicting osteoporosis within the 
coeliac cohort were analysed using ROC analysis (Table 7.11). Five and 10 year risk 
scores for each algorithm performed in a very similar fashion, and once again the hip 
fracture risk performs somewhat better than the all fracture risk in predicting 
osteoporosis.  With an AUC of 0.799, the QFracture neck of femur algorithm 
appeared to perform somewhat better than the FRAX neck of femur score (AUC 
0.767) though the confidence intervals overlapped widely. 
  
Prediction variable  Area under curve Std Error 95% CI 
QFracture NOF 5 yr 0.799 0.036 0.728-0.871 
QFracture NOF 10yr 0.799 0.036 0.727-0.870 
QFracture Any 5 yr 0.779 0.038 0.705-0.854 
QFracture Any 10yr 0.779 0.038 0.705-0.854 
Table 7.11 ROC curve analysis of the QFracture tool output variables in predicting 




If  a threshold of 10% is taken with the QFracture 10 year all fracture risk in line 
with recent SIGN guidelines then this yields a test with a poor sensitivity of 33.3%, 
though excellent specificity of 92.8%. This finding highlighted important differences 
between FRAX and QFracture in terms of the absolute risk predicted and the dangers 
of assuming equivalence when setting threshold of risk for example in referral for 
bone density scanning. Setting a lower QFracture 10-year all fracture risk of 5% 
would give a sensitivity of 68.9% and specificity 76.1% which shows poorer 
sensitivity to FRAX whilst improving specificity. Overall this would suggest there 
remains a need for improved risk stratification within the context of the coeliac 
population. 
7.7.3 Identification of disease specific risk factors 
Identification of further disease specific factors with a possible contribution to the 
development of osteoporosis were identified by case note review. The distribution of 
these factors between cases and controls is illustrated in Table 7.12 (2 sided student 










Baseline TTG off 
scale 
12/45 (26.7%) 33/209 (15.8%) 0.09 
Duration of disease 92.91 (±94.37) 115.41 (±120.00) 0.23 
<2 yrs disease 
duration 
13/45 (28.9%) 46/209 (22.0%) 0.33 
Number TTG 
positive 
0.84 (±1.29) 0.74 (±1.43) 0.68 
% TTG test positive 25.0% (±34.9) 22.6% (±36.9) 0.72 
Biopsy grading 
(n=129) 
Marsh 1: 0/21 
Marsh 2: 0/21 
Marsh 3a: 14/21 
Marsh 3b: 4/21 
Marsh 3c: 3/21 
Marsh 1: 10/108 
Marsh 2: 0 
Marsh 3a: 65/108 
Marsh 3b: 9/108 




0.60 (±0.81) 0.39 (±0.69) 0.08 
OPG Ab 
concentration 
6.67 RU (±6.52) 4.71 RU (±4.24) 0.01 
OPG antibody status 5/45 (11.1%) 6/209 (2.9%) 0.03 
Ca intake (daily) 875mg (± 297) 896mg (± 355) 0.72 
Age of menopause 
(n=112) 
47.12 (± 5.57) 48.88 (± 4.56) 0.08 
Premature 
menopause (<45 yrs) 
9/45 (20%) 12/209 (5.7%) <0.01 
Table 7.12 Disease specific risk factors for osteoporosis in coeliac disease cohort. 
OPG antibody determined by ELISA II. Antibody status defined as level greater than 




Only OPG antibody (whether as a continuous variable or categorical variable) and 
premature menopause were significantly associated with osteoporosis in this case 
control analysis. Premature menopause remained significantly associated with 
development of osteoporosis even on multivariate analysis including gender and age 
(p=0.015) suggesting that this could be a useful risk modifier. A markedly elevated 
TTG levels at baseline and the number of comorbidities missed statistical 
significance relatively narrowly and may be worth pursuing in a larger cohort. 
Overall duration of disease was not correlated with development of osteoporosis 
though it is plausible that both short duration (due to the immediate effects of coeliac 
disease) and long disease duration (simply due to an association with ageing) would 
be associated with increased risk of osteoporosis. As evidence of the latter 
phenomenon a strong correlation was observed between disease duration and age at 
recruitment (Pearson correlation coefficient 0.19, p=0.002). Interestingly a disease 
duration <2 years is associated with osteoporosis on a multivariate analysis that 
included age as a covariate (p<0.05) suggesting that this could be a useful addition to 
a multivariate risk prediction model. Although biopsy grading has been reported to 
be a predictor of osteoporosis159 in coeliac disease this was not replicated in this 
dataset. Unfortunately in this cohort the pathological report was available in just over 
half of cases only, and the Marsh grading had to be inferred from the report, rather 
than being consistently reported which are significant limitations in this analysis. A 
number of measures aimed at assessing dietary compliance indirectly using TTG 
levels showed no evidence of difference between the groups. 
7.7.4 Utility of novel factors in a risk prediction model  
Whilst the number of cases within this cohort remains small, a preliminary 
assessment of the utility of the identified variables in a risk prediction model was 
performed. Variables with significant association with osteoporosis status were 
selected, namely OPG antibody titre, premature menopause and disease duration less 
than 2 years and modelled in female patients. The QFracture and FRAX hip scores 
were taken forward as performing slightly better on the ROC analysis than their 
respective all fracture prediction counterparts. In combination with either of these hip 
scores OPG antibody titre, premature menopause and disease duration less than 2 
years were analysed by best subset analysis on Minitab. The output generated with 
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inclusion of the FRAX hip score (Table 7.13) and QFracture hip score (Table 7.14) 
















1 17.1% X    
1 6%  X   
1 4.4%   X  
1 0.4%    X 
2 21% X X   
2 21.3% X  X  
2 18.1% X   X 
2 10.6%  X X  
2 6.6%  X  X 
3 25.4% X X X  
3 22.1% X X  X 
3 22.8% X  X X 
3 11.6%  X X X 
4 27.1% X X X X 
Table 7.13 Best subset analysis incorporating FRAX hip score 
The greatest contributors in each case are the individual fracture risk scores 
explaining 15.7 to 17.1% of the variability and both significantly associated with 
osteoporosis status (p<0.001). Premature menopause contributed 6% of the R2 
individually, and approximately 5% increase in R2 in combination whilst remaining 
significantly associated with outcome (p=0.001). Inclusion of OPG antibodies 
increased the R2 value by 4% either alone or in combination and was also 
significantly associated with outcome in this model (p=0.001). Disease duration  less 
than 2 years contributed a modest 0.4% increase in the R2 value only and in this 
analysis was not significantly associated with outcome (p=0.11) suggesting that it 

















1 15.7% X    
1 6.0%  X   
1 4.4%   X  
1 0.4%    X 
2 19.6% X X   
2 19.9% X  X  
2 16.4% X   X 
2 10.6%  X X  
2 6.6%  X  X 
3 24% X X X  
3 20.4% X X  X 
3 20.9% X  X X 
3 11.6%  X X X 
4 25.2% X X X X 
Table 7.14 Best subset analysis incorporating QFracture hip score 
A model incorporating FRAX hip score, premature menopause and OPG antibody 
improved all parameters over the FRAX score alone with an R2 of 27.1. Similar 
results were seen with the use of the QFracture hip score with a modestly lower R2 of 








OPG autoantibodies were significantly raised in patients with coeliac disease 
compared to healthy controls with a prevalence of 5% (ELISA protocol II). Within 
this cohort the presence and titre of OPG autoantibody was associated with 
significantly lower spine BMD, and a non-significant trend to lower BMD at the hip.  
The association is driven by a relatively small number of positive cases and needs to 
be treated with some caution. The association is robust and unaffected by log 
transformation of the data, which will reduce the influence of more extreme results. 
Similarly the association withstood multivariate analyses of potential confounders 
such as age, sex, weight and height and is consistent with a pathogenic role for these 
antibodies in a subset of patients with coeliac disease.  
 
Within the IBD cohort whilst numerically lower bone density scores were seen in 
patients with OPG antibodies, the statistical association was weaker than in the 
coeliac cohort. Significant association between OPG antibodies and reduced BMD 
was seen only with hip Z scores on univariate analysis, though adjustment for age 
revealed significant association with hip T scores also. These associations were 
confounded by features of worsened disease severity since the patients with OPG 
antibodies suffered a significantly longer disease duration as well as all having 
Crohn’s disease. Perhaps unsurprisingly for a condition not associated with 
autoantibody production, the absolute titres of OPG antibody were not significantly 
raised in this cohort when compared to healthy controls. From this small cohort it 
was not possible to conclude that OPG antibodies are associated with the 
development of osteoporosis in IBD therefore. 
 
The clinical utility of measuring OPG antibodies has not been established. Whilst 
OPG antibodies appeared to be an independent predictor of osteoporosis in coeliac 
disease further work will be required to demonstrate that there is a clinical utility in 
identifying OPG antibodies.  A number of observations can still be made from this 
modelling work. In general the available fracture risk scores do not provide a 
clinically useful guide to the development of osteoporosis in coeliac disease. In 
women premature menopause appears to be a useful additional factor in a risk 
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prediction model with increased explanatory power apparently added in models 
incorporating both premature menopause and OPG antibodies, and it will be 
interesting to explore the utility of these factors in a larger cohort of coeliac patients. 
 
The finding that only a proportion of the serum samples with OPG antibodies were 
able to demonstrate functional inhibition of OPG may go some way to explain the 
difficulties in establishing  a link between the presence of OPG antibodies and 
clinical outcomes. It is well established that naturally occurring antibodies 
recognising self-antigens occur, though these are typically thought to be of low 
affinity and rarely pathogenic. Such natural antibodies are usually IgM antibodies 
which would not be expected to be purified in the Protein G agarose beads that were 
used here, however IgG natural autoantibodies are also recognised198. It is of course 
important to consider not just the affinity but also the epitope specificity of the 
antibody with recognition of a non-functional domain of the OPG presumably less 





Chapter 8: Discussion 
8.1 Introduction 
Many different factors are involved in the determination of peak bone mass and 
subsequent bone loss. In all patients identified as having osteoporosis a search should 
be undertaken for underlying conditions that may predispose toward osteoporosis. 
The very severe phenotype of the patient presented in Chapter 3 prompted extensive 
further investigation into an underlying cause. Such investigations are justified on 
two counts. Firstly the identification of a treatable underlying condition will directly 
affect the management of the individual patient. Secondly the investigation of 
patients with extreme phenotypes can yield important insights into the pathogenesis 
and treatment of disease in patients with more typical presentations199.  
 
This patient was identified as having coeliac and thyroid disease yet his bone density 
deteriorated despite appropriate management of these conditions. Whilst osteoporosis 
is a common complication of many autoimmune diseases it is typically attributed to 
disease specific factors or steroid treatment rather than a direct autoimmune 
process147, 200. It is well recognised however that patients with an autoimmune 
condition are more likely to develop other autoimmune diseases193 and 
autoantibodies to endogenous cytokines are increasingly recognised as a cause of 
disease pathogenesis174. This prompted a search for an autoimmune aetiology of the 
patient’s high bone turnover osteoporosis, and ultimately led to the identification of 
autoantibodies to OPG. 
 
This is the first report of a bone disease occurring in association with the 
spontaneous development of autoantibodies to OPG. OPG antibodies have 
previously been reported, but occurred in the context of treatment with a recombinant 
immunoglobulin Fc region-OPG construct resulting in the discontinuation of 
treatment but no apparent disease 191. The bone disease in this index patient was 
extreme, with bone density T score falling to a nadir of -7.1 in the spine, multiple 
vertebral fractures resulting in height loss of 6cm and very high bone turnover. 
Unlike many patients with coeliac disease there was no improvement in his bone 
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density with a gluten-free diet and calcium and vitamin D replacement, yet his 
response to treatment with the anti-resorptive zoledronate (Aclasta) was astonishing. 
Treatment with the anti-RANKL monoclonal denosumab (Prolia) did not prove as 
effective in this patient despite this intuitively being a more attractive approach. It is 
possible that the usual treatment regime for osteoporosis was inadequate in this 
patient, and even conceivable that the loss of efficacy was the result of a further 
autoantibody response to the denosumab treatment, though this is speculation. The 
high and persisting levels of OPG antibody seen in the index patient even raise the 
possibility of treatment with B cell depleting therapies such as rituximab (Mabthera), 
though given the potentially serious adverse effects reported with the therapy this 
approach has not been adopted to date201. 
8.2 Challenges 
8.2.1 Identification of OPG autoantibodies 
The first aim of this thesis was to establish if immunoglobulins isolated from the 
index patient were capable of recognising OPG in-vitro. An assay for OPG 
autoantibodies was developed initially by modifying a commonly used 
immunoprecipitation technique for the identification of cellular proteins. Instead of 
probing for the presence of a protein with specific antibody however, OPG was 
introduced and the assay used to test for the presence of recognising antibody. This 
technique did indeed result in robust precipitation of OPG using serum from the 
index case providing an initial proof of concept that OPG autoantibodies were 
present. As has been discussed in Section 4.8 even with serum from the index case 
there was substantial variability in the intensity of bands seen despite attempts to 
standardise the assay and whilst an OPG signal was seen in a small number of 
patients with severe osteoporosis and coeliac disease this proved both laborious and 
difficult to quantify. Given these practical limitations attention turned to developing 
an alternative assay. 
 
There were considerable challenges in developing a quantifiable, and high 
throughput, assay for OPG autoantibodies. The initial indirect ELISA approach 
(Section 2.3.1) again demonstrated proof of principle that serum from the index case 
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would compete out the signal from commercial anti-OPG autoantibodies, but the 
dynamic range of the assay was very limited and unlikely to yield a test capable of 
recognising anything but a very strong signal equivalent to that seen in the index 
case. Subsequently a direct ELISA was developed which did show a greater than 10 
fold increase in signalling with the positive control over negative serum samples, and 
appeared much more promising to use as a screening tool. A major challenge with 
this assay has been ensuring reproducibility of results using the direct ELISA. (a 
detailed discussion of the refinements to the assay are given in Section 4.8). The 
variability in results seen, as well as the essentially arbitrary nature of any threshold 
chosen to define the presence of an antibody mean that the estimates of prevalence of 
antibodies in different populations must be treated with caution. At a fundamental 
level these results support the thesis that the occurrence of OPG autoantibodies was 
not a unique event, but is also occurring in a small proportion of patients with 
established osteoporosis or immune mediated disease.  
8.2.2 Demonstration of inhibition of OPG function 
The pathological significance of any autoantibody is likely to be influenced by a 
combination of titre, affinity and epitope specificity, with the most compelling 
evidence of pathogenicity provided by transmission of disease in vivo with transfer 
of autoantibody. The ELISA assay is able to demonstrate the presence of 
autoantibody recognising part(s) of the whole OPG protein, but in order to provide 
additional evidence of possible pathological effect an in-vitro assay was developed to 
identify if the autoantibody was also capable of blocking the effects of OPG in vitro.  
 
A number of cell signalling systems were explored in this respect (Section 2.2) with 
more physiological systems based on the generation of alkaline phosphatase in 
macrophage based RAW cell lines unfortunately not proving suitable as the cells 
were not responsive to RANKL. Fortuitously a HEK 293 cell line that was stably 
transfected with an Nf-κB luciferase reporter was found to respond to RANKL and 
with this it proved possible to demonstrate that serum from the index patient and 
serum from a proportion of the positive samples found from populations screened 
were capable of inhibiting the function of OPG in vitro. This result corroborated the 
result of the IP assay and ELISA, and also lends credence to the concept that the 
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autoantibodies identified were capable of inhibiting the function of OPG in-vivo and 
so causing disease.   The finding that only a proportion of the serum samples with 
OPG antibodies were able to demonstrate functional inhibition of OPG may go some 
way to explain the difficulties in establishing a link between the presence of OPG 
antibodies and clinical outcomes, with these positive samples by ELISA potentially 
representing false positives, antibodies directed against non-functional epitopes or 
low affinity antibodies incapable of interfering in OPG function.  
 
8.2.3 Clinical significance of OPG autoantibodies 
Within a general population autoantibodies to OPG were identified in 1.6% based on 
an arbitrary cut-off of the mean plus 3 standard deviations of healthy controls. No 
correlation with bone density or bone turnover was observed in these patients 
suggesting that these antibodies are not pathological and represent false positives or 
non-functional antibodies. This also implies that OPG antibodies are not a common 
cause of osteoporosis in the general population. An association with vascular 
calcification was observed which conflicts with the conclusion that these OPG 
antibodies are benign but requires replication in view of the small number of samples 
with positive OPG antibodies in this cohort. If confirmed, this could be explained by 
the identified OPG antibodies being a marker for a previous episode of high bone 
turnover resolved by some compensatory biological response, or by OPG antibodies 
being directly implicated in vascular calcification independently of effects on bone. 
Equally this result could be explained by OPG antibodies representing an 
epiphenomenon of increased bone turnover or vascular calcification. 
  
Within a cohort of patients with osteoporosis, an increased prevalence of OPG 
antibodies was observed, though this does not act as a marker of lower bone density 
and was associated with inconsistent changes in markers of bone turnover. Within 
this cohort, most patients have already been treated with antiresorptive therapies 
which would be expected to influence these results. An increased prevalence of OPG 
antibodies was also seen in patients with coeliac disease, which is unsurprising given 
the manifest tendency to autoimmunity in these patients. In this cohort, the presence 
of OPG antibodies is associated with lower bone density again consistent with a 
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pathological role of the antibodies, though compatible also with OPG antibodies 
being an epiphenomenon of bone disease ie association does not prove causality. The 
in-vitro studies showing that a proportion of these antibodies are functional support 
the conclusion that for some patients at least OPG antibodies contribute to the 
pathogenesis of osteoporosis.  
 
The clinical utility of measuring OPG antibodies has not been established however. 
In an exploratory analysis it would appear that identification of OPG antibodies 
might help in identifying osteoporosis in coeliac patients, though it is unlikely that 
this small additive benefit would mean a move away from current practice of 
screening all newly diagnosed patients by DEXA scanning. Similarly in the 
osteoporosis cohort the subgroup of patients identified as having OPG autoantibodies 
did not respond differently to treatment than the patients without antibodies. At 
present these results provide evidence for an additional autoimmune mechanism of 
disease in osteoporosis, but have not demonstrated that identification of OPG 
autoantibodies would materially influence the management of any individual patient.  
 
In a study of this nature there is an inherent danger of over interpreting chance 
observations in the context of relatively small disease cohorts. The significant 
associations observed between OPG antibody presence and reduced bone mineral 
density in the IBD and coeliac cohorts are driven by relatively small numbers of 
patients with the highest antibody concentrations. Given the extreme phenotype seen 
in the index case excluding the most extreme results runs the risk of excluding the 
most relevant patients from the study, but at the same time such outliers will heavily 
influence the results. The association of OPG antibody with reduced hip bone density 
observed in the IBD cohort may indeed be a chance effect influenced by confounding 
features of increased disease severity. The association of OPG antibody with reduced 
spine bone density in the coeliac cohort appears more robust. Standard regression 
diagnostics confirmed that the model satisfied assumptions of linear regression, and. 
repeating the analysis with log transformed data did not materially alter the 
conclusions. Equally the finding was not affected by inclusion of common 
confounders in a multivariate analysis, and a search for potential disease associated 
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confounders did not reveal any significant correlations with OPG antibody. Clearly 
in a complex disease such as osteoporosis it is difficult to control for all the many 
potential confounding disease and treatment associated factors and given these 
difficulties it will be critical to see these results replicated in larger and independent 
cohorts. 
 
8.3 Context of the current study 
The current case report remains the only description of disease associated with the 
development of autoantibodies to OPG202. In the original published report an 
immunoprecipitation assay was used to identify autoantibodies and, as has been 
discussed already (Section 4.2), this assay was found to be unsuitable for population 
screening. Developing a more sensitive and reproducible assay has been difficult 
even with a positive control sample with which to guide optimisation of assay 
conditions. It is disappointing, though perhaps not surprising, that to date no further 
case of disease associated with OPG autoantibodies has been reported. The only 
work published to date that has attempted to replicate this work screened a small 
cohort of 30 coeliac patients using the immunoprecipitation assay without finding 
any positive samples203.   
 
Naturally occurring self-reactive autoantibodies have long been recognized, though 
their role in normal physiology, as well as in disease pathogenesis, is the subject of 
ongoing research 174, 194, 204. This appears to be a promising field of research offering 
insights into diverse conditions previously considered unexplained or idiopathic. 
This is an expanding field with the power of protein arrays and mass spectrometry 
technologies facilitating the identification of novel autoantigens. What this thesis 
highlights is the many practical difficulties that translating a proof of concept that a 
novel autoantibody does occur naturally, into knowledge that can be used in some 
clinically useful manner. This includes the difficulty of developing robust assays to 
both identify and characterise novel autoantibodies, but equally given the many 
contributors to complex diseases such as osteoporosis it highlights the importance of 
building biobanks of samples from well phenotyped patients to allow the clinical 




OPG was identified as a key inhibitor of osteoclast development and this thesis has 
naturally focussed primarily on the possible skeletal manifestations of autoantibodies 
to OPG, but there are other potential applications of the study. As has been 
mentioned in the introduction (Section 1.3.5) there is already substantial evidence for 
a role of OPG in the development of vascular calcification with this concept 
supported by human studies, animal models and in-vitro work104,105,106 107. This may 
be explained by effects on RANKL with elevated levels of RANK and RANKL 
having been identified in atherosclerotic lesions where they are associated with 
increased expression of BMP-2 as well as decreased expression of matrix Gla protein 
(MGP) a key inhibitor of mineralisation108, however an alternative mechanism 
independent of RANKL has also been suggested. OPG acts as a decoy receptor for 
TNF related apoptosis inducing ligand (TRAIL) and both TRAIL and OPG have 
been identified in atherosclerotic plaques, with TRAIL also shown to enhance the 
mineralisation of VSMCs in-vitro114.  
 
TRAIL is primarily known as a lymphokine that induces apoptosis in tumour cells, 
implicating OPG in cancer biology205. This is in addition to the direct recognition of 
OPG via a heparin binding domain that has been implicated in myeloma bone 
disease206. Further complexity is added by studies showing the proteoglycans in the 
tumour milieu are capable of binding OPG and interfering with OPG activity in a 
mouse model of osteosarcoma207. An array of reported roles for OPG has recently 
been reviewed with the binding of glycosaminoglycans by OPG potentially 
contributing to chemotaxis of monocytes and even the migration of endothelial cells, 
and an interaction with von Willebrand factor and Factor VII/von Willebrand factor 
complex suggesting a role for OPG in vascular injury and thrombus formation208. To 
date the index case has not been identified as having any other serious manifestations 
of disease associated with OPG deficiency, though mild vascular calcification was 




8.4 Future aims 
The immediate priority will be to expand the numbers of patients with coeliac 
disease and established osteoporosis that have been presented here, and reassess the 
associations with bone mineral density and fracture in larger numbers, as well as the 
clinical significance of identified OPG antibodies. It is anticipated that these results 
should be available for submission within the year. Current collaborations have 
already looked at the results of the OPG ELISA in cohorts of patients with rheumatic 
disease such as rheumatoid arthritis and ankylosing spondylitis209. There great 
potential to expand this work with interest expressed from a number of potential 
collaborators already in possession of serum samples from well phenotyped 
population and study cohorts. The rate limiting factor in this has been the 
performance of the ELISA which has hindered development of such collaborations. 
Some modifications have been made by Prof Bill Fraser in University of East Anglia 
and approaches have been made to biotechnology companies interested in this field 
which it is hoped will allow replication of these findings in other settings. This is 
progressing, albeit slowly. 
   
The current ELISA uses whole recombinant OPG as a capture antigen in order to 
identify autoantibodies recognising all exposed epitopes of OPG. The results 
presented in this thesis have shown that functional inhibition of OPG is demonstrable 
only in a proportion of the positive samples identified by ELISA. It is possible that 
only antibodies against specific regions within OPG are capable of inhibiting 
function, and as such work has already been undertaken to generate recombinant 
fragments of OPG in order to fine map this immune response. OPG consists of four 
amino terminal cysteine rich domains required for the binding of RANKL210, 211, as 
well as a heparin binding domain and two death domain homologous regions at the 
carboxy terminal end210, 212. Two large ~100 amino acid fragments of OPG from the 
functional domains of OPG have been expressed in bacterial plasmids and both have 
shown reactivity to serum from the index patient and selected positive samples213. 
The large fragments used in these experiments were unable to detect any differential 
epitope specificity in the serum samples analysed although this work has already 
established that the OPG autoantibody response is capable of recognising diverse 
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epitopes within OPG in keeping with a polyclonal antibody response. Further work 
with smaller fragments could be useful to fine map these responses.  
 
8.5 Conclusions 
The results presented here identify a novel mechanism of osteoporosis mediated by 
autoantibodies to OPG. Whilst the clinical presentation of the index case was 
exceptionally severe and appears rather unique, the results of screening populations 
of idiopathic osteoporosis patients and patients with coeliac disease are consistent 
with a pathogenic role for OPG antibodies in a number of these patients with more 
typical presentations of osteoporosis. Whilst this is an interesting observation, it 
should be tempered by the practical observation that no clinical utility in identifying 
the presence of OPG antibodies has been demonstrated in either cohort. Clearly it 
remains possible that an analysis of larger cohorts, or better characterisation of the 
antibody functionality may yet yield clinically useful insight. It will also be 
important to identify patients who have recently developed OPG antibodies in whom 
treatment effect, or potentially physiological compensation, will not have occurred. 
The coeliac cohort lends itself particularly well to this work, since they are clearly a 
population at heightened risk of developing autoantibodies in whom intervention 
with antiresorptive therapies is not usually given in the initial period after diagnosis, 
hence removing this important confounding effect on bone density and bone 
turnover. Work is ongoing to build a large cohort of coeliac patients in whom these 
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A1 Materials and Reagents 
 
All materials and reagents are listed in the table below in an alphabetical order. 
Materials and reagents Supplier 
Α Minimum Essential Medium (α MEM) Sigma Aldrich, Dorset, UK 
alamarBlueTM reagent Invitrogen, Paisley, UK 
Amersham HybondTM-P GE Healthcare Life Sciences, 
Buckinghamshire, UK 
Bicinchoninic acid (BCA) protein assay Sigma Aldrich, Dorset, UK 
Bovine serum albumin (A7906) Sigma Aldrich, Dorset, UK 
Bromophenol blue BDH Laboratory Supplies, Poole, Dorset, 
UK 
Centrifuge tubes (15 and 50ml) Fisher Scientific, Leicestershire, UK 
Coating buffer (C3041) Sigma Aldrich, Dorset, Kent 
Copper (II)-sulfate Sigma Aldrich, Dorset, UK 
Costar ELISA plate (3369 EIA/RIA) Fisher Scientific, Leicestershire, UK 
CriterionTM XT pre-cast gels (12% Bis-Tris) Bio-Rad Laboratories, Hertfordshire, UK 
D Minimum Essential Medium (dMEM) Sigma Aldrich, Dorset, UK 
DL-Dithiothreitol (DTT) Sigma Aldrich, Dorset, UK 
DMSO Sigma Aldrich, Dorset, UK 
EDTA Sigma Aldrich, Dorset, UK 
Electrophoresis power supply Anachem, Bedfordshire, UK 
Ethanol absolute Fisher Scientific, Leicestershire, UK 
Extra thick blot papers Bio-Rad Laboratories, Hertfordshire, UK 
Fetal calf serum (FCS) Fisher Scientific, Leicestershire, UK 
HEK 293 luciferase reporter cell line 
(RC0014) 
eBioscience Ltd,Hatfield, UK 
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Human recombinant RANKL Gift from Dr. Patrick Mollat (Proskelia 
SASU) 
IgG elution buffer (Cat 21004) Fisher Scientific, Leicestershire, UK 
Jackson ImmunoResearch Anti-rabbit 
secondary antibody 
Stratech Scientific Unit, Newmarket 
Suffolk, UK 
Kaleidoscope markers Bio-Rad Laboratories, Hertfordshire, UK 
L-Glutamine Invitrogen, Paisley, UK 
LPS (IMG-2204) Imgenex,2B scientific, Oxford, UK 
Low molecular weight DNA ladder New England Biolabs, Hertfordshire, UK 
Magic Marker Invitrogen, Paisley, UK 
Melon™ Gel IgG Spin Purification Kit 
Thermo Scientific 45206 
Fisher Scientific, Leicestershire, UK 
Methanol Fisher Scientific, Leicestershire, UK 
Micro titre plate (Sterilin, 611F96) Fisher Scientific, Leicestershire, UK 
Neubauer haemocytometer Hawksley, Lancing, UK 
Osteoprotegerin (Human recombinant Cat 
185-05) 
R&D Systems, Abingdon, UK 
Osteoprotegerin ELISA Biomedica, BI-20403 Oxford Biosystems, Oxford, UK 
PBS tablets Invitrogen, Paisley, UK 
Penicillin/Streptomycin Invitrogen, Paisley, UK 
Pierce Protein G IgG Binding Buffer 21019 Fisher Scientific, Leicestershire, UK 
Pierce SuperSignal® West Dura Extended 
Duration Substrate 
Fisher Scientific, Leicestershire, UK 
Pierce Protein G spin columns Fisher Scientific, Leicestershire, UK 
Primary mouse monoclonal antibody to OPG  
(Cat Ab1194 – clone number 98A1071) 
AbCam, Cambridge, UK 
Primary rabbit polyclonal antibody to OPG 
(Cat Ab 9986) 
AbCam, Cambridge, UK 
Primary rabbit polyclonal antibody to-OPG 
biotin conjugated (Cat Ab18068) 
AbCam, Cambridge, UK 
Protein G IgG Binding Buffer (Cat 21019) Fisher Scientific, Leicestershire, UK 
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Quant-iTTM PicoGreen® assay Invitrogen, Paisley, UK 
RANKL ELISA Total (Biovendor 
RD193004200R) 
Oxford Biosystems, Oxford, UK 
RANKL ELISA Free (Biomedica BI-20452) Oxford Biosystems, Oxford, UK 
RAW 264.7 SEAP reporter cell line (IML-
120)  
Imgenex, 2B Scientific, Oxford, UK 
RAW 264.7 cell line (91062702) ECACC, Porton Down, UK 
SEAP reporter Alkaline Phosphatase assay  
(Imgenex Cat 10055K) 
Imgenex, 2B Scientific, Oxford, UK 
Secondary anti-human peroxidase conjugated 
antibody (109-035-088) 
Stratech Scientific Unit, Newmarket 
Suffolk, UK 
Secondary anti- mouse secondary antibody 
(Cat 715-035-151) 
Stratech Scientific Unit, Newmarket 
Suffolk, UK 
Sodium dodecyl sulphate (SDS) Bio-Rad Laboratories, Hertfordshire, UK 
Steady-Glo reagent Promega, Southampton, UK,  
Stripettes (5, 10, 25 and 50ml)  Sarstedt Ltd, Leicester, UK 
Syngene BIO imaging system Fisher Scientific, Leicestershire, UK 
Syringes (all sizes) Becton Dickinson, Berkshire, UK 
TBS 10x (T5912) Sigma Aldrich, Dorset, UK 
TBE buffer 10X Invitrogen, Paisley, UK 
2%TCH (serum replacement) MP-Biomedicals, Cambridge, UK 
Tissue culture 75cm2 flasks Fisher Scientific, Leicestershire, UK 
Tissue culture microplates (6– 96well plates) Fisher Scientific, Leicestershire, UK 
TMB Stop solution (50-85-06) KPL, Maryland, USA 
Toluidine Blue Sigma Aldrich, Dorset, UK 
Tris Bio-Rad Laboratories, Hertfordshire, UK 
Tris-EDTA buffer Sigma Aldrich, Dorset, UK 
Triton X-100TM Sigma Aldrich, Dorset, UK 
Trizol reagent Invitrogen, Paisley, UK 
Trizol® Reagent Invitrogen, Paisley, UK 
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Trypsin/EDTA Sigma Aldrich, Dorset, UK 
Tween-20 (27,434-8) Sigma Aldrich, Dorset, UK 
UV 96 well plates for plate reader Fisher Scientific, Leicestershire, UK 
XT-MOPS Bio-Rad Laboratories, Hertfordshire, UK 




All apparatus are listed in the table below in alphabetical order.  
 
Apparatus Supplier 
AA Hoefer® protein transfer apparatus Fisher Scientific, Leicestershire, UK 
Balancer Fisherbrand Fisher Scientific, Leicestershire, UK 
Bench-top centrifuge SciQuip, Shropshire, UK 
Benchtop Eppendorf centrifuge Fisher Scientific, Leicestershire, UK 
Bio-Tek Synergy HT plate reader Fisher Scientific, Leicestershire, UK 
Envair Bio2 safety cabinets  H&V Commissioning Services Ltd., 
Ayrshire, UK 
Grant OLS 200 water bath Thistle Scientific, Glasgow, UK 
Nichiryo America Inc. Pipettes (2, 10, 100, 200 and 
1000μl) 
Thistle Scientific, Glasgow, UK 
NoAir Class II Biological safety cabinet TripleRed Ltd., Buckinghamshire, UK 
Origo PSU-400/200 power supply for electrophoresis, Anachem, Bedfordshire, UK 
PowerPac basicTM Bio-Rad Laboratories, Hertfordshire, 
UK 
Syngene GeneGenius Gel Bio-Imaging system Fisher Scientific, Leicestershire, UK 
SynSyngene GeneGnome Bio-Imaging system for 
chemiluminescence 
Fisher Scientific, Leicestershire, UK 






All software are listed in the table below in alphabetical order. 
 
Software Supplier 
Bio-Tek Gen5TM plate reader software Fisher Scientific, Leicestershire, UK 
Minitab Release 16.2.4 Minitab Inc., Pennsylvania, US 
SPSS statistics 19 SPSS Inc 
Syngene GeneSnap software Fisher Scientific, Leicestershire, UK 







APPENDIX 3.1 SOLUTIONS FOR PAGE AND WESTERN BLOT 
i.  Electrophoresis running buffer 
50ml of XT-MOPS (20X) in 1000ml of dH2O 
 
ii. Sample  loading protein buffer (5X stock) 
5.2ml of 1M Tris-HCl pH adjusted to 6.8, 1g of DL-Dithiothreitol (DTT), 3g SDS, 
6.5ml glycerol and 130μl of 10% (w/v) bromophenol blue. Stored at -20˚C.   
 
iii. Transfer buffer 
3.63g of Tris, 14.4g of glycine, 200ml of methanol and 3.75ml of 10% (w/v) SDS 
made up to 1,000ml with dH2O. Stored at room temperature. 
 
iv. TBS 
1M of Tris and 1M Tris-HCl, pH adjusted to 7.9 prior to addition of 3M sodium 
chloride. Stored at room temperature. 
 
v. TBST 
0.1% (v/v) Tween-20 in TBS. Stored at room temperature. 
 
vi. Stripping buffer 
1mM DTT, 2% (w/v) SDS and 62.5mM Tris-HCl (pH 6.7). Stored at room 
temperature. 
 
APPENDIX 3.2 SOLUTION FOR CELL LYSIS  
RIPA Lysis buffer 
1% Triton 100X, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) sodium dodecyl 
sulphate (SDS), 50mM Tris-HCl (pH 7.4) and 150nM sodium chloride were 





APPENDIX 3.3 SOLUTION FOR ELISA  
 
TBST wash buffer 
0.05 % (v/v) Tween 20 in TBS (pH 7.4) made up in dH2O. 
 
Coating buffer 
Carbonate/bicarbonate buffer 0.2 M, pH 9.6, prepared commercially with 






A4 Protocols for assays of functional inhibition of OPG 
A number of models were explored to find a system that would demonstrate the 
functional activity of OPG antibodies, but were found not to be suitable. I 
acknowledge the technical assistance of Tamara Gilchrist in the performance of these 
assays. 
A4.1 Principles of the AlphaLISA  assay 
A potential functional assay of OPG antibodies was investigated using the 
AlphaLISA bead based protocol (Perkin Elmer). This is a proximity assay of protein 
interactions, in which a signal is emitted when coupled beads are brought together by 
linked protein pairs. 
 
In this exploratory assay, OPG was bound to ‘donor’ beads and RANKL bound to 
separate ‘acceptor’ beads. If a robust dose response to increasing OPG beads could 
be established, then this in turn could potentially be inhibited by the presence of OPG 
antibodies. Diminution of signal in such an assay would allow both the quantification 
of antibodies to OPG (or indeed RANKL) and simultaneously demonstrate that these 
antibodies were functional inhibitors of the OPG-RANKL interaction. 
The beads are supplied with a variety of ligands with glutathione acceptor beads 
linked to GST tagged RANKL, and Nickel chelate donor beads then linked with his-
tagged OPG. Dose ranging experiments were performed using a variety of 
concentrations of OPG and RANKL. Inconsistent results were observed despite a 
variety of blocking buffers being assessed to see if these could improve the assay   




A4.2 Protocol for the AlphaLISA assay 
All beads prepared in subdued lighting (covered in foil for all incubations). 
1) Add 10μl of the appropriate 1x buffer to the corresponding wells (see plate plan).  
 Prepare 5ml of 1% BSA in TBST  
 Prepare 5ml of 1x AlphaLISA Universal buffer (5 x stock) by adding: 
1ml stock to 4ml of 0.2μM filtered dH20 
 Prepare 5ml of 1x AlphaLISA HiBlock buffer and AlphaLISA Immunoassay 
buffer (10x stock) by adding: 
500μl stock to 4.5ml 0.2μM filtered dH20 
 
2) Prepare 4 x 180nM OPG and RANKL protein solutions (1 in each buffer) and use 
to prepare 5 x concentrated working stock solutions to create a concentration gradient 
for each buffer: 
 
 Produce 4 x 55μl of a 180nM his-tagged OPG solution by adding: 
      0.9μl of OPG stock (0.5 mg/ml) to 54.1μl of the appropriate buffer 
 Prepare 4 x 55μl of a 180 nM GST-tagged RANKL solution by adding: 
46.5μl of RANKL stock (10 μg/ml) to 8.5μl of the appropriate buffer 
 Use the 180nM protein solutions to prepare 4 lots of the following OPG and 












36nM 180nM 55μl of 180nM 
solution 
None 
8.0nM 40nM 11μl of 180nM 
solution 
38.5μl 
2.4nM 12nM 15μl of 40nM solution 35μl 
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0.0nM 0.0nM None 50μl 
 
3) Add 10μl of OPG and 10μl of the RANKL solutions to the appropriate wells (see 
plate plan).  
 
4) Seal plate firmly, wrap in foil and incubate at 37oC (± 2oC) for 1 hour. 
 
5) Prepare 4 x working solutions of Glutathione Acceptor beads (1 in each buffer): 
 
 Prepare 4 x 175μl of 100 μg/ml solutions (5 x) of glutathione acceptor beads 
by adding 3.5μl beads (at 5 mg/ml) to 171.5μl of the appropriate buffer 
 
6) After initial incubation, allow plate to equilibrate to room temperature for 5 minutes. 
Subsequently, add 10μl of the 100μg/ml acceptor beads (final concentration 20μg/ml) 
to the appropriate wells of the plate (See plan). 
 
7) Seal plate firmly, cover in foil and incubate at room temperature (24oC ± 2oC) for 1 
hour. 
 
8) Prepare 4 x working solutions of Nickel chelate donor beads: 
 
 Prepare 4 x 175μl of 100μg/ml solutions (5x) of Nickel chelate donor beads by 
adding 3.5μl beads (at 5mg/ml) to 171.5μl of the appropriate buffer. 
  
9) After second incubation, add 10μl of the 100μg/ml donor beads (final 
concentration 20μg/ml) to each well. 
 
10) Seal plate, cover in foil and incubate at room temperature (24˚C ± 2˚C) for 1 
hour. 
 




  1 2 3 4 5 6 7 8 9 - 24  
A 
 
36 nM OPG 36 nM OPG 36 nM OPG 36 nM OPG 36 nM OPG 36 nM OPG 36 nM OPG 36 nM OPG  
36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL 36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL Blank 
1 % BSA TBST 1 % BSA TBST 1 % BSA TBST 1 % BSA TBST Universal buffer Universal buffer Universal buffer Universal buffer  
B 
 
8 nM OPG 8 nM OPG 8 nM OPG 8 nM OPG 8 nM OPG 8 nM OPG 8 nM OPG 8 nM OPG  
36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL 36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL Blank 
1 % BSA TBST 1 % BSA TBST 1 % BSA TBST 1 % BSA TBST Universal buffer Universal buffer Universal buffer Universal buffer  
C 
 
2.4 nM OPG 2.4 nM OPG 2.4 nM OPG 2.4 nM OPG 2.4 nM OPG 2.4 nM OPG 2.4 nM OPG 2.4 nM OPG  
36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL 36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL Blank 
1 % BSA TBST 1 % BSA TBST 1 % BSA TBST 1 % BSA TBST Universal buffer Universal buffer Universal buffer Universal buffer  
D 
  
0 nM OPG 0 nM OPG 0 nM OPG 0 nM OPG 0 nM OPG 0 nM OPG 0 nM OPG 0.0 nM OPG  
36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL 36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL Blank 
1 % BSA TBST 1 % BSA TBST 1 % BSA TBST 1 % BSA TBST Universal buffer Universal buffer Universal buffer Universal buffer  
E 
  
36 nM OPG 36 nM OPG 36 nM OPG 36 nM OPG 36 nM OPG 36 nM OPG 36 nM OPG 36 nM OPG  
36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL 36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL Blank 












8 nM OPG 8 nM OPG 8 nM OPG 8 nM OPG 8 nM OPG 8 nM OPG 8 nM OPG 8 nM OPG  
36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL 36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL Blank 












2.4 nM OPG 2.4 nM OPG 2.4 nM OPG 2.4 nM OPG 2.4 nM OPG 2.4 nM OPG 2.4 nM OPG 2.4 nM OPG  
36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL 36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL Blank 












0 nM OPG 0 nM OPG 0 nM OPG 0 nM OPG 0 nM OPG 0 nM OPG 0 nM OPG 0.0 nM OPG  
36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL 36 nM RANKL 8  nM RANKL 2.4 nM RANKL 0 nM RANKL Blank 










I - P 
 
Blank Blank Blank Blank Blank Blank Blank Blank Blank 
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    Table A4.1 Results of AlphaLISA assay 
 
AlphaScreen Protocol - raw 
  OPG Concentration 

























0.0 nM  1,299 1,549 1,718 1,686 1,855 2,086 2,311 2,394 
2.4 nM  1,334 1,619 1,764 1,638 1,929 2,140 2,025 2,553 
8.0 nM  1,510 1,854 1,732 1,841 1,979 2,531 2,200 2,701 




























0.0 nM  732 730 822 714 852 840 854 954 
2.4 nM  671 732 776 738 764 836 952 1022 
8.0 nM  810 794 847 788 902 994 958 922 
36 nM  805 811 909 975 921 1,019 1,011 979 
          
AlphaScreen Protocol- corrected 
  OPG Concentration 

























0.0 nM  1,386 1,652 1,831 1,739 1,917 2,155 2,390 2,391 
2.4 nM  1,426 1,730 1,885 1,750 2,063 2,286 2,162 2,730 
8.0 nM  1,612 1,980 1,847 1,903 2,112 2,704 2,345 2,792 




























0.0 nM  782 779 878 760 881 868 882 983 
2.4 nM  693 781 828 788 789 892 1,017 1,091 
8.0 nM  866 848 904 839 964 1,062 1,023 981 
36 nM  832 866 971 1,042 952 1,087 1,079 1,045 
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A4.3 TRAP assay 
RAW 264.7 cells were maintained in 75ml flasks containing supplemented D-MEM 
(with 1% penicillin/streptomycin, 1% L-Glutamine and 10 % FCS) with media 
refreshed every 2 days. Cells split by trypsinisation prior to assay (4ml trypsin added 
to flask then cells liberated by shaking). Pooled cells were counted in a modified 
Neubauer cell counter.  
 
Cells were made up to a final concentration of 200,000 cells/ml by adding the 
appropriate volume of supplemented D-MEM to the cells.  
 
Either 100μl of the 200,000 cell/ml suspension (20,000 cells/well) or 50μl of 200,000 
cell/ml suspension (10,000 cells/well) were added to 3 x 96 well micro-titre plates as 
shown below. To wells with 50μl of cells, a further 50μl of supplemented media was 
added to give a final volume of 100μl. 
 
Plates and flask were incubated at 37oC overnight. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A - - - - - - - - - - - - 
B - 10,000 10,000 10,000 10,000 10,000 20,000 20,000 20,000 20,000 20,000 - 
C - 10,000 10,000 10,000 10,000 10,000 20,000 20,000 20,000 20,000 20,000 - 
D - 10,000 10,000 10,000 10,000 10,000 20,000 20,000 20,000 20,000 20,000 - 
E - 10,000 10,000 10,000 10,000 10,000 20,000 20,000 20,000 20,000 20,000 - 
F - 10,000 10,000 10,000 10,000 10,000 20,000 20,000 20,000 20,000 20,000 - 
G - 10,000 10,000 10,000 10,000 10,000 20,000 20,000 20,000 20,000 20,000 - 
H - - - - - - - - - - - - 
 
The following 10X samples were prepared and incubated at 37 oC with shaking: 
 
Control  = 140μl supplemented D-MEM 
500ng/ml RANKL  = 0.7μl of 100μg/ml RANKL + 139.3μl sup D-MEM 
1000ng/ml RANKL  = 1.4μl of 100μg/ml RANKL + 138.6μl sup D-MEM x 2  




To one 140μl aliquot of the 1000ng/ml RANKL, 1.4μl of 100,000 ng/ml (100ng/μl) 
OPG (R&D systems, 185-OS-025 CF) was added to give a solution of  1000 ng/ml 
RANKL and 1000 ng/ml OPG. 
 
To each well of the 3 seeded microtitre plates 90μl of supplemented D-MEM was 
added. Then, to the appropriate wells, 10μl of the corresponding treatment was added, 
thus giving the treatment plan shown below (R = RANKL):  
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 



































C - - 
D - - 
E - - 
F - - 
G - - 
H - - - - - - - - - - - - 
 
One plate was incubated for 24 hours, the second for 48 hours and the third for 72 
hours. 
 
From the 24 hour plate, two 20μl aliquots of supernatant were drawn off without 
disturbing the cells and transferred to two fresh 96-well plates. These were stored at  
-20oC until required. The remaining cells were rinsed twice with PBS and then fixed 
with 4% Formaldehyde for 10 minutes. Finally, cells were rinsed twice in PBS and 
stored at 4oC until required. 
 





TRAP supernatant reaction buffer comprised: 
 
1M acetate   - 29.5ml 100 % acetic acid 
0.5% Triton X-100 - 2.5ml Triton X-100 
1M NaCl  - 29g NaCl 
10mM EDTA  - 1.86g EDTA 
The above reagents were added to 350ml of dH20 and then the pH adjusted to 5.5 
with 6M NaOH (6 g in 25ml). The solution was made up to a final volume of 500ml 
with dH20. Note: Buffer was cooled down to dissolve completely. 
 
To treat the supernatants from one plate for each of the time points, the following 
solutions were prepared fresh: 
 
8.8mg/ml L-Ascorbic acid in dH20 (0.044g in 5ml dH20) 
46mg/ml Di-sodium tartrate in dH20 (0.23g in 5ml dH20) 
18mg/ml 4-Nitrophenylphosphate in dH20 (0.09g in 5ml dH20) 
 
1ml of each of these solutions was used to prepare 8ml TRAP solution (made up with 
2ml reaction buffer and 3ml dH20) per plate, ie for 3 plates use 3ml each solution, 
6ml reaction buffer and 9ml dH20.  
 
To the 20μl supernatant aliquots, 80μl of the TRAP solution was added. The plate 
was covered with foil to protect from light and evaporation and incubated on a 
shaker (300-400 rpm) at 37oC for 1 hour. 
The reaction was then stopped by the addition of 0.3 M NaOH (6g in 500ml dH20).  
The absorbance at 650nm was measured subtracting the OD405nm values as 
background values. 
 
The plates of fixed cells from each time point were also stained as below: 
 
A 10mg/ml Naphtol-AS-BI-phosphate solution was prepared in Dimethylformamide 




Staining solution A was prepared by mixing the following in a clean GLASS test 
tube: 
450μl of Naphtol-AS-BI-phosphate 
2,250μl of Veronal buffer (see below) 
2,700μl of Acetate buffer 
2,700μl of Acetate buffer with 100 mM Tartrate 
 
Staining solution B was prepared by mixing (NOT vigorously) the following in a 
clean GLASS test tube: 
360μl of Pararosanilin  
360μl of Sodium Nitrite (4 %) (Toxic cabinet)  
 
TRAP staining solution was prepared by mixing solutions A and B and 0.45 μM 
filter sterilised into a further clean glass test tube. 
Cells were covered in 80μl TRAP staining solution and incubated for 50-60 minutes 
at 37oC. Cells were then rinsed twice with PBS and then covered with 200μl of 70 % 
ethanol (per well). Plate was then wrapped in cling film and stored at 4 oC. 
 
Experiment was unsuccessful; no staining of the cells or supernatant was achieved. 
Presumption made was that the stored RAW cells used had deteriorated. 
 
Stock solutions for cell staining : 
Veronal buffer: dissolve the following in 100ml of dH20: 
1.17g sodium acetate anhydrous 
2.94g veronal (sodium barbiturate) 
Acetate buffer: Adjust the pH of (a) to a pH of 5.2 with (b) 
a. 0.82g sodium acetate anhydrous (dissolve in 100ml of dH20) 
b. 600μl glacial acetic acid (make up to 100ml with dH20) 
Pararosanilin: 
Add 1g to 20ml of dH20, add 5ml of concentrated HCl and heat carefully in a water 
bath while stirring. Filter once cooled. 
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A4.4 Secreted alkaline phosphatase (SEAP) assay 
A4.4.1 SEAP Protocol 
A RAW 264.7 cell line expressing the SEAP reporter gene under the transcriptional 
control of a NF-kB response element (IML-120 Imgenex) was investigated for use in 
a functional model of OPG inhibition. SEAP catalyses the hydrolysis of 
pNitrophenyl phosphate (PNPP) producing a yellow product that can be read in a 
spectrophotometer or ELISA reader at 405nm. 
 
A vial of prepared frozen cells was thawed quickly and mixed with 9ml freshly 
prepared pre-warmed media (dMEM). This was then centrifuged at 1,000rpm for 10 
minutes to pellet the cells. The supernatant was discarded and the cells re-suspended 
in a further 9ml of fresh, pre-warmed media (dMEM containing 10% FCS, 2mM L-
glutamine, 4.5g/l glucose, 100u/ml penicillin, 100ug/ml streptomycin and 100ug/ml 
normocin) and transferred to a small tissue culture flask. The flask was incubated at 
37oC and split when approaching confluence (~90–95% confluence). 
 
For the assay, cells from 3 confluent tissue flasks were liberated with a cell scraper in 
warm PBS. Cells were centrifuged at 1,000rpm for 10 minutes to pellet the cells. The 
supernatant was discarded and the cell pellet re-suspended in 10ml warmed test 
medium (dMEM as above with heat inactivated FCS). Cells were counted in a 
modified Neubauer cell counter and resuspended at a concentration of 550,000 
cells/ml. 100μl cells (ie 55,000 cells/well) were added to a black 96-well plate (to 
minimise transference of signal). The outer wells had 100μl of media alone added to 
minimise effects of evaporation. The plate was incubated at 37 oC for 16 hours (± 2 
hours). 
 
Commercial LPS solution (IMG-2204, 1mg/ml) was diluted to a 100 μg/ml working 
stock solution by adding 10μl to 90μl of culture media to provide a positive control.  
 
Treatments with RANKL and OPG were prepared at 10X concentration and 





(10 x concentrated) 
100 μl 
Volume of stock solution required (μl) Volume of media 









-ve 0 0 0 500 
R100 2 0 0 98 
R200 4 0 0 96 
R400 6 0 0 94 
R800 8 0 0 92 
R1,600 16 0 0 84 
R200, O200 4 4 0 92 
L200 0 0 2 98 
L400 0 0 4 96 
L5,000 0 0 50 50 
 
e.g. R200 = 200 ng/ml final concentration per well of RANKL and 
L200 = 200 ng/ml final concentration per well of LPS 
0200 = 200 ng/ml final concentration per well of OPG 
 
 
From each well, using a multichannel pipette, 10μl of cell supernatant (or media only) 
was discarded. Then, 10μl of the 10X concentrated samples was added to the 
remaining 90μl of D-MEM in which the cells had been incubated overnight (or media 
only). Each treatment sample was added to all eight wells in a column 
 
Secreted alkaline phosphatase was measured using the provided buffers and standards 
(Alkaline Phosphatase assay - Imgenex Cat. No.10055K). The 10X sample dilution 
buffer and 10 x PNPP buffer provided were diluted to 1X with sterile dH20 (eg 1ml of 
10X buffer + 9ml of sterile dH20). SEAP standards were prepared with serial doubling 
dilutions of the 400ng/ml SEAP standard stock solution to a final volume of 100μlin 
dilution buffer. After stimulation, 5μl of supernatant from each well of cells was 
transferred to a fresh 96 well plate and diluted 1:2 by the addition of 5μl of dilution 
buffer. Standards were arranged in duplicate with 10μl per well. The plate was sealed 
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with a plate sealer and incubated at 65oC for 30 minutes to inactivate any endogenous 
alkaline phosphatase and allow for precise quantification of SEAP. 
 
During this incubation, to the remaining 95μl of media containing stimulated 9.5μl 
Alamar Blue (10X ready-to-use solution) was added and cells were incubated at 37oC 
for a further 3 hours. Also during this incubation period, the PNPP substrate was 
prepared. This was done by dissolving two 5mg PNPP substrate tablets in 10ml of 1X 
PNPP buffer (to give a final concentration of 1 mg/ml). 
 
After incubation the plate was spun briefly to return all liquid to the bottom of the well 
and then the plate sealer was removed. To each well, 100μl of the freshly prepared 1 
mg/ml PNPP substrate solution was added and the plate incubated at room temperature. 
Absorbance readings at 405nm were recorded after 2 hours, 4 hours and approximately 
24 hours using a plate reader. Cell viability of the cultures cells after 3 hours was 
determined by measuring absorbance at 570nm.  
 
A4.3.2 SEAP Assay results 
LPS induced RAW cell secretion of ALP robustly and at all time-points, confirming 
that the cells were viable, functioning as anticipated, and that the assay was performed 
correctly. Alamar blue staining confirmed cells were still viable for 3 hours after the 
supernatant samples had been removed for the SEAP assay, with similar levels of 
viability in all wells. Disappointingly there was no signal observed at any 
concentration of RANKL meaning that this line could not be used as hoped (Table 
A4.2). Even though this cell line is thought to be of monocyte/macrophage lineage 








Table A4.2 Results of the Alkaline Phosphatase assay at 2, 4 and 24 hours. 






Sample Neg R100 R200 R400 R800 R1,600 
R200, 
O200 
L200 L400 L5,000 
Result <0.0 <0.0 <0.0 <0.0 <0.0 <0.00 <0.00 43.3 40.7 63.8 
SD N/A N/A N/A N/A N/A N/A N/A 6.94 5.467 9.917 
CV 
(%) 












L200 L400 L5,000 
Result <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 42.6 40.4 63.8 
SD N/A N/A N/A N/A N/A N/A N/A 6.74 4.7 9.30 











L200 L400 L5,000 
Result <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 77.6 73.7 122 
SD N/A N/A N/A N/A N/A N/A N/A 14.7 12.8 18.7 













Lothian Osteoporosis Service 
Western General Hospital 
Phone 0131-537-2155 
 
We would be grateful if you could try and complete the following questionnaire. Don’t worry if you 
can’t answer all the questions, since any information you provide will be helpful and we will go over 
the questions with you when you come for your scan 
 
Section 1.  Personal Details 
Name  GP’s Name 
Address  Date of Birth 
Please tick   the box if you are: 
Postcode  Male   Female   
 
Section 2.  Fractures (broken bones)  
 
  Yes  No  
Have you ever suffered a fracture? (broken bone)  






If you ticked YES, please list the site of these fractures below, describe how they occurred and tell us what age 
you were when the fractures occurred.  
Site of Fracture  
(e.g. hip, wrist, shoulder, ankle, etc.) 
Cause of Fracture 
(e.g. fell or tripped, car accident)  
Age  
(at time of fracture) 
   
   
   
   
   
  
Section 3.  Steroid Treatment  
 
  Yes  No  
Are you taking steroid tablets at present?   






If you answered YES, please write down the month and year you started 
the tablets and please bring them (or your prescription) with you when 
you come for your scan 
 
 
(office use only, please leave blank) 
Steroid name 
Steroid/dose 
  Yes  No  
Have you previously taken steroid tablets? 
(for example, prednisolone or dexamethasone - please tick   the box) 
   
 
  
If you answered YES, please write down the month and year when you 
started and stopped the steroid tablets  






Section 4.  Medication and Medical Conditions   
Do you suffer from any of the following medical conditions?  
(please tick   the boxes for all those that apply)  
 
Ankylosing Spondylitis    Rheumatoid Arthritis   
 
Anorexia     Thyroid overactive   
 
Crohn’s Disease    Thyroid underactive   
 
Coeliac Disease    Ulcerative Colitis   
 
Gastrectomy    Heartburn   
 
Hyperparathyroidism    Dypepsia   
 
Kidney Failure    Stomach Ulcer   
 
Malabsorption       
  
Section 5. Medications 
Are you being treated with any of the following medications for osteoporosis?  
(please tick   the boxes for all those that apply)  
 
Calcium / Vitamin D    Strontium  (Protelos)   
 
Calcitonin    Teriparatide   
 
Alendronate (Fosamax)    Pamidronate (Aredia)   
 
Risedronate (Actonel)    Didronel   
 
Ibandronate (Bonviva)    Raloxifene   
 
  Other   
 
Are you being treated with any of the following medications for pain, heartburn or dyspepsia? 
(please tick   the boxes for all those that apply) 
 
Anti-inflammatory tablets       
 
Antacid medication       
 
Section 6. Diet, Alcohol and Smoking 
We would like to know about your diet. Please fill in the table below to tell us how many times per week on 
average you eat the following foods or drinks.  
Food Item Number per week  
Cups of tea or coffee with milk  
Milk or milk drinks (e.g. hot chocolate)  
Cereal or porridge with milk  
Milk puddings (custard, ice cream, yoghurt etc.)  
Chocolate bars  
Slices of bread  
Portions of cheese   
Lasagne, macaroni cheese, mousaka, or pizza.  
Portions of cottage cheese  
Eggs  
Biscuits  
Portions of Cake  
Portions of green vegetables  
Portions of sardines/pilchards  
Portions of other fish  
Oranges  
  





  Yes  No  
Do you smoke?  (please tick   the box)     
  
If you answered YES, please enter in this box how many cigarettes or cigars per day.  
  
  Yes  No  
Did you smoke previously (please tick   the box)     
  
  Yes  No  
Do you drink alcohol regularly?    






If you answered YES, please estimate how many units of alcohol you take per week.  (1 unit equals 




Section 7.  Falls   
 
  Yes  No  
Have you fallen in the past 12 months? 
(please tick   the box) 
   
 
  
If you answered YES, how many falls have you had in the past 12 months  
 
 
(office use only, please leave blank) 
Get up and go test                      Passed / Failed 
Falls referral                               Yes / No 
 
Section 8.  Physical Activity and Sports   
 
  Yes  No  
Are your on your feet for more than 4 hours a day?  
(please tick   the box) 
   
 
  
  Yes  No  
Do you take part in impact sports regularly?  
(e.g. football, rugby, hockey, squash, running; please tick   the box) 
   
 
  
  Yes  No  
Do you take part in non impact sports regularly?  
(e.g. swimming, cycling, golf, walking, riding; please tick   the box) 
   
 
 
Section 9.  Family History of Osteoporosis 
 




Has your father suffered a hip fracture? (please tick   the box) 
   
 
  
Has your mother suffered a hip fracture? (please tick   the box) 
   
 
 
Has your brother or sister suffered a hip fracture?   
(please tick   the box) 
   
 
  
Has your father been diagnosed with osteoporosis?  
(please tick   the box)? 
   
 
  
Has your mother been diagnosed with osteoporosis?  
(please tick   the box)? 
   
 
  
Have any of your brothers been diagnosed with osteoporosis? 
(please tick   the box) 
   
 
  
Have any of your sisters been diagnosed with osteoporosis? 
(please tick   the box) 






Section 10.  Your Ethnic Background  
How would you describe yourself with regard to your ethnic background?  
(please tick  boxes that apply; you can tick more than one box if you are of mixed ethnic background) 
 
White Scottish    Pakistani   
 
White other British    Asian any other   
 
White Irish    Black Caribbean   
 
White any other    Black African   
 
Asian Indian    Black any other   
 
Asian Pakistani    Mixed   
 
Asian Bangladeshi    Other   
 
Asian Chinese       
 
Section 11.  Periods and Menopause (Women only) 
 
   Age (yrs)   
What age were you when your periods first started? 
(please enter the age in the box) 
   
 
  Yes  No  
Are you having periods regularly? 
(please tick   the box) 
   
 
  
  Yes  No  
Are your periods irregular? 
(please tick   the box) 
   
 
  
  Yes  No  
Have your periods stopped  altogether? 
(please tick   the box) 
   
 
  
If your periods have stopped what age were you when this happened?   
Section 12.  Hysterectomy and Hormones (Women only) 
 
  Yes  No  
Have you had a hysterectomy? 
(please tick   the box) 
   
 
  
If you answered YES what age were you when you had the hysterectomy?   
 
 
  Yes  No  
Have you had your ovaries removed? 
(please tick   the box) 
   
 
  





  Yes  No  
Are you taking HRT at present?   
(please tick   the box) 
   
 
  
If you answered YES, please enter for how long you have taken HRT 
(e.g. Jan 2002- present date)  
 
 
  Yes  No  
Did you ever take HRT in the past?   
(please tick   the box) 
   
 
  
If you answered YES, please write down the month and years when 
you started and stopped HRT (e.g. Jan 2002-Feb 2004)  
 
 






Are you using PROVERA (the Jag) contraceptive   
(please tick   the box) 
   
 
  





Thank you! Remember to bring the completed questionnaire with you when you come for the scan. 
 
(For use of Osteoporosis Service Only) 
 
(Office Use only) Source of Referral 
(please tick  one box 
DADS  
FLS  
Hospital referral  
Other (please specify)  
 
 
